Rhythmic Masticatory Muscle Activity during Sleep: Etiology and Clinical Perspectives by Carra, Maria Clotilde
 Université de Montréal 
 
 
Rhythmic Masticatory Muscle Activity during Sleep: 
Etiology and Clinical Perspectives 
 
 
 
par 
Maria Clotilde Carra 
 
 
Programme de Sciences Biomédicales  
Faculté de Médecine  
 
 
 
Thèse présentée à la Faculté de Médecine  
en vue de l’obtention du grade de Doctorat 
en Sciences Biomédicales  
option générale 
 
 
 
Juin, 2012 
 
 
 
© Maria Clotilde Carra, 2012 
  
 
Université de Montréal 
Faculté des études supérieures et postdoctorales 
 
 
 
 
Cette thèse intitulée: 
 
Rhythmic Masticatory Muscle Activity during Sleep: Etiology and Clinical Perspectives  
 
 
 
 
Présentée par: 
Maria Clotilde Carra  
 
 
 
 
a été évaluée par un jury composé des personnes suivantes : 
 
 
Dr Arlette Kolta, président-rapporteur 
Dr Gilles Lavigne, directeur de recherche 
Dr Roger Godbout, membre du jury 
Dr Celyne Bastien, examinateur externe 
Dr Antonio Zadra, représentant du doyen de la FES 
  
 
i
Résumé 
L’activité rythmique des muscles masticateurs (ARMM) pendant le sommeil  se 
retrouve chez environ 60% de la population générale adulte. L'étiologie de ce mouvement 
n'est pas encore complètement élucidée.  Il est cependant démontré que l’augmentation de 
la fréquence des ARMM peut avoir des conséquences négatives sur le système 
masticatoire. Dans ce cas, l'ARMM est considérée en tant que manifestation d'un trouble 
moteur du sommeil connue sous le nom de bruxisme. Selon la Classification Internationale 
des Troubles du Sommeil, le bruxisme est décrit comme le serrement et grincement des 
dents pendant le sommeil. La survenue des épisodes d’ARMM est associée à une 
augmentation du tonus du système nerveux sympathique, du rythme cardiaque, de la 
pression artérielle et elle est souvent en association avec une amplitude respiratoire accrue. 
Tous ces événements peuvent être décrits dans le contexte d’un micro-éveil du sommeil. 
Cette thèse comprend quatre articles de recherche visant à étudier i) l'étiologie de 
l’ARMM pendant le sommeil en relation aux micro-éveils, et à évaluer ii) les aspects 
cliniques du bruxisme du sommeil, du point de vue diagnostique et thérapeutique. 
Pour approfondir l'étiologie de l’ARMM et son association avec la fluctuation des 
micro-éveils, nous avons analysé le patron cyclique alternant (ou cyclic alternating pattern 
(CAP) en anglais), qui est une méthode d’analyse qui permet d’évaluer l'instabilité du 
sommeil et de décrire la puissance des micro-éveils. Le CAP a été étudié chez des sujets 
bruxeurs et des sujets contrôles qui ont participé à deux protocoles expérimentaux, dans 
lesquels la structure et la stabilité du sommeil ont été modifiées par l'administration d'un 
médicament (la clonidine), ou avec l'application de stimulations sensorielles (de type 
vibratoire/auditif) pendant le sommeil. Dans ces deux conditions expérimentales 
caractérisées par une instabilité accrue du sommeil, nous étions en mesure de démontrer 
que les micro-éveils ne sont pas la cause ou le déclencheur de l’ARMM, mais ils 
représentent plutôt la «fenêtre permissive» qui facilite l'apparition de ces mouvements 
rythmiques au cours du sommeil. 
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Pour évaluer la pertinence clinique du bruxisme, la prévalence et les facteurs de 
risque, nous avons effectué une étude épidémiologique dans une population pédiatrique (7-
17 ans) qui était vue en consultation en orthodontie. Nous avons constaté que le bruxisme 
est un trouble du sommeil très fréquent chez les enfants (avec une prévalence de 15%), et il 
est un facteur de risque pour l'usure des dents (risque relatif rapproché, RRR 8,8), la fatigue 
des muscles masticateurs (RRR 10,5), les maux de tête fréquents (RRR 4,3), la respiration 
bruyante pendant le sommeil (RRR 3,1), et divers symptômes liés au sommeil, tels que la 
somnolence diurne (RRR 7,4). Ces résultats nous ont amenés à développer une étude 
expérimentale pour évaluer l'efficacité d'un appareil d'avancement mandibulaire (AAM) 
chez un groupe d'adolescents qui présentaient à la fois du bruxisme, du ronflement et des 
maux de tête fréquents. L'hypothèse est que dans la pathogenèse de ces comorbidités, il y a 
un mécanisme commun, probablement lié à la respiration pendant le sommeil, et que 
l'utilisation d'un AAM peut donc agir sur plusieurs aspects liés. 
À court terme, le traitement avec un AAM semble diminuer l'ARMM (jusqu'à 60% 
de diminution), et améliorer le ronflement et les maux de tête chez les adolescents. 
Cependant, le mécanisme d'action exact des AAM demeure incertain; leur efficacité peut 
être liée à l'amélioration de la respiration pendant le sommeil, mais aussi à l'influence que 
ces appareils pourraient avoir sur le système masticatoire. Les interactions entre le 
bruxisme du sommeil, la respiration et les maux de tête, ainsi que l'efficacité et la sécurité à 
long terme des AAM chez les adolescents, nécessitent des études plus approfondies. 
 
Mots-clés: Bruxisme du sommeil, micro-éveil, adolescents, appareil d’avancement 
mandibulaire. 
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Abstract 
Approximately 60% of the general adult population experiences rhythmic 
masticatory muscle activity (RMMA) during sleep. The etiology of this movement is not 
yet understood. However, it has been demonstrated that an increased frequency of RMMA 
may have detrimental consequences on the stomatognathic system. In this case, RMMA is 
considered the manifestation of a sleep-related motor disorder known as sleep bruxism 
(SB). According to the definition of the International Classification of Sleep Disorders, SB 
is the activity of tooth grinding and clenching during sleep. The occurrence of SB-related 
activity, i.e., RMMA, is associated with rises of sympathetic tone, heart rate, blood 
pressure, and it is frequently concomitant with larger respiratory breaths. All these events 
can be described within a sleep arousal.  
The present thesis includes four research articles aimed to study i) the etiology of 
RMMA during sleep in relation to sleep arousal; and ii) the clinical perspectives of SB 
assessment and management.  
To further investigate the etiology of RMMA and its association with sleep arousal 
fluctuations we analyzed the cyclic alternating pattern (CAP), a scoring method to assess 
sleep instability and describe sleep arousal pressure. CAP was scored in SB subjects and 
controls that participated in two experimental protocols in which sleep architecture and 
stability were altered by either a medication (i.e., clonidine), or sensory stimulations (i.e., 
vibratory/auditory). Under these experimental conditions known to increase sleep 
instability, we were able to show that sleep arousal is not the trigger or cause of RMMA, 
rather the “permissive window” that facilitates the occurrence of RMMA during sleep.  
To evaluate the clinical relevance of SB, we conducted a survey on a 7-17 year old 
orthodontic population to investigate the prevalence and risk factors associated with SB. It 
appeared that SB is a highly prevalent sleep disorders in children (15% of prevalence), and 
is a risk factor for tooth wear (odds ratio, OR 8.8), jaw muscle fatigue (OR 10.5), frequent 
headache (OR 4.3), loud breathing during sleep (OR 3.1), and several sleep complaints, 
such as daytime sleepiness (OR 7.4). These findings led us to design an experimental trial 
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using a mandibular advancement appliance (MAA) in adolescents in order to investigate 
the possible relationship between SB, snoring, and headache. We hypothesized that a 
common underlying mechanism related to breathing during sleep may be responsible for all 
concomitant conditions.  
The short-term use of an MAA appeared to reduce SB (up to 60%), and improve 
snoring and headache complaints in adolescents. However, the precise mechanism of action 
of MAA remains under debate; its effectiveness can be either related to the improvement of 
breathing during sleep, or its influence on the masticatory system. The interactions between 
SB, breathing, and headache as well as the long-term effectiveness and safety of the MAA 
in adolescents need further investigations. 
 
Keywords: Sleep bruxism, sleep arousal, adolescents, mandibular advancement appliance. 
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Riassunto 
L’attività ritmica dei muscoli masticatori (ARMM) durante il sonno si osserva in 
circa il 60% della popolazione generale adulta. L'eziologia di questo movimento non è stata 
ancora del tutto compresa. Tuttavia, è dimostrato che un’aumentata frequenza di ARMM 
può avere conseguenze negative sul sistema stomatognatico. In questo caso, l’ARMM è 
considerato la manifestazione di un disturbo motorio del sonno noto come bruxismo. 
Secondo la Classificazione Internazionale dei Disturbi del Sonno, il bruxismo è l'attività di 
digrignamento e serramento dei denti durante il sonno. La comparsa di episodi di ARMM 
durante il sonno è associata a un aumento del tono del sistema nervoso simpatico, della 
frequenza cardiaca, della pressione arteriosa, ed è spesso in concomitanza con un 
aumentato volume inspiratorio. Le variazioni di questi parametri fisiologici sono compresi 
nel contesto di un arousal (micro risveglio) del sonno. 
Questa tesi comprende quattro articoli di ricerca volti a studiare i) l'eziologia 
dell’ARMM durante il sonno in relazione all’arousal, ed a valutare ii) l’inquadramento 
clinico del bruxismo nel sonno. 
Per approfondire l'eziologia dell’ARMM e l’associazione con l’arousal nel sonno, 
abbiamo analizzato il cyclic alternating pattern (CAP), che permette di valutare l'instabilità 
del sonno e descrivere la potenza degli arousals. Il CAP è stato esaminato in soggetti con 
bruxismo e soggetti controllo che hanno partecipato in due protocolli sperimentali, in cui la 
struttura e la stabilità del sonno sono stati modificati con la somministrazione di un farmaco 
(la clonidina), o con l’applicazione di stimolazioni sensoriali (di tipo vibratorio/uditivo) 
durante il sonno. In queste condizioni sperimentali caratterizzate da un’aumentata 
instabilità del sonno, siamo stati in grado di dimostrare che l’arousal non è la causa o il 
generatore dell’ARMM, ma piuttosto la "finestra permissiva" che facilita il verificarsi di 
questi movimenti ritmici durante il sonno. 
Per valutare la rilevanza clinica del bruxismo, abbiamo condotto uno studio 
epidemiologico in una popolazione pediatrica afferente alla clinica di ortodonzia per 
studiare la prevalenza e i fattori di rischio associati al bruxismo. Questa ricerca ha 
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evidenziato che il bruxismo è un comune disturbo del sonno nei bambini (con una 
prevalenza del 15%), ed è un fattore di rischio per usura dentale (odds ratio, OR 8.8), fatica 
dei muscoli masticatori (OR 10.5), mal di testa frequenti (OR 4.3), respirazione rumorosa 
durante il sonno (OR 3.1), e diversi sintomi legati al sonno, quali la sonnolenza diurna (OR 
7.4). Questi risultati ci hanno portato a progettare uno studio sperimentale per valutare 
l’efficacia di un apparecchio di avanzamento mandibolare (AAM) in un gruppo di 
adolescenti che presentavano al contempo bruxismo, russamento e frequenti cefalee. 
L’ipotesi è che nella patogenesi di tali comorbidità, vi sia un meccanismo comune, 
probabilmente legato alla respirazione durante il sonno, e che l’utilizzo di un AAM possa 
quindi avere un beneficio multiplo.  
Il trattamento a breve termine con un AAM sembra diminuire l’ARMM (fino al 
60%) e migliorare il russamento e i mal di testa negli adolescenti. Tuttavia, l'esatto 
meccanismo di azione degli AAM rimane incerto; la loro efficacia può essere correlata sia 
al miglioramento della respirazione durante il sonno, ma anche all’influenza che questi 
apparecchi svolgono sul sistema masticatorio. Le interazioni tra il bruxismo nel sonno, la 
respirazione, e le cefalee, così come l'efficacia e la sicurezza a lungo termine degli AAM 
negli adolescenti, necessitano di ulteriori studi clinici. 
 
Keywords: Bruxismo nel sonno, arousal, età pediatrica, apparecchi di avanzamento 
mandibolare. 
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Few episodes of rhythmic masticatory muscle activity during sleep occur in 
approximately 60% of the general adult population as a physiologic jaw movement 
probably related to swallowing and breathing. However, this motor behavior may fall into a 
pathological range if occurring with increased frequency during sleep and if associated with 
clinical signs and symptoms. In this case, we talk about sleep bruxism, a sleep-related 
movement disorder included in the International Classification of Sleep Disorders as the 
oral parafunction of grinding and clenching of the teeth during sleep. 
Although the precise etiology of sleep bruxism remains unclear, its pathophysiology 
is researched in the complex mechanisms that regulate sleep. Sleep is a highly organized 
brain state of quiescence that entails several important functions, such as physical and 
psychological recovery, biochemical refreshment, memory consolidation and emotional 
regulation. Within sleep, physiological, endocrine and neurological functions follow a 
cyclic fluctuation controlled by the homeostatic and ultradian drives. It seems probable that 
also phasic events during sleep, such as sleep arousals and sleep bruxism, obey to this 
fluctuating pattern of occurrence.  
From a clinical perspective, sleep bruxism has been frequently described in 
association with other sleep disorders (e.g., obstructive sleep apnea), pain complaints (e.g., 
headache), and, especially in children, with behavioral problems (e.g., inattention and 
hyperactivity). Thus, tooth-grinding should be considered more than an oral parafunction 
causing tooth wear, rather it should be accounted in a wider clinical assessment of the 
patient’s health.   
The present thesis aims to better understand the pathogenesis and regulation of 
rhythmic masticatory muscle activity during sleep to untimely provide support for an 
evidence-based management of sleep bruxism.  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 1: Literature Review  
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1.1 Historical Aspects of Bruxism  
The word “bruxism” originates from the Greek word βρυγµός (brygmós), meaning 
gnashing of the teeth. The first description of the phenomenon in the scientific literature is 
dated 1907, when the French term bruxomanie was used to describe an involuntary and 
”nervous” grinding of the teeth, as observed in patients who were afflicted with lesions in 
the central nervous system like meningitis, dementia, and epilepsy (1). Later in 1931, 
Frohman, a physician, was one of the earliest to use the word bruxism, defined as a 
problem of a dental nature resulting from non-physiological movements of the mandible 
related to psychological factors (2).  From then on, multiple definitions and several terms 
have been referred to bruxism: “occlusal habit neurosis”, “neuralgia traumatic”, “teeth 
gnashing-grinding”, and “parafunction” (3, 4). Few authors also attempted to distinguish 
between different forms of bruxism. Miller alluded to bruxism to indicate the teeth grinding 
during sleep, whereas bruxomania was used to denote the habit of grinding during daytime 
(5). Ramfjord and Ash described clenching as a “centric bruxism”, while grinding as 
“eccentric bruxism” (6). From the perspective of different medical disciplines, bruxism 
ranged from being considered a neurological tic or automatism, to a parasomnia or a sleep-
related movement disorder (7). The many descriptions and classifications applied to this 
disorder merely reflect the variety of etiologic factors that over the years have been deemed 
to cause bruxism.  
 
 
1.2 Definition and Classification of Sleep Bruxism  
According to the Glossary of Prosthodontic Terms, bruxism is considered an oral 
parafunction consisting of involuntary rhythmic or spasmodic nonfunctional gnashing, 
grinding, or clenching of the teeth (8). Although this definition describes the main 
movement-related characteristics of the disorder, it lacks a substantial and important 
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distinction between the wake and sleep states in which this oral parafunction may occur. 
There is clinical and research evidence to consider the wake-time habit of clenching, 
grinding, or gnashing the teeth a distinct nosologic entity, probably with different etiology 
and pathophysiology, that should be distinguished from bruxism during sleep (7).  
The American Academy of Orofacial Pain, indeed, defines bruxism as the diurnal or 
nocturnal parafunctional activity of clenching, bracing, gnashing, and grinding of the teeth 
(9). However, the use of the words “diurnal” and “nocturnal” is obsolete; the more precise 
“wake-time” and “sleep-related” terms should be preferred since they respect the fact that 
being awake or asleep does not always coincide with daytime and nighttime, respectively.  
According to the International Classification of Sleep Disorders, second edition 
(ICSD-II), published by the American Academy of Sleep Medicine in 2005 (10), sleep 
bruxism (SB) is classified as a sleep-related movement disorder. The characteristic 
electromyography (EMG) pattern of SB is found in repetitive and recurrent episodes of 
rhythmic masticatory muscle activity (RMMA) of the masseter and temporalis muscles that 
are usually associated with sleep arousals (7, 10). The RMMA shows a frequency of 1 Hz 
and typically occurs cyclically during sleep (Figure 1.1). RMMA episodes are observed in 
60% of the general adult population as physiological activity of the jaw muscles during 
sleep (11, 12). Many other forms of masticatory and facial muscle activity are also 
observed during sleep, such as swallowing, coughing, sleep talking, smiling, lip sucking, 
jaw movements, and myoclonus (7, 13). These orofacial activities account for 
approximately 85% of EMG events scored on the masseter and temporalis muscles in 
control subjects and 30% in SB subjects (14-16). In fact, RMMA frequency is three times 
higher in SB subjects than in controls, and is typically associated with tooth grinding 
sounds (in 45% of cases), as reported by the patient, bed partner, parents, or siblings (7).  
SB may be an extreme manifestation of a physiological orofacial motor behavior 
during sleep (RMMA and chewing-like activity) whereby certain factors increase its 
occurrence until it falls into the pathological range of jaw-muscle activity. Therefore, SB 
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refers to the sleep motor disorder, whereas RMMA is the characteristic EMG pattern that is 
scored during sleep to make a polysomnographic diagnosis of SB. 
 
 
1.3 Assessment and Diagnosis of Sleep Bruxism 
The assessment and diagnosis of SB are often challenging. Generally, the 
assessment is based on reports of tooth-grinding sounds during sleep and the presence of 
clinical signs and symptoms (10). However, only an electromyographic (EMG) recording 
of the masticatory muscles can confirm the SB diagnosis. A number of portable diagnostic 
tools have been developed to record masseter and/or temporalis EMG activity during sleep 
in order to avoid using the more sophisticated but highly cost- and time-consuming 
polysomnography (PSG). However, the reliability of most portable devices has not yet been 
validated, and their use may be considered only as a support in the clinical assessment of 
SB. In fact, the SB diagnosis is usually clinical, although the gold standard remains a full-
night PSG with audio-video recording (Table 1.1). The future direction for SB assessment 
would be to develop a handy tool that can directly, reliably, and rapidly measure ongoing 
bruxism activity, and that can be used in both clinical (for diagnosis, treatment outcome 
evaluation, and follow-up) and research settings.  
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Figure 1.1 Hypnogram and polysomnographic tracing showing an episode of rhythmic 
masticatory muscle activity (RMMA) during sleep.  
 
 
 
 
 
 
 
 
 
 
 
 
The full night hypnogram (graph in the upper left represents sleep stage distribution in non-
REM sleep 1, 2, 3, 4 and REM sleep) and a 20-sec polysomnographic page with a clear 
example of RMMA during sleep are shown. The subject is in non-REM sleep stage 2. 
RMMA is defined when at least 3 consecutive EMG bursts (frequency 1 Hz) lasting ≥ 0.25 
sec are scored on the masseter and temporalis channels. Corresponding with the RMMA 
episode, note the increased frequency in cortical activity (EEG central (C3A2) and occipital 
(O1A2) derivations), increased heart rate (on the ECG channel), and increased amplitude of 
respiratory airflow (naso-cannula). Immediately before the RMMA onset, an increase in the 
EMG activity of the suprahyoid muscle (EMG channel) and a leg movement (LegL 
channel) are observed (From ambulatory PSG recording Siesta, Compumedics).  
LOC: left electrooculogram; ROC: right electrooculogram; EMG: electromyographic 
activity of the suprahyoid muscle; C3A2: the central derivation of the electroencephalogram 
(EEG); O1A2: the occipital derivation of the EEG; ECG: electrocardiogram; LegL: EMG of 
the left tibialis muscle; MasR and MasL: EMG of the right and left masseter muscles; 
TempR and TempL: EMG of the right and left temporalis muscles; SpO2: oxygen saturation 
level (expressed as %); Airflow: naso-cannula airflow; Mic: microphone.  
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Table 1.1 Methods for assessing sleep bruxism.  
 
 
SB: sleep bruxism; SDB: sleep-disordered breathing; EMG: electromyogram; RMMA: 
rhythmic masticatory muscle activity; EEG: electroencephalogram; EOG: 
elecrooculogram; ECG: electrocardiogram; PLMS: periodic limb movement during sleep; 
RLS: restless leg syndrome; RBD: REM sleep behavior disorder 
(Carra MC. based on (7, 17)) 
 
 
 
 
 
Methods for assessing sleep bruxism (order of increasing reliability) 
Method Notes 
•! Patient’s history Many subjects may not be aware of their tooth-grinding habit during sleep. More reliable if the bed 
partner, parents, or siblings report current tooth grinding sounds during sleep. 
•! Clinical assessment To assess the clinical signs and symptoms that suggest SB (e.g., tooth wear; refer to Box 1) and the 
presence of potential risk factors for other comorbidities (e.g., enlarged tonsils, skeletal Class II, 
and Mallampati score III or IV for the risk of concomitant SDB). 
•! Questionnaires To investigate the patient’s general and oral health, sleep quality, sleep habits, oral parafunctions, 
presence and characteristics of pain, headache, fatigue, depression, anxiety and stress, and 
comorbidities. 
•! Ambulatory EMG monitoring Allows recording EMG activity during sleep from the temporalis or masseter muscles, depending 
on the device used. However, very low specificity and sensitivity in distinguishing actual RMMA 
episodes from the many other orofacial and motor activities that occur dung sleep. Furthermore, no 
monitoring on awakening from sleep, arousal, sleep staging, or other sleep variables. This could be 
a valuable tool in the clinical assessment of SB and in large-sample studies (e.g., general 
population epidemiological studies).  
•! Ambulatory PSG recording 
(Type II, III, and IV)  
Usually performed at the patient’s home. Normally, no audio-video monitoring. Specificity and 
sensitivity in detecting RMMA depends on the device used, and more particularly, on the number 
of variables monitored (EEG, EOG, ECG, EMG, and respiratory channels). This method may be 
used for scoring sleep stages, sleep arousals, leg movements, and EMG activity, and for 
monitoring breathing.    
•! Full audio-video PSG recording 
(Type I) 
Remains the gold standard for the diagnosis of SB and the assessment of comorbidity with other 
sleep disorders (e.g., SDB, PLMS, RLS, RBD, parasomnias). Normally, it allows full-night 
monitoring of EEG, EOG, EMG, ECG, leg movements, respiratory effort, airflow, and oxygen 
saturation. Concomitant audio-video recording increases the specificity and sensitivity in RMMA 
detection and scoring by distinguishing between RMMA episodes and orofacial (e.g., swallowing, 
coughing, sleep talking) and other muscular activities (e.g., head movements, eye blinking) that 
occur during sleep.   
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1.3.1 Clinical Diagnosis of Sleep Bruxism  
The clinical diagnosis of SB should be based on the international diagnostic criteria 
proposed by the American Academy of Sleep Medicine (Table 1.2) (10, 18). Grinding 
sounds due to tooth contacts are the pathognomonic sign of SB, and they are usually 
reported by the patient, bed partner, siblings, or parents. However, not all RMMA episodes 
are accompanied by tooth grinding, and many patients or family members may not be 
aware of this.  
A clinical examination of the oral cavity allows identifying signs and symptoms that 
are markers of tooth-grinding activity and a clenching habit. These signs and symptoms 
include hypertrophy of the masseter and temporalis muscles, tongue indentation, tooth 
wear, jaw muscle tenderness or pain on digital palpation, and reports of morning headache 
(7, 19). However, none of these signs and symptoms constitutes direct proof of current SB 
activity. For example, although tooth wear is widely reported in the literature as the classic 
dental sign of bruxism (both awake and during sleep), it may be related to many other 
factors that can induce attrition and erosion on dental surfaces (e.g., age, occlusal 
conditions, enamel characteristics, diet, carbonated drinks, medications, gastroesophageal 
reflux, and alimentary disorders)(7, 19-23). Moreover, it was recently demonstrated that 
tooth wear cannot be used as an absolute criterion to assess SB severity: no difference in 
tooth wear grade was found between low and high frequency of muscle contractions in 
young adults with SB (21). 
During the clinical examination, dental clinicians can also identify early risk factors 
for SB and other sleep or medical disorders (e.g., sleep-disordered breathing), and promote 
further investigations when necessary. In particular, the risk of having or developing sleep-
disordered breathing (SDB) increases with retrognathia, micrognathia, macroglossia, 
adenotonsillar hypertrophy, and a Mallampati score of III and IV (24). The Mallampati 
score qualifies oropharyngeal obstruction, with I standing for no obstruction (tonsils, 
pillars, and soft palate are clearly visible) and IV for high obstruction (where only the hard 
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palate is visible)(25). In addition, clinicians can directly observe breathing habits (mouth 
breathing vs. nasal breathing), behavioral attitudes (agitation, anxiety), and a tendency to 
fall asleep. Although it remains under investigation, some of these factors have been 
associated with an increased risk for both SB and SDB. 
Appropriate questionnaires can also be used to investigate general health, quality of 
life, pain, headache, sleep quality, and sleepiness. Some questionnaires have been validated 
for both clinical and research purposes (e.g., the Pittsburg Sleep Quality Index and the 
Epworth Sleepiness Scale). Questionnaire assessments may give the clinician an indication 
of the risk of comorbidity between SB and other, more severe sleep disorders, such as SDB 
or restless leg syndrome (RLS) (Table 1.1).  
 
Table 1.2 American Academy of Sleep Medicine (AASM) clinical diagnostic criteria 
for sleep bruxism.  
  
*None of these signs and symptoms constitutes direct proof of current SB activity. Full-
night PSG with audio-video recording remains the gold standard for SB diagnosis.  
(Carra M.C. based on (7, 10)) 
 
AASM clinical diagnostic criteria for sleep bruxism 
1)! Patient history: 
Recent patient’s and/or parent’s and/or sibling’s report of tooth grinding sounds occurring 
during sleep for at least 3 to 5 nights per week in the last 6 months 
2)! Clinical evaluation:* 
- Abnormal tooth wear 
- Hypertrophy of the masseter muscles on voluntary forceful clenching  
- Discomfort, fatigue, or pain in the jaw muscles (and transient morning jaw muscle pain  
and headache) 
3)! Jaw muscle activity cannot be better explained by another current sleep disorder, medical or 
neurologic disorder, medication use, or substance use disorder.   
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1.3.2 Ambulatory Assessment of Sleep Bruxism 
A number of portable EMG monitoring systems have been developed to assess SB 
activity. They differ in degree of complexity, ranging from miniature self-contained EMG 
detectors to ambulatory PSG systems (levels II, III, and IV)(17), which allow monitoring 
only a limited number of channels (Table 1.1). These devices enable multiple-night 
recordings in the patient’s home at minimal expense, and could be useful research tools in 
large sample studies. However, the lack of standardized scoring criteria and evidence-based 
validity limit their application to both clinical and research settings.  
Because automatic EMG detectors and analyzers usually use a unique algorithm for 
RMMA activity scoring, their validity remains to be demonstrated. Conversely, ambulatory 
PSG recordings provide very good quality EMG signals, and depending on their 
complexity, they can usually assess other sleep parameters, such as sleep EEG (essential for 
sleep staging) or respiratory variables. In addition, on the masseter and/or temporalis EMG 
channels, RMMA episodes can be distinguished as phasic, tonic, or mixed. Furthermore, 
episode and burst frequency and muscular strength can be calculated (Table 1.3)(7). 
However, ambulatory PSG is usually performed in the patient’s home without audio-video 
monitoring. This may lead to overestimation of RMMA episodes due to confounding and 
non-SB-specific motor activities during sleep. We are currently validating RMMA scoring 
criteria on ambulatory PSG recordings, and have observed a modest concordance rate 
between RMMA scored with and without video on the same night (Carra et al., 
unpublished data). Although preliminary, this finding suggests that, in the absence of 
audio-video recording, more rigorous criteria should be applied to the clinical assessment 
and EMG scoring of SB-related activity. 
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Table 1.3 Polysomnographic research diagnostic criteria for sleep bruxism  
 
 
*Best level of reliability when performing audio-video PSG recordings and the presence of 
at least 2 RMMA episodes associated with tooth-grinding sounds.  
(Carra MC. based on (7, 10, 15, 26-29)). 
 
1.3.3 Polysomnographic Diagnosis of Sleep Bruxism 
PSG for SB is mainly used for research purposes (Table 1.1). The research 
diagnostic criteria have been developed on the basis of PSG with audio-video recordings 
performed in a hospital setting with a sleep technician attending full-night monitoring (15, 
18). This PSG (referred to as level I)(17) allows assessing several sleep physiological 
parameters (e.g., electroencephalogram, electrooculogram, electromyogram, 
electrocardiogram, airflow, respiratory effort, oxygen saturation), while audio-video 
recording enables documenting tooth grinding sounds and distinguishing between RMMA 
Polysomnographic research diagnostic criteria for sleep bruxism  
for scoring rhythmic masticatory muscle activity (RMMA) episodes 
Mean EMG amplitude: at least 10% of maximum voluntary clenching activity  
Types of RMMA episodes: 
•! PHASIC: at least 3 EMG bursts lasting ! 0.25 sec and < 2 sec 
•! TONIC: 1 EMG burst lasting > 2 sec 
•! MIXED: phasic and tonic bursts  
EMG bursts must be separated by < 2 sec to be considered part of the same episode. 
SB diagnosis can be made based on:* 
•! The RMMA INDEX: number of RMMA episodes per hour of sleep 
•! The BURST INDEX: number of EMG bursts per hour of sleep 
•! The BRUXISM TIME INDEX (%): total time spent bruxing / total sleep time x 100  
•! TOOTH-GRINDING SOUNDS: at least 1 RMMA episode with tooth grinding sounds 
Positive SB diagnosis (based on the frequency of EMG episodes with positive tooth grinding history or 
confirmation in a sleep laboratory):* 
•! LOW FREQUENCY: when the RMMA Index ! 2 and < 4 
•! HIGH FREQUENCY: when the RMMA Index is ! 4 and/or the Burst Index ! 25  
Box 2 
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and orofacial (e.g., swallowing) and other muscular activity (e.g., head movements) during 
sleep. The validated criteria for a sleep laboratory diagnosis of SB showed 72% sensitivity 
and 94% specificity (15). Based on RMMA index (number of episodes/h of sleep), the 
diagnosis of SB is made when RMMA index ≥ 2 (low-frequency SB – mild bruxism). A  
RMMA index greater than 4 is considered moderate to severe bruxism (high-frequency SB)  
(Table 1.3)(7, 15, 30).  
PSG recordings are not usually indicated for subjects who report SB only. However, 
the clinician should refer the patient to a sleep physician for further investigation and 
diagnosis if other sleep disorders are suspected (e.g., sleep apnea, sleep-related epilepsy, 
REM sleep behavior disorder, periodic limb movement, or other neurological disorder).  
 
 
1.4 Epidemiology of Sleep Bruxism  
In large population-based studies, it is difficult to assess SB by objective measures 
such as PSG recordings. The epidemiology of SB is therefore largely determined by 
questionnaires, self-reports, and/or clinical findings (e.g., tooth wear).  
SB is reported by 8% of the general adult population (31, 32). It typically peaks 
during childhood (with prevalence approaching 40% below the age of 11 years)(33-38), 
and tends to decrease after adulthood. During elderly (>60 years of age) SB is reported with 
a low prevalence (3%)(31, 32). However, this may be explained by the presence of 
edentulism, denture wearing, and changes in sleeping behaviors (i.e., in isolation) that are 
often observed in elderly populations. Overall, no gender difference has been observed (31, 
38, 39).  
 Many confounding factors should be considered when interpreting the 
epidemiology of SB. The wide prevalence range (from 8% to 40%) reported in the 
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literature is most probably because many studies failed to distinguish between wake-time 
and sleep-related bruxism or to assess the presence of medical comorbidities that may 
influence its occurrence. Indeed, SB is frequently concomitant (approximately one third of 
the subjects) with wake-time bruxism, which is characterized mainly by a tooth clenching 
habit (40). Wake-time bruxism tends to increase with age, with an estimated prevalence of 
13% in children (38) and over 30% in adults (41-43).  
Notwithstanding the limitations related to its objective assessment, SB is a common 
sleep disorder and its actual prevalence is probably much higher since individuals are often 
un-aware of sleep-related motor behaviors, especially if subjects sleep alone. 
 
 
1.5 The Masticatory System during Wake and Sleep 
Rhythmic masticatory movements, like chewing, are controlled by the central 
nervous system. Specifically, it is the trigeminal system that is responsible for the 
activation and regulation of the masticatory muscles (44). Indeed, the muscles of the jaw 
are innervated by trigeminal motoneurons located in the trigeminal motor nucleus, in the 
rostral part of the pons. Trigeminal motoneurons receive both excitatory (i.e., 
glutamatergic) and inhibitory (i.e., GABA-ergic and glycinergic) synapses. The excitatory 
and inhibitory inputs onto trigeminal motoneurons are coming from premotoneurons 
surrounding the trigeminal motor nuscleus. During mastication, trigeminal motoneurons 
fire to produce very regular and repetitive jaw movements on the three planes of the space. 
These jaw movements are determined by the activation (i.e., contraction) of the jaw-
opening muscles (e.g., digastric muscles) during mouth opening, and of the jaw-closing 
muscles (e.g., masseter and temporalis muscles) during mouth closing. The rhythmical and 
alternated activation of the jaw muscles is produced by the brainstem nuclei that compose 
the central pattern generator (CPG) (45). The CPG is responsible of initiating and 
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maintaining the motor activity through pattern generation and rhythm generation. These 
activities in the CPG can be triggered both from the cortex and from the sensory signals 
from the periphery. In facts, although chewing can continue without feedback, the 
movement is fine-tuned by sensory signals acting through the action of reflexes (e.g., the 
stretch reflexes; the periodontal reflexes) (46). This mechanism guarantees that muscle 
activity, muscle force, and jaw position are adjusted to deal with the changing conditions 
that occur when different foods are being chewed. Therefore, mastication is neither a purely 
voluntary movement nor a purely reflex (44, 46). A complex combination of both drives the 
rhythmicity and coordination of the masticatory muscles, whose movement is centrally 
programmed (47). 
Chewing-like rhythmic jaw movements during wakefulness can also be cortically 
evoked by electrical stimulation, resulting in a pattern of jaw-opening and jaw-closing 
muscle activity that resembles natural food chewing (48). Conversely, rhythmic masticatory 
movements during sleep (e.g., RMMA) occur spontaneously without any food triturating 
purpose, and with a co-contraction of both the jaw-closing and jaw-opening muscles. 
Moreover, RMMA occurs without apparent cortical involvement—unlike chewing, which 
is initiated at the cortical level— and it is strongly influenced by autonomic nervous system 
activity and arousals during sleep (20, 49, 50). Nevertheless, many studies suggest that SB 
is centrally regulated—probably in the brainstem—and its genesis is more likely 
multifactorial (7, 51-53).  
The brainstem neuronal networks which control the genesis of rhythmic masticatory 
movements during wakefulness has been studied in animal models, which allowed 
describing the cortico-bulbar pathway that drives mastication (45, 47). In particular, it 
seems that cortico-bulbar inputs to controlateral brainstem structures first activate a relay in 
the medial pontomedullary reticular formation that eventually reaches the trigeminal motor 
nuclei and activates jaw-opening or jaw-closing muscles to produce jaw movements (47, 
54). During sleep, these cortico-bulbar influences are not dominant, rather they seem to be 
partially de-activated to preserve sleep continuity (55, 56). Interestingly, several of the 
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brainstem reticular nuclei that are involved in the masticatory regulation are also involved 
in sleep genesis and maintenance, as well as in respiratory control (51).  
The ascending arousal system originating in the brainstem is crucial in maintaining 
wakefulness with well-defined cell groups involved in two major pathways (57). The major 
inputs come from the cholinergic pedunculopontine and laterodorsal tegmental nuclei. 
These nuclei activate thalamic relay neurons and the thalamic reticular nucleus that are 
crucial for transmission of information to the cerebral cortex. The other pathway originates 
in centers in the upper brainstem and caudal hypothalamus, including the locus coeruleus, 
dorsal and median raphe nuclei, ventral periaqueductal gray matter, and the 
tuberomammillary nucleus. This ascending arousal pathway bypasses the thalamus, 
activating the lateral hypothalamus and basal forebrain and then the cerebral cortex. The 
activity of both the wake-promoting pathways is inhibited by a system of gamma-
aminobutyric acid (GABA)-containing neurons, in which the lateral hypothalamic 
ventrolateral preoptic nucleus (VLPO) appears to play a key role (58). Wake- and sleep-
promoting systems have mutually inhibitory influences on each other. Indeed, during 
wakefulness the activity of the VLPO is strongly inhibited by the noradrenergic locus 
coeruleus and other wake-promoting centers. As the activity of these centers decreases at 
sleep onset, the VLPO becomes active, in turn reciprocally inhibiting wake-promoting 
neuron activity. This mutually inhibitory self-reinforcing loop has the characteristic of a 
“flip-flop switch” that acts to produce stable states of wakefulness or sleep with sharp 
transitions between them (57). Glycinergic and GABAergic inhibitory neurons active 
during sleep are known to directly project to the respiratory centers, such as the hypoglossal 
motor nucleus (59), and to influence the activity of the masticatory CPG nuclei. In fact, 
during sleep there is a general reduction in muscle tone in comparison with wakefulness. 
This could result from a reduction in the cortico-bulbar drive, and/or tonic 
hyperpolarization of masticatory muscle motoneurons, making them less excitable, and/or a 
reduction in the arousal driven monoaminergic tone (51). Similar to the decrease in postural 
muscle tone, sleep causes the suppression of masticatory muscles activity, which typically 
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occur immediately at sleep onset indicating a primary suppressant effect of sleep neural 
mechanisms. This inhibition (i.e., decrease in trigeminal motoneurons excitability) is higher 
during REM sleep, a sleep stage characterized by powerful generalized muscle “atonia” (or 
better hypotonia) of the limb and jaw muscles. However, even during REM sleep transient 
and sudden periods of increased trigeminal motoneurons excitability are observed, and 
RMMA activity can be manifest (50, 51).  
 
 
1.6 Etiology and Pathogenesis of Sleep Bruxism  
The exact etiology and pathophysiology of SB are still unknown (60). The putative 
etiologic mechanisms for the genesis of RMMA during sleep include sleep arousal, 
autonomic sympathetic cardiac activation, genetic predisposition, neurochemicals, 
psychosocial components, exogenous factors, and comorbidities (Table 1. 4).  
 
1.6.2 Sleep Arousal  
As stated in the ICSD-II definition, the majority of RMMA episodes occur in 
association with sleep arousals (10, 18, 61). This association was first observed by Reding 
et al. (62) in 1968 and by Satoh and Harada (63) in 1971, who described  tooth-grinding 
activity as an “arousal reaction”. Since then, many studies have used polysomnography and 
electrophysiology to investigate the complex relationship between SB and sleep arousal 
(60, 61, 64-67). 
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Table 1.4 Etiology and pathophysiology of sleep bruxism.  
 
*Strength of available scientific evidence. 
+ weak evidence; ++ moderate evidence; +++ strong evidence  
(Carra MC. based on (7, 20, 51, 60, 61, 64, 68-74)). 
 
1.6.2.1 The sleep arousal system 
Sleep arousal is defined as a brief awakening from sleep (for at least 3 seconds) 
characterized by an abrupt shift toward higher EEG frequencies (including alpha, theta 
and/or frequencies greater than 16 Hz, but not spindles), generally associated with cortical, 
autonomic and behavioral activations in the absence of the return of consciousness (18). 
Arousals normally reoccur from 6 to 14 times per hour of sleep as the response of the 
Etiology and pathophysiology of sleep bruxism  
Putative etiologic factors and mechanisms Evidence* 
Sleep arousal  
Over 80% of RMMA episodes occur in association with sleep arousal. However, sleep arousal is considered the 
‘permissive window’ that facilitates RMMA occurrence during sleep rather than a trigger or cause of SB.  
+++ 
Autonomic sympathetic cardiac activity 
A rise in sympathetic cardiac activity precedes the majority onset of the majority of RMMA episodes. This rise is 
also followed by rise in heart rate and blood pressure immediately before the muscular activity of the jaw opening 
and closing muscles.  
+++ 
Neurochemicals 
The potential role of catecholamines (adrenaline, noradrenalin, and dopamine). SB subjects appear to have higher 
urinary levels of catecholamines. The putative role of other neurochemicals: GABA, orexin, serotonin, and 
acetylcholine (all involved in the genesis and maintenance of wake and sleep. As yet unknown roles).  
+ 
Genetic and familial predisposition 
In more than 80% of cases, SB persists from childhood to adulthood. Higher concordance in monozygotic than 
dizygotic twins. Approximately one-third of SB subjects have a direct family member with a positive tooth 
grinding history. 
+ 
Psychosocial factors 
Anxiety and stress are risk factors for SB. Subjects with SB appear to have maladaptive coping strategies and a 
more task-oriented personality than subjects without SB.  
++ 
Exogenous factors 
Alcohol, caffeine, cigarette smoking, illicit drug use (e.g., cocaine, ecstasy), and medication intake (e.g., SSRI) 
can trigger or increase wake-time bruxism and SB activity.  
++ 
Comorbidity 
A common underlying pathogenetic mechanism is suspected, e.g., SB and SDB: does SB play a role in reinstating 
airway patency following an apnea event, or is SB an apnea-related arousal reaction?  
++ 
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sleeping brain to external (environmental) and internal (physiological or pathological) 
stimuli. In the presence of certain sleep disorders, breathing anomalies or chronic pain, 
arousals are more frequent. 
Although sleep is defined as a reversible behavioral state of reduced responsiveness 
to environmental stimuli, the sleeping brain is still active and able to control the autonomic, 
metabolic and hormonal changes that take place within the body. Some cerebral areas 
remain gradually and partially activated and they are able to scan and weight information 
filtered through the thalamocortical pathways, and simultaneously trigger behavioral 
responses to given external stimuli. Such activation is stimulated by the arousal system (57, 
75). The arousal system comprises cholinergic, monaminergic, histaminergic, and 
orexinergic neurons located in the brainstem, which fire at different rate during 
wakefulness, NREM and REM sleep (57, 76). Their activity finely regulates the sleep-wake 
transition and the sleep cycle (57). Sleep arousals can be seen as the body’s attempt to 
prepare the sleeping individual (who is in a low vigilance state) to react to a potential risk, 
i.e., a « fight or flight » state. However a high arousal index (number of arousals per hour of 
sleep) is also a sign of sleep fragmentation, a detrimental alteration of sleep architecture, 
and thus a poor quality of sleep (75).  
The arousal threshold (the probability to elicit an arousal from sleep) changes 
throughout the night. In the wake-to-sleep transition, usually sleep stage N1, the arousal 
threshold is very low and thus sleep can be easily discontinued by environmental stimuli. In 
stage N2 and N3 an incrementally more intense stimulus is required to produce arousal. 
Conversely, the arousal threshold during REM sleep is quite variable throughout the night 
(77, 78). Beside the behavioral state, the arousal response depends also on the nature of 
sensory stimulations (e.g., intensity, modality) (79). 
RMMA episodes are observed predominantly during sleep stages N1 and N2 (light 
sleep), whereas only the 10% of episodes occur during REM sleep (7, 61). Between 70% 
and 88% of RMMA episodes are temporally correlated with an arousal (61, 64), and related 
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autonomic-cardiac activations (See Section 1.5.2). Although the number and index of 
arousal do not generally differ between young otherwise healthy SB subjects and controls, 
experimental evidence suggested that SB subjects may have a higher responsiveness to 
sleep arousal (65). Whether this condition may influence the onset and recurrence of 
RMMA is unclear.  
 
1.6.2.2 The cyclic alternating pattern  
The cyclic alternating pattern (CAP) is a marker of cerebral activity occurring under 
conditions of reduced vigilance (e.g., sleep). CAP is considered the expression of a basic 
arousal modulator, which represents states of sleep instability but also belongs to 
physiological sleep (80-82). Terzano and colleagues have extensively studied the features 
of CAP for 30 years, and they have demonstrated that most of the arousal-related phasic 
events, which can appear either spontaneously or after external perturbation, follow this 
cyclic and rhythmic time organization during NREM sleep (83, 84). CAP is described as 
the structural framework that ties together both sleep-preserving features (low EEG 
frequency, high amplitude bursts) and sleep-disrupting events within 20-40 seconds 
periodicity.  
During NREM sleep, CAP is composed by the alternation of two EEG patterns 
(phase A and phase B) each lasting 2 to 60 seconds. Phase A is considered the active phase 
associated with heightened arousal levels, while phase B corresponds to the periodic 
replacement of the background EEG activities peculiar to the specific NREM sleep stage. 
On the basis of the reciprocal correlations between EEG and polygraphic parameters, it is 
possible to distinguish three types of CAP phase A (of increasing arousal pressure)(85):  
- Phase A1: comprising exclusively synchronized EEG patterns that generally show 
only slight simultaneous variations in muscle tone and autonomic functions. It 
represents the weakest arousal power; 
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- Phase A2: composed of a mixture of slow and fast rhythms. It represents a 
transition phase and fits an intermediate arousal power level; 
- Phase A3: characterized predominantly by EEG desynchronized patterns. It 
corresponds to the most powerful arousal pressure, as it is usually accompanied by 
relevant changes in muscle tone, heart rate and respiratory activity.  
When the interval between 2 consecutive phase A and phase B exceeds 60 seconds, the 
CAP sequence ends and sleep enters the non-CAP (NCAP) mode characterized by stable 
EEG rhythms with very few and randomly distributed arousal-related phasic events (Figure 
1.2). On the basis of the reciprocal occurrence and respective meaning of both CAP 
(marker of unstable sleep) and NCAP (stable and consolidated sleep), it is possible to 
define the sleep variable CAP rate (the ratio of total CAP time over the total NREM sleep 
time) as the measure of arousal instability during sleep (83). CAP rate is enhanced when 
sleep is disturbed by internal or external factors and its variations correlate with the 
subjective appreciation of sleep quality, with higher CAP rate associated with poorer sleep 
quality (82). CAP rate in normal sleepers shows a low intra-individual variability from 
night-to-night, while remarkable age-related differences have been reported. In particular, 
CAP rate was found to be progressively increasing from pre-school age to adolescence, and 
then U-shaped with a minimum in young adults and increasing again in late adulthood and 
elderly (86-88).  
The distribution of CAP has been proven to be different across the sleep cycle. CAP 
sequences normally predominate in close temporal connection with major dynamic events, 
such as falling asleep, sleep stage shift, NREM/REM sleep transitions, nocturnal 
awakenings and body movements. It has been hypothesized that the abundance of A1 
subtypes in the descending phase of the sleep cycle is the EEG expression of the cerebral 
mechanisms involved in the build-up and maintenance of deep NREM sleep, whereas 
subtypes A2 and A3 are predominant in the period preceding the onset of REM sleep 
(ascending phase) and may express the subject’s arousability (89). This hypothesis is also 
supported by the topographic distribution of CAP A phases. Indeed, the A1 activity is 
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thought to be generated primarily by the frontal lobes where also slow waves are 
predominantly detected, whereas CAP A2 and A3 activity is thought to be generated by the 
posterior brain regions (90). 
 
 
Figure 1.2 Schematic representation of cyclic alternating pattern (CAP).  
 
 
 
1a. Histogram of physiological sleep in which CAP sequence (comb-like oscillation) and 
NCAP sequence (horizontal stretches) are outlined. 1b. A specimen of sleep stage 2 is 
expanded to highlight the sequence of 4 CAP cycles (phase A + phase B) framed between 
portion of NCAP. (From Parrino et al. 1996, J Clin Neurophysiol)(91). 
W, wakefulness; SREM, REM sleep; S1, S2, S3, S4, NREM sleep stages. 
 
 
 
1a
. 
1b 
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CAP and arousals are considered active adaptive responses of the sleep regulatory 
mechanisms, which tend to remove the stimulus-disturbance effect and re-establish an 
internal equilibrium. The total amount of CAP can be seen as the effort to maintain sleep at 
the microstructural level. While a limited amount of CAP is considered physiological, 
larger quantities reflect the brain difficulties to consolidate and preserve sleep and they may 
be associated with detrimental effects. The arousal system plays a cardinal 
neurophysiologic role in protecting and tailoring sleep duration and depth. CAP oscillation 
participates in the dynamic organization of sleep. Physiologic, paraphysiologic and 
pathologic motor activities during NREM sleep are associated with a stereotyped arousal 
pattern characterized by an initial increase in EEG delta power and heart rate, followed by a 
progressive activation of faster EEG frequencies (91-93).  
In this perspective, there is evidence that supports the hypothesis that the frequency 
of RMMA episodes is modulated by the cyclic occurrence of sleep arousals, i.e. CAP (60, 
61, 64). As previously mentioned, RMMA episodes are more frequently observed in 
NREM sleep stages 1 and 2 (light sleep), in sleep stage shifts, and especially in the 
transition period from non-REM to REM sleep (64). Over 80% of RMMA episodes are 
time-correlated with CAP phase A, and they recur in rhythmic clusters, with a periodicity 
of 20 to 30 seconds, which is similar to the physiological arousal rhythm of CAP.  
Notwithstanding this association between sleep arousal and the occurrence of SB, 
the role of CAP and sleep instability in the pathogenesis of RMMA remains to be 
elucidated.  
 
1.6.3 Autonomic Sympathetic-Cardiac Activity 
Recent evidence on SB pathophysiology highlights the role of the autonomic 
nervous system (60, 64, 94). It has been well demonstrated that RMMA onset is associated 
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with a sequence of physiological events that occur within a sleep arousal. Briefly, the 
genesis of most RMMA episodes is preceded by the following cascade of events (7):  
- A rise in the autonomic sympathetic-cardiac activity with a concomitant withdrawal of 
parasympathetic influences (from 8 to 4 minutes before RMMA onset)(64) 
- The appearance of rapid-frequency EEG cortical activity (sleep arousal; approximately 4 
seconds before RMMA onset)(60)  
- A rise in heart rate of about 25% (beginning 1 second before RMMA onset), 
concomitant with  
- An increase in jaw opener muscle tone (the suprahyoid muscle, probably responsible for 
mandible protrusion and airway opening), concomitant with  
- An increase in the amplitude of the respiratory effort (nasal airflow)(69), preceding or 
concomitant with  
- A rise in diastolic and systolic blood pressure (95) 
- And finally, an observable EMG incident in the jaw-closing muscles (masseter and 
temporalis), scored as RMMA with or without tooth-grinding sounds (7).  
Almost 60% of RMMA episodes are followed in the 5 to 15 seconds after onset by 
swallowing (96) (Figure 1.3). 
 
The activity of autonomic nervous system is physiologically modulated during sleep 
(97, 98). NREM sleep is characterized by a period of relative autonomic stability, with a 
vagal nerve dominance and sinusoidal modulation of heart rate variation due to a coupling 
with respiratory activity. Hypotension, bradycardia, and reduction of cardiac input are also 
progressively observed with deepening stages of NREM sleep. Conversely, during REM 
sleep the brain’s increased excitability can result in major surges in cardiac sympathetic 
nerve activity, striking fluctuations of blood pressure and heart rate, and marked episodes 
of tachycardia and bradycardia (97). Finally, as describe above, significant autonomic 
changes (approximately 90% increase in sympathetic activity and 35% decrease in 
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parasympathetic activity)(99) accompany electrocortical arousals from sleep as well as 
periodic movements during sleep (64, 95, 98).  
The autonomic nervous system activity can be non-invasively assessed by analyzing 
the heart rate variability during both wakefulness and sleep (100). Power spectral analysis 
of heart rate can then be evaluated as low frequency (LF: 0.04-0.15 Hz) and high frequency 
(HF: 0.15-0.5 Hz) ranges of modulation, reflecting the sympathetic+parasympathetic, and 
parasympathetic activities respectively. By calculating the LF/HF ratio, an index of 
sympathovagal balance can be obtained (100, 101). It has been reported that SB subjects 
have higher LF power and higher LF/HF ratio during wake compared to healthy controls, 
supporting that heart rate variability in SB subjects might be altered toward an increase in 
sympathetic activity also during wakefulness (94). This hypothesis was already suggested 
by the observation of phenomena like peripheral vasoconstriction, tachycardia and skin 
potential changes during tooth-grinding events, which might be a consequence of increased 
sympathetic activity (67). However, the power spectral analysis of heart rate variability 
during sleep showed no difference between SB subjects and controls for LF and HF 
powers, neither for the sympathovagal balance, even though a rise in sympathetic cardiac 
activity is registered in the minutes preceding RMMA episodes (64).  
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Figure 1.3 Genesis of an RMMA episode (schematic representation of the cascade of 
physiologic events that precedes RMMA onset)  
 
 
 
EEG: electroencephalogram; ECG: electrocardiogram; SH: EMG of the suprahyoid 
muscle; BP: blood pressure; Mas-R and Mas-L: EMG of the right and left masseter 
muscles; LM: laryngeal movements.  
(Lavigne G., Huynh N. based on (60, 64-66, 69)). 
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1.6.4 Neurochemicals 
Many neurochemicals and neurotransmitters may be involved in the genesis and 
modulation of jaw movements during sleep, especially those that participate in controlling 
motoneuron activity and regulating sleep and wake states (acetylcholine, noradrenalin, 
dopamine, orexin) (51, 57). The dopaminergic system was first investigated after the early 
observation of tooth-grinding activity in a patient with Parkinson’s disease treated with L-
dopa (102). However, further studies using dopamine precursor L-dopa and domaninergic 
agonist bromocriptine demonstrated only a modest effect on SB (103-105). Dopamine is 
not usually very active during sleep, but it may be linked to sleep arousal re-activation 
(106). Conversely, clonidine, an adrenergic agonist, reduced RMMA episodes by 60%, 
supporting the role of sympathetic cardiac activation, adrenaline, and noradrenalin in the 
genesis of RMMA (64). Because noradrenergic action is critical during non-REM sleep in 
the minutes preceding REM sleep onset, it may participate in the transition from NREM to 
REM sleep, a state associated with muscle hypotonia (107). 
Other neurotransmitters, such as serotonin, gamma-aminobutyric acid (GABA), 
cholecystokinin, and orexin, may have a role in modulating RMMA during sleep. Ionic 
channels, receptors, and their cellular expression may be also involved in SB genesis. 
However, either data are not yet available or the findings are supported by indirect evidence 
only, derived from case reports on drug and medication use. Prospective and randomized 
control experimental trials are needed before firm conclusions can be drawn on 
neurochemical participation in SB genesis.  
 
1.6.5 Genetic Factors 
There is evidence for a genetic predisposition for SB. Children of SB subjects are 
more likely to be affected than children of individuals who never had SB or who suffer 
from wake-time bruxism only (108). From 20% to 50% of SB subjects have a direct family 
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member who ground his or her teeth in childhood, and childhood SB persists in adulthood 
in 87% of subjects (70, 109). In a Finnish twin cohort study, higher concordance was found 
among monozygotic than dizygotic twins (68, 109).  
Despite this early evidence of a genetic basis for SB, the inheritance pattern remains 
unknown, and no genetic marker has been identified to date. Further research on 
population-based samples is needed to explore and delineate the probable genetic 
component in SB genesis. It would be more likely related to genetic polymorphism than a 
single gene mechanism. Moreover, links to other wake and sleep behaviors would probably 
emerge (110, 111). It is worth noting that SB assessment tools in large populations—
frequently based on a positive history of tooth grinding alone—have yet to be validated for 
acceptable sensitivity and specificity, especially in the general population. A clinical 
diagnosis of SB supported with portable systems or single-channel EMG recording is 
feasible and promising, but still lacking in specificity. 
 
1.6.6 Psychosocial Factors: Stress, Anxiety, and Behavior  
Aside from a probable genetic predisposition, many other causal or risk factors may 
play a role in the genesis of SB activity. Psychosocial components in particular, such as 
anxiety and stress, have frequently been associated with SB (32, 72, 73, 112-114). Both 
child and adult subjects reporting SB were found to have higher levels of urinary 
catecholamines (adrenaline, noradrenaline, dopamine) than controls (115-117). These 
results were attributed to stress factors that activate the hypothalamic-adrenal axis, which 
controls the catecholamine release. Other studies, mainly questionnaire-based, suggest that 
SB subjects may have maladaptive coping strategies: they appear to be more anxious, 
stressed, and task-oriented as a result of their personality and coping style (e.g., type A 
personality)(32, 73, 112, 113, 118, 119). Especially in children, SB has been associated 
with behavioral habits and complaints. These include neuroticism, perfectionism, 
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aggressiveness, lack of concentration and attention (e.g., at school), thought disorders, 
antisocial behaviors, and conduct disorders (120-122). Moreover, all these psychosocial 
factors may be also related to wake-time bruxism. In fact, tooth clenching may be an 
adaptive or reactive learning behavior—to cope with stress, anxiety, and social life—that 
may also occur during sleep. However, the overlapping and interactions between wake-time 
and sleep-time bruxism are still matters of debate. 
Alternatively, SB has been considered a tic, an automatism, a movement fragment, 
or tardive dyskinesia, which may manifest during wake-time and persist during sleep (123). 
In any case, the many and contrasting findings in the literature indicate that further research 
is needed to better understand the role of psychosocial factors in SB pathophysiology (72).  
 
1.6.7 Exogenous Factors and Comorbidities 
Several exogenous factors and medical conditions have been associated with SB or 
bruxism-like activities during either sleep or wake-time. The exogenous risk factors for SB 
include alcohol consumption, cigarette smoking, caffeine intake, medication use (e.g., 
SSRI), and drug use (e.g., ecstasy)(32, 71, 124-133). Sensory stimulations, experimentally 
applied or naturally occurring during sleep, may also influence SB occurrence. However, 
this effect seems to be indirect: it has been shown that sensory perturbing stimuli (e.g., 
vibratory and auditory) can induce arousals from sleep, and therefore increase the chance of 
RMMA occurrence (65, 79). Nociceptive stimuli as well interfere with sleep continuity and 
trigger fluctuation in the autonomic nervous system (134, 135). However, the effects of 
pain stimulations delivered during sleep in SB subjects are unknown. 
SB may also be observed in comorbidity with medical disorders such as attention 
deficit hyperactivity disorder (ADHD)(136, 137), movement disorders (e.g., Parkinson’s 
disease and Huntington’s disease)(138, 139), dementia (140-142), epilepsy (143-145), 
gastroesophageal reflux (96), and other sleep disorders such as parasomnias (e.g., sleep 
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walking, sleep talking, enuresis, REM sleep behavior disorder), periodic limb movements, 
restless leg syndrome (RLS), and sleep-disordered breathing (SDB) (Table 1.5)(74, 146-
149). It remains to be assessed, however, whether these are cases of intersecting prevalence 
between two parallel disorders or if one condition causes or exacerbates the other (150).  
In the past, SB was considered a consequences of occlusal interferences, 
malocclusion and tooth pre-contacts, which were advocated as the major causes and risk 
factors for the development of this oral parafunction during sleep. There is little scientific 
evidence, however, to support a predominant role for peripheral factors, such as occlusal 
interferences, in the etiology of SB (53, 151, 152).  
When SB is associated with medication or drug intake or with medical diseases, it is 
defined as secondary or iatrogenic SB. Conversely, in the absence of medical causes, SB is 
considered to be primary, or idiopathic, and it can in turn lead to several clinical 
consequences on the stomatognatic system, such as tooth wear, tooth damage, tooth 
fractures, muscle fatigue, orofacial pain, temporomandibular disorders (TMD), and 
headache (7).  
 
1.6.7.1 Sleep bruxism, orofacial pain, and temporomandibular disorders 
Orofacial pain is reported by 66% to 84% of SB subjects (153, 154). However, the 
presence or intensity of pain does not appear to be directly correlated with the frequency of 
RMMA episodes (26, 155, 156). In fact, SB subjects with low frequency of RMMA (2–4 
episodes/h of sleep) appear to have higher risks for orofacial pain and headache than SB 
subjects with high frequency of RMMA (>4 episodes/h of sleep)(26, 157). Furthermore, 
note that SB may coexist with wake-time tooth clenching and other oral parafunctions (e.g., 
lip, cheek, or nail biting), which can also cause or contribute to the development and 
persistence of orofacial pain (158-163).  
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SB has been largely considered a sign and/or cause of TMD in both adult and 
pediatric populations (164-169). Several studies suggest that SB may play a role in TMD 
genesis—especially the myogenous component—due to muscle hyperactivity during sleep. 
Nevertheless, TMD pain and morning jaw muscle pain may be different entities. Most 
patients with TMD report a pain intensity peak in the late afternoon, whereas SB subjects 
report transient masseter and temporalis muscle pain or soreness mainly in the morning (26, 
170, 171). The association between SB and TMD needs to be further elucidated (172).  
 
Table 1.5 Sleep bruxism and comorbidities.  
 
(Carra MC. based on (26, 96, 136-138, 143, 144, 149, 153, 156, 173, 174)). 
Sleep bruxism and comorbidities 
Parasomnias 
Enuresis 
Sleep talking 
Sleep walking 
REM sleep behavior disorder (RBD) 
Other sleep-related disorders 
Sleep-disordered breathing (snoring, obstructive sleep apnea) 
Sleep-related epilepsy  
Periodic limb movements (PLM) and restless legs syndrome (RLS) 
Sleep-related gastroesophageal reflux 
Medical and psychological conditions 
Hypertrophic tonsils and/or adenoids 
Allergies 
Attention deficit hyperactivity disorder (ADHD) 
Headaches 
Orofacial pain and temporomandibular disorders (TMD) 
Stress and anxiety 
Neurological and psychiatric disorders (e.g., dementia; depression)  
Movement disorders (e.g., Parkinson’s disease; oralmandibular dystonia; tics) 
Oral habits and parafunctions 
Tics 
Nail biting, pen biting, etc 
Wake-time tooth clenching 
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1.6.7.2 Sleep bruxism and headaches  
SB has been frequently associated with headaches (148, 174-179). From 30% to 
50% of adult SB subjects complain of headache either in the morning (most frequently) or 
during the day (176). However, the exact mechanism underlying the possible interactions 
between SB and headaches remains unknown. It can be hypothesized that SB, which is 
characterized by repetitive rhythmic and sustained contractions of the masticatory muscles 
during sleep, may cause tension-type headaches during daytime. In fact, this comorbidity is 
controversial due to the overlap with forms of TMD pain and TMD-related headaches (180, 
181). Furthermore, the presence of an underlying sleep disorder, such as sleep-disordered 
breathing (SDB), has often been associated with both SB and headache. In this latter case, 
the role of intermittent hypoxia and hypercapnia and sleep fragmentation (subsequent to 
obstructive respiratory events) may be the actual cause of the headaches (Figure 1.4). 
Alternatively, SB, headache, and SDB may share common risk factors or 
pathophysiological substrates without a specific cause-and-effect relationship. For example, 
it has been shown that children with headaches frequently have concomitant sleep 
problems, such as SB and SDB, and a higher incidence of TMD (182, 183).  
 
1.6.7.3 Sleep bruxism and sleep-disordered breathing  
Although SB and SDB (e.g., upper airway resistance, obstructive sleep apnea, and 
central sleep apnea) have frequently been associated, the possible cause-and-effect 
relationship has not yet been elucidated (32, 184-186). Two clinical open studies and one 
case report have provided indirect evidence for this relationship by showing a decrease in 
SB after different SDB treatments (e.g., adenotonsillectomy and continuous positive airway 
pressure)(187-189). These findings support the hypothesis that RMMA may be an 
oromotor activity that helps reinstate airway patency following an obstructive respiratory 
event during sleep (69). An alternative hypothesis considers RMMA a physiological motor 
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event that is required to lubricate the oropharyngeal structures during sleep, a period when 
salivary flow and swallowing rate are normally reduced (96, 190). The factors that induce 
RMMA to reach abnormal frequency in SB subjects remain to be elucidated.  
 
Figure 1.4 Comorbid sleep bruxism, headache, and sleep-disordered breathing: 
putative mechanisms.  
 
RMMA: rhythmic masticatory muscle activity.  
(Carra MC.) 
 
 
1.7 Sleep Bruxism and Sleep Quality 
Sleep quality can be objectively and subjectively assessed by using respectively 
PSG recordings or self-report questionnaire. In general, healthy individuals with SB show 
and report a good sleep quality. 
SB may be noticed in children, usually by the child parents, once the teeth erupt. 
The frequency of RMMA may largely vary during childhood and adolescence, and 
frequently persisting toward adulthood (7). Generally, children and adolescents do not 
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report disrupted sleep because of SB, rather they may present modifications of the normal 
sleep architecture related to growth or associated medical or sleep disorders.  
It is known that in children and adolescents slow wave sleep (i.e., deep NREM 
sleep) is largely represented, while drastically decreases (-40-60%) by the age of 20 years 
old (191-194). This decline appears to be related more to chronological age than to the 
pubertal maturation (195), although it cannot be excluded that common neuronal and 
hormonal triggers might underlie these two phenomena. In both pre-pubertal children and 
adolescents, as in adults, slow wave activity (SWA) follows the homeostatic decline across 
successive NREM sleep episodes (196). The occurrence of SB does not seem to influence 
this parameter (64). During adolescence, sleep is also characterized by an increased 
proportion of stage 2, a reduction of total sleep time and a phase delay of the sleep-wake 
cycle (194, 197, 198). These modifications are not only a consequence of psychosocial, 
life-style and environmental factors that typically accompany adolescence, but they are also 
attributed to maturational processes in the biologic, circadian and homeostatic regulation of 
sleep that occur during adolescence (199, 200). Whether these natural changes in sleep 
physiology may influence the occurrence of RMMA remains unknown and definitely 
deserves further investigation. Moreover, the microstructure of sleep in children with SB 
has rarely been evaluated. This analysis may give clues on the objective quality of sleep 
and the actual influence of this motor disorder on childhood and adolescence sleep.  
SB, however, may be concomitant with other medical conditions, which in turn can 
influence sleep quality and structure. During childhood, SB has been frequently observed in 
association with chronic respiratory problems, allergy, gastroesophageal reflux, ADHD, 
night terrors, somnambulism, parasomnias, and sleep disordered breathing (201, 202). In 
these cases, sleep quality may be drastically worsened, and diagnostic and treatment 
consultations are necessary.   
Young adult SB subjects generally display normal sleep architecture in terms of 
total sleep time, sleep latency, sleep efficiency and percentage of sleep stage distribution 
(15, 61, 64). Most RMMA episodes occur during light NREM sleep and occasionally 
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during REM sleep, without disturbing the regular succession of sleep cycles. The main 
sleep parameters used to quantify the level of sleep disruption, such as SWA, sleep stage 
shift, and sleep arousal index (number of sleep arousal/h of sleep), are generally in the 
normal ranges and do not differ from control subjects (12, 15, 61, 64, 65). Conversely, 
differences have been observed at the micro-structural level of sleep, i.e., CAP. SB subjects 
have higher number of CAP phase A3, associated with the most powerful activation of 
muscle tone and autonomic cardiac activity (61). However, it must be mentioned that the 
majority of PSG studies on the pathophysiology of SB have been conducted on young and 
otherwise healthy SB subjects, which did not have any additional medical or sleep 
disorders. Sleep parameters may be different in older SB subjects with concomitant sleep 
disorders, such as insomnia, restless leg syndrome, sleep disordered breathing, or medical 
problems, such as pain syndromes.   
In absence of pain, SB subjects generally report a good quality of sleep, and they are 
not disturbed by the tooth-grinding activity (7). On the contrary, the bed-partner frequently 
complains for the annoying noises that are produced by tooth contacts during RMMA. 
Indeed, this usually represents the chief complaint that drives SB subjects to have a medical 
consultation for treatment.  
 
 
1.8 Management of Sleep Bruxism  
No therapy to date has been proven effective to cure SB. The available treatment 
approaches aim at managing and preventing the harmful consequences of SB to the 
orofacial structures (Table 1.6) (203, 204). 
 
  
 
36
1.8.1 Behavioral Strategies 
SB can be managed by behavioral strategies, including the avoidance of SB risk 
factors and triggers (e.g., consumption of tobacco, alcohol, caffeine, and drugs), patient 
education (e.g., control of wake-time oral parafunctions), relaxation techniques, sleep 
hygiene, hypnotherapy, biofeedback, and cognitive behavioral therapy (205-209). 
However, the majority of these strategies have not been adequately tested in controlled 
trials. Nevertheless, a recent study showed that a new biofeedback device that applies 
electrical pulses to inhibit EMG activity in the temporalis muscle was effective in the short 
term in reducing EMG activity during sleep, without disrupting sleep quality (205, 210). In 
addition, a 12-week cognitive behavioral therapy (CBT) session with SB subjects was 
found to reduce SB, but showed no significant benefits over occlusal splint therapy (207). 
Although these behavioral techniques have not yet shown clear or persistent effects, they 
appear to improve the patient’s well-being, and should be considered the first-line 
management approach in SB subjects.  
 
1.8.2 Oral Appliances 
In order to protect dental surfaces and relax the masticatory muscles, occlusal 
splints, either on the maxillary or the mandibular arch, have been extensively used in 
clinical practice. However, the exact mechanism of action is still under debate, and there is 
no evidence to support their role in halting SB. Moreover, the lack of well-designed 
randomized controlled clinical trials and long-term studies in the literature makes it difficult 
to assess their effectiveness (211). The majority of studies show a decrease (40%–50%) in 
the RMMA index in the first period of treatment (2–6 weeks), regardless of the type of 
occlusal splint (i.e., covering the occlusal teeth surfaces or just the palate)(29, 212-214). 
However, the effect appears to be transitory, with values returning to baseline after a short 
time, and the outcomes are highly variable between subjects. Moreover, it has been 
  
 
37
reported that approximately 20% of SB subjects show increased EMG activity during sleep 
when wearing an occlusal splint, especially the soft mouth guard type (215, 216). A 
placebo effect, related to the behavioral intervention of the doctor toward the patient, can be 
also advocated to explain the transitory benefit that occlusal and palatal splints appear to 
have in SB subjects.  
 
Table 1.6 Management of sleep bruxism.  
 
*Only in long-term treatment 
NTI: Nociceptive trigeminal inhibition system; OSA: obstructive sleep apnea; TMJ: 
temporomandibular joint; CNS: central nervous system. 
(Carra MC. based on (7)). 
 
Management of sleep bruxism  
Clinical approach Functions Potential side effects 
Behavioural strategies 
Patient education, sleep hygiene, relaxation 
techniques, hypnotherapy, biofeedback, and 
cognitive behavioral therapy  
•! Avoid SB risk factors (e.g., smoking, 
alcohol, caffeine, drugs) 
•! Control wake-time oral parafunctions 
•! Improve sleep habits and sleep 
environment 
•! Control and reduce stress and anxiety 
(coping) 
•! Relax muscles and reduce EMG 
activity during sleep 
None identified to date 
Intraoral appliances  
•! Occlusal or stabilization splint  
•! NTI 
•! Mandibular advancement appliances 
(commonly used for snoring and mild to 
moderate OSA) 
•! Protect tooth surfaces 
•! Reduce EMG activity (?) 
•! Reposition and stabilize the lower jaw, 
tongue, and soft tissues 
•! Open the upper airway space 
•! Impaired occlusion* 
•! Increased SB activity 
•! Posterior dental overeruption or anterior 
dental intrusion (for NTI)* 
•! Excessive salivation or dry mouth 
•! Tenderness in the teeth, TMJ, muscles  
•! Perception of abnormal occlusion in the 
morning  
•! Occlusal changes (e.g., reduced overjet 
and overbite)* 
Pharmacotherapy 
(recommended in the short-term only) 
•! Reduce SB activity + extra effects 
related to the kind of medication used 
(e.g., hypnotic, analgesic) 
•! Depends on the medication used: 
- Clonazepam: tolerance, physiologic 
dependence, fatigue, somnolence 
- Clonidine: hypotension 
- Botulinum toxin: risk of retrograde 
transportation from the site of injection to 
CNS with systemic side effects 
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Occlusal and anterior tooth appliances (e.g., the nociceptice trigeminal inhibition 
system, NTI) are also used in cases of SB comorbid with orofacial pain and TMD in order 
to relief muscle and joint pain (217-221). Their effectiveness is still controversial, as they 
rarely halt RMMA occurrence (222). However, it has been hypothesized that these devices 
may make patients more conscious of their oral parafunctional habits by altering 
proprioceptive inputs, thus helping them reduce clenching activity, albeit mainly during 
wake-time (223, 224). TMD patients appear to find relief with occlusal splints compared to 
other or no treatment, especially the most severe cases with TMD pain (225). 
Physiotherapy sessions targeting the masticatory muscles may also be useful in cases of SB 
associated with orofacial pain and/or TMD (226, 227). 
It is worth mentioning that occlusal appliances and anterior tooth splints are not free 
of unwanted side effects, including changes in dental occlusion, single tooth positioning, 
dental hypersensitiveness, and worsening of orofacial pain and SDB (228). For example, in 
a pilot study in 10 patients with obstructive sleep apnea (OSA), a maxillary occlusal splint 
was found to increase the hypopnea/apnea index (AHI) in half the subjects, probably by 
reducing the intraoral space for the tongue, which changes the tongue position during sleep 
(228). When SB is concomitant with OSA, or when SDB are suspected, a mandibular 
occlusal splint—custom-made for the lower jaw—or a mandibular advancement appliance 
would be preferable. 
Mandibular advancement appliances (MAA), which are currently used to treat 
snoring and mild to moderate forms of OSA, have also been tested in the short term to 
challenge the role of the airways in the genesis of RMMA episodes and to assess 
therapeutic benefits in SB patients. These oral devices are generally custom-made double 
arch appliances designed to retain or protrude the mandible in order to enlarge the upper 
airway space. An MAA was demonstrated effective in decreasing SB (up to 70%), 
especially when worn in advanced positions (50%–75% of the maximum protrusion) (229, 
230). They also appear to relieve daily morning headaches in patients with low frequency 
of RMMA during sleep (231). The possible mechanisms of action, which may explain the 
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reduction of RMMA with the MAA, include: dimension and configuration of the appliance, 
restriction of jaw movements, presence of pain, or change in airway space and breathing 
during sleep. Although the use of an MAA for SB showed good effectiveness (203), all 
these studies assessed the effect after short-term treatment only (2 weeks average). It 
remains to assess their effectiveness and side effects in long-term studies (232, 233).  
 
1.8.3 Pharmacotherapy 
Several medications and drugs have been associated with decreased or increased SB 
activity, supporting the probability of central mechanisms for SB genesis (Table 1.7) (124). 
In particular, the dopaminergic, serotoninergic, and adrenergic systems are thought to be 
involved in this orofacial motor activity. However, evidence is lacking on both the 
effectiveness and safety of using medications in SB subjects. Therefore, in symptomatic 
and most severe patients, pharmacological treatments should be considered as a short-term 
therapy only (7). 
A recent placebo-controlled study demonstrated a 40% reduction in SB activity with 
an acute dose of clonazepam (1 mg)(234, 235). Clonazepam is a benzodiazepine with 
hypnotic, anxiolytic, anticonvulsive, and myorelaxing effects. It acts at various levels of the 
central nervous system. The beneficial effect on SB genesis may result from actions on 
different systems linked to muscle activity, emotions, and behaviors. However, there is no 
available data on long-term treatment or potential side effects such as sleepiness (risk of 
transportation or work-related accidents), pharmaco-behavioral tolerance, and dependence. 
Antidepressant drugs have also been recommended for SB, as well as for chronic 
orofacial pain. However, there is little evidence to support their use. Low doses of 
amitriptyline (a tricyclic antidepressant) were found to be ineffective against SB (236, 237), 
and SSRI medications (e.g., fluexetine, sertraline, paroxetine) actually increased tooth-
grinding and clenching (130, 238, 239). 
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Adrenergic beta-blockers such as propranolol were shown to be ineffective on SB 
(240). Conversely, an acute dose (0.3 mg) of the alpha2-adrenergic agonist clonidine 
reduced SB by 60%, supporting the role of autonomic cardiac activation in the genesis of 
this sleep-related motor disorder. However, clonidine is associated with sleep structure 
changes (e.g., less REM sleep) and severe morning hypotension (240). Its use for SB 
therapy is highly controversial.  
Anecdotal reports suggest a positive effect on SB of gabapentin (241), tiagabine 
(242), buspirone (243), topiramate (244), and botulinum toxin (245, 246). However, their 
effectiveness and safety need to be assessed in randomized controlled clinical trials. 
Potential candidates for more specific or more potent medications are substances that 
regulate the wake–sleep balance (e.g., acetylcholine, noradrenaline, dopamine, orexin, 
histamine, serotonin), ionic channels, and cellular receptors (on neurons and glia). 
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Table 1.7 Effect of medications and chemical substances on sleep bruxism and SB-like 
activities.  
 
*The scientific evidence is based primarily on case reports (except for two randomized 
controlled clinical trials with PSG (235, 240)). No long-term studies have assessed safety 
or benefits. 
(Carra MC. based on (104, 124-126, 132, 234, 235, 238, 240, 241, 244, 246-248)). 
 
Effect of medications and chemical substances on sleep bruxism (SB) or SB-like activity* 
Increased SB activity •! SSRI (e.g., paroxetine, fluoxetine, sertraline) 
•! NSRI (e.g., venlafaxine) 
•! Antipsychotic (e.g., haloperidol)  
•! Flunarizine  
•! Amphetamines (e.g., methylphenidate) 
•! MDMA (ecstasy)  
•! Cocaine 
•! Caffeine 
•! Nicotine  
•! Alcohol 
Decreased SB activity •! Clonazepam  
•! Diazepam  
•! Methacarbamol 
•! Buspirone 
•! Levodopa  
•! Pergolide 
•! Clonidine  
•! Gabapentin  
•! Topiramate  
•! Botulinum toxin  
No effect on SB activity Propranolol, Bromocriptine, L-Tryptophan 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 2: Thesis Objectives and Hypotheses 
  
 Sleep bruxism is a sleep disorder in which both clinicians and researchers show 
great interest. Only in the last 10 years, more than 250 scientific articles have been 
published in the English literature. This great interest is probably driven by the several 
clinical consequences that are associated with SB, such as orofacial pain, TMD, headache, 
tooth wear, and failing dental restorative treatments. However, a considerable attention is 
also reserved to research the etiology of this spontaneous rhythmic masticatory muscle 
activity (RMMA) that occurs apparently unpurposely during sleep. Recent hypotheses 
suggested a possible role in lubricating the oropharynx and reinstating the upper airway 
patency during sleep.  
Despite the large amount of available literature, it remains difficult to establish a 
valid and accurate diagnosis of SB (except for the use of in lab audio-video PSG) and to 
manage this condition in an effective and reliable way. Indeed, it is still a matter of debate 
the distinction between wake-time and sleep bruxism, the etiologic role of central vs. 
peripheral factors, and the nature of the association between SB and other comorbid 
conditions (e.g., sleep disordered-breathing). All these open questions on the genesis of 
RMMA make arduous to support evidence-based treatments.  
The objectives of the present thesis were i) to elucidate the pathogenesis of RMMA 
in relation to sleep arousal fluctuation, and ii) to investigate the clinical perspectives of SB 
in association with other orofacial, sleep and behavioral complaints. All these conditions 
should be considered and addressed in SB assessment and management.  
 
 
 
 
 
2.1 Objectives 
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2.2 Hypotheses 
The present thesis is built on two distinct although related hypotheses, covering the 
etiology and physiology of RMMA (Section 2.2.1), and the SB-related clinical aspects 
(Section 2.2.2).  
 
2.2.1 First Hypothesis 
The first hypothesis concerns the relationship between RMMA and sleep arousal. 
Since the early work of Satoh and Harada in 1971 (63), “tooth-grinding” during sleep has 
been suggested as an arousal reaction, the consequence of an arousal-related reactivation of 
the sympathetic nervous system, and the final outcome of a cascade of physiological events 
that naturally occur within an arousal (60, 61, 63, 64, 66, 67). However, many questions are 
still unanswered: 
- Is there a cause-effect relationship between sleep arousal and RMMA? Is sleep 
arousal fluctuation the trigger or the cause of rhythmic masticatory movements 
during sleep in SB subjects?  
- What is the role of sleep instability on RMMA occurrence?  
- Is the cyclic arousal fluctuation, described as cyclic alternating patter (CAP), the 
pacemaker of the RMMA episodes during sleep?   
- Do the responsiveness to sleep arousal in SB subjects differ from control subjects? 
The hypothesis is that RMMA occurrence is influenced and paced by arousal fluctuations 
that occur in period of sleep instability.  
The first two research articles included in Chapter 3 aimed to investigate this hypothesis 
and attempted to answer the aforementioned questions (Sections 3.1 and 3.2). 
 
 
  
 
45
2.2.2 Second Hypothesis 
The second hypothesis is related to SB and its frequent association with other sleep 
disorders and medical conditions (26, 32, 74, 175, 179, 184, 249-251). However, these 
associations are mainly supported by indirect evidence, which need further investigations. 
In particular:  
- Are SB subjects more at risk of having, headache, orofacial pain, sleep disorders 
(e.g., SDB), and behavioral problems?  
- What is the role of breathing and breathing abnormalities in the genesis of RMMA? 
Is there a cause-effect relationship?  
- From the clinical perspective, if SB is concomitant with other sleep disorders (e.g., 
snoring or sleep apnea) and/or it is manifest with clinical symptoms, such as 
headache, is there a treatment that, by addressing the underlying conditions, will be 
of benefits for all comorbid disorders? 
The hypothesis is that SB and certain comorbidities may share common underlying 
pathogenetic mechanisms, which may occur during sleep.  In particular, we hypothesized 
that breathing anomalies may lead to arousal and increased sleep instability; concomitant 
RMMA episodes may occur as part of the reaction mechanisms that help to reinstate the 
upper airway patency. In this perspective, HA complaints, frequently associated with both 
SB and SDB, may be the consequence of the repetitive rhythmic and sustained contractions 
of the masticatory muscles during sleep, or the result of the intermittent hypoxia and sleep 
fragmentation, which follow the obstructive respiratory events (See Figure 1.4, page 28).  
The last two research articles included in Chapter 3 were designed to investigate the 
association and risk factors of sleep bruxism with comorbid conditions (Section 3.3), and to 
test the effectiveness of a mandibular advancement appliance in adolescents reporting SB, 
snoring, and headache (Section 3.4).  
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2.3 Materials and Methods 
As described above, the present thesis is divided into two sections related to two 
different hypotheses: i) focused on the pathophysiologic mechanisms that may explain the 
genesis of RMMA episodes during sleep; ii) focused on the clinical aspects related to the 
disorder, sleep bruxism.  Four research articles have been included to support this work.  
i. The first hypothesis was tested by quantitatively assessing EEG spectral activity, CAP 
variables and time correlation between RMMA and sleep arousal in two different 
studies in which sleep was experimentally disturbed by:  
- The administration of a single dose of clonidine, a cardio-active medication 
known to reduce sympathetic nervous system activity (Section 3.1);  
- The application of repeated sensory stimulations while the subjects was 
asleep (Section 3.2).  
ii. The second hypothesis was investigated in: 
-  A population-based survey on the prevalence and risk factors of wake-time 
and sleep-related bruxism conducted in a pediatric population seeking 
orthodontic treatments (Section 3.3); 
-  An experimental trial using a mandibular advancement appliance in sixteen 
adolescents reporting concomitant SB, snoring, and headache (Section 3.4).  
 
Detailed information on the methods applied can be found in the specific “Materials and 
Methods” section of each research article (Chapter 3).  
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Chapter 3: Research Articles  
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3.1 First article: “Clonidine Has a Paradoxical Effect on 
Cyclic Arousal and Sleep Bruxism during NREM Sleep” 
 
 
Maria Clotilde Carra, DMD1,2; Guido M. Macaluso, MD, DDS, MDS3; Pierre H. Rompré, 
MSc1; Nelly Huynh, PhD1,2; Liborio Parrino, MD4; Mario Giovanni Terzano, MD4; Gilles 
J. Lavigne, DMD, PhD, FRCD1,2 
 
1 Facultés de Médicine Dentaire, Université de Montréal, Québec, Canada;  
2 Centre d'étude du Sommeil et des Rythmes Biologiques, Hôpital du Sacré-Cœur de 
Montréal, Québec, Canada;  
3 Sezione di Odontostomatologia, Università degli Studi di Parma, Parma, Italy;  
4 Centro di Medicina del Sonno, Dipartimento di Neuroscienze, Università degli Studi di 
Parma, Parma, Italy 
 
 
Published in SLEEP, 2010, Dec 1;33(12):1711-1716. 
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Abstract 
Study Objective: Clonidine disrupts the NREM/REM sleep cycle and reduces the 
incidence of rhythmic masticatory muscle activity (RMMA) characteristic of sleep bruxism 
(SB). RMMA/SB is associated with brief and transient sleep arousals. This study 
investigates the effect of clonidine on the cyclic alternating pattern (CAP) in order to 
explore the role of cyclic arousal fluctuation in RMMA/SB.  
Design: Polysomnographic recordings from a pharmacological study.  
Setting: University sleep research laboratory.  
Participants and Interventions: Sixteen SB subjects received a single dose of clonidine or 
placebo at bedtime in a crossover design.  
Measurements and Results: Sleep variables and RMMA/SB index were evaluated. CAP 
was scored to assess arousal instability between sleep-maintaining processes (phase A1) 
and stronger arousal processes (phases A2 and A3). Paired t-tests, ANOVAs, and cross-
correlations were performed. Under clonidine, CAP time, and particularly the number of 
A3 phases, increased (P ≤ 0.01). RMMA/SB onset was time correlated with phases A2 and 
A3 for both placebo and clonidine nights (P ≤ 0.004). However, under clonidine, this 
positive correlation began up to 40 min before the RMMA/SB episode.  
Conclusions: CAP phase A3 frequency increased under clonidine, but paradoxically, 
RMMA/SB decreased. RMMA/SB was associated with and facilitated in CAP phase A2 
and A3 rhythms. However, SB generation could be influenced by other factors besides 
sleep arousal pressure. NREM/REM ultradian cyclic arousal fluctuations may be required 
for RMMA/SB onset.  
 
Keywords: Clonidine, sleep bruxism, rhythmic masticatory muscle activity, cyclic 
alternating pattern. 
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Introduction   
Clonidine, a selective α2-agonist, is known to alter the ultradian NREM/REM sleep 
cycle by reducing REM sleep in a dose-dependent manner (1-3). Clonidine also has been 
shown to decrease sleep bruxism frequency by 61% (4). Sleep bruxism (SB) is a sleep-
related movement disorder characterized by frequent rhythmic masticatory muscle activity 
(RMMA) associated with tooth grinding and clenching (5-7). The pathophysiology of 
RMMA/SB has been studied in relation to sleep arousal, both spontaneous and 
experimentally induced (8-11). More recently it was suggested that RMMA/SB is the final 
event in a sequence of naturally occurring neurovegetative changes during sleep (12). Most 
RMMA/SB episodes are preceded by increased sympathetic cardiac activity (8 to 4 min 
before RMMA/SB onset), electroencephalographic (EEG) arousal (4 sec before), 
accelerated heart rate, and increased breathing amplitude (1 sec before)(12-15). 
Furthermore, RMMA/SB events appear to follow the ultradian NREM/REM sleep cycle, 
with peak activity during the NREM to REM transition, which is stronger for the second 
and third sleep cycles (12-15). Thus, the effect of clonidine on RMMA/SB may be linked to 
its influence on sympathetic/ parasympathetic balance, sleep structure, and motor activities 
during sleep. However, the effect of clonidine on cyclic sleep arousal fluctuation has not 
yet been investigated.  
Fluctuations in sleep arousal over time (i.e., sleep microstructure) can be evaluated 
by examining the cyclic alternating pattern (CAP). CAP is composed of electrocortical 
events that can be visually scored as patterns of sleep periods under arousal pressure during 
NREM (16-18). CAP displays a 20–40 s cyclic pattern characterized by arousal-related 
phasic events (phase A) followed by deactivation (phase B). Phase A is further classified 
into three subphases of increasing arousal strength: A1, A2, and A3. Phase A1 is thought to 
be an EEG correlate of events that promote sleep onset and maintenance. Phase A2 is a 
transient phase toward increased arousal pressure. Phase A3, the higher arousal phase, is 
characterized by desynchronized EEG patterns. Phases A2 and A3 are associated with 
increased muscle tone and cardiorespiratory rate (19-21). The A-B alternating pattern 
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(cycle) is clustered in sequences. CAP variables, e.g., CAP time, CAP rate (% ratio of total 
CAP time to total NREM sleep time), and CAP sequence, are markers of sleep 
fragmentation and arousal instability (17). During NREM sleep, 88% of RMMA/SB 
episodes occur in clusters, following the same rhythm as the CAP oscillation. RMMA/SB 
activity has been observed mainly within CAP phase A3 (9). 
Although advances have been made in understanding SB pathophysiology, the exact 
generator of RMMA/SB events during sleep remains unknown. The aim of this study was 
to examine CAP variables to explain the effect of clonidine on arousal fluctuation and to 
explore the role of sleep arousal instability on RMMA/SB occurrence. As clonidine reduces 
SB activity and modifies sleep macrostructure, we hypothesized that the probable 
alterations in sleep microstructure would influence RMMA/SB occurrence. 
 
Methods 
Subjects 
We analyzed polysomnographic data of 16 SB subjects (6 males and 10 females; 
mean age 24.5; range 21 to 31) in our laboratory from 2000 to 2004 (4). Subjects were 
selected based on a history of tooth-grinding (>3 nights/week) and clinical signs and 
symptoms of SB (tooth wear, masseter muscle hypertrophy, morning jaw muscle fatigue or 
tenderness). SB diagnosis was confirmed if subjects met the standard polysomnographic 
research criteria (>4 episodes of RMMA/hour of sleep) in the second night of sleep 
recording (22). The experimental protocol was approved by the research ethics board of the 
Hôpital du Sacré-Coeur, Montreal.  
 
Study Design 
All subjects underwent 4 nights of audio-video polysomnographic recordings. The 
first night was for habituation and the second for SB diagnosis. The experimental protocol 
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was conducted during the third and fourth nights. Subjects received a single dose of either 
placebo or clonidine (0.3 mg by mouth) 1 hour before bedtime in a randomized double-
blind crossover design. A 1-week washout interval between the 2 experimental nights was 
provided (4). According to its pharmacokinetic profile, clonidine reaches a plasmatic peak 
within approximately 2 h following oral administration (3,23).  
 
Sleep Data Collection and Scoring 
The following polysomnographic variables were recorded and analyzed blind to 
medication or placebo allocation: EEG (C3A2, O2A1), electrooculogram (EOG), 
electrocardiogram (EKG), chest respiratory movements, and electromyographic (EMG) 
activity in the suprahyoid, masseter, temporalis and anterior tibialis muscles. All signals 
were digitalized at 128 Hz using commercial software (Harmonie, Stellate, Montreal, 
Canada), as described elsewhere (4). Sleep stages, sleep arousals, and RMMA/SB episodes 
were scored according to standard criteria (7,22,24,25). CAP was scored according to the 
published rules (26). Each CAP phase A was visually detected during NREM sleep on the 
C3A2 derivation by the use of Somnologica (Embla, Germany), then classified into 
subtypes A1, A2, or A3. The following CAP parameters were evaluated: total CAP time, 
CAP rate, number and duration of CAP sequences, number and duration of A phases, 
number and duration of B phases, and number and percent of subtypes A1, A2, and A3.  
 
Data Analyses and Statistics 
Duration of the first 4 NREM/REM sleep cycles was normalized within each subject 
by dividing NREM periods into 20 intervals and REM periods into 5 intervals, for 100 
intervals over the entire night (27,28) Each sleep cycle was then averaged into 4 NREM 
sections and 1 REM section (each comprising 5 intervals). Both placebo and clonidine 
nights were normalized. However, for clonidine nights, REM sections were time estimated 
due to the strong reduction in REM sleep duration. Frequency distributions of RMMA/SB 
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episodes and CAP phases A1, A2, and A3 per hour of sleep were calculated over sleep 
cycles.  
Statistical analyses were performed using SPSS (SPSS Inc., Chicago, IL, USA). The 
paired t-test was applied for within-group comparison (placebo vs. clonidine) and repeated 
measures ANOVAs (treatment × cycle × section) were applied to CAP variables and 
RMMA/SB episode distribution over sleep cycles. Placebo and clonidine nights were 
compared for NREM sleep only, as CAP cannot be scored during REM. Repeated measures 
ANOVAs were also performed for each NREM cycle (treatment x section) due to the 
clonidine pharmacokinetics profile. The Huynh-Feldt correction for sphericity was applied 
to all ANOVA calculations. P-values were considered significant at ≤0.05. 
RMMA/SB episodes were cross-correlated with CAP phases A1, A2, and A3. 
Cross-correlation plots are used to identify temporal associations between 2 series of events 
at individual time lags. Each time lag corresponds to 4 minutes. A significant correlation at 
lag 0 indicates that the 2 events occur at the same time. Correlations at positive lags relate 
values in the first series to subsequent values in the second series. Similarly, correlations at 
negative lags relate values in the first series to preceding values in the second series.  
 
 
Results 
CAP Variables and Sleep Bruxism 
CAP time and CAP sequence increased significantly (≤0.001) with clonidine 
compared with the placebo night. Because clonidine increased the duration of both total 
CAP time and NREM sleep, the CAP rate did not change. The number of CAP A3 phases 
increased significantly with clonidine compared with the placebo night (P = 0.01) (Table 
3.1.1). As previously reported (4), both RMMA/SB and sleep variables change significantly 
under the influence of clonidine. RMMA/SB index decreased by 61% (P = 0.02), sleep 
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stage 2 increases, and REM sleep was markedly reduced (both P < 0.001). The number of 
sleep arousals per hour of sleep did not change under clonidine.  
 
RMMA/SB and CAP Phase A Distribution over Sleep Cycles 
Clonidine blunted the linear crescendo pattern of RMMA/SB occurrence across the 
NREM/REM transition period compared to placebo (overall treatment effect P = 0.002). 
This effect was stronger in the third and fourth sleep cycles (ANOVA for cycles 3 and 4, P 
= 0.001). Under clonidine, phase A1 frequency (number/hour of sleep) was slightly reduced 
(overall treatment effect, P = 0.02), but no difference was observed between placebo and 
clonidine nights for the phase A1 ultradian NREM/REM fluctuation pattern. In contrast, 
phase A2 and A3 distributions across the sleep cycle changed markedly under clonidine 
(overall treatment x section interaction, P = 0.0005 and 0.0009, respectively). Within each 
cycle, the linear crescendo mode of phase A2 and A3 frequencies disappeared from cycles 
2 to 4 (ANOVA for each cycle, placebo linear contrast P < 0.002; clonidine linear contrast 
P > 0.2) (Fig. 3.1.1).  
 
Cross-Correlation Analysis between RMMA/SB Episodes and CAP A Phases 
For both placebo and clonidine nights, an equipotent positive correlation was found 
between RMMA/SB episodes and CAP phases A2 and A3 (Fig. 3.1.2). During the placebo 
night the time correlation for phase A2 was significant at lag 0 (RMMA/SB onset), and 
lasted for the next 8 min (lag 0 coefficient = 0.287, P = 0.004). For phase A3, a significant 
time correlation began in the 4 min preceding RMMA/SB episodes and lasts for the next 8 
min (lag 0 coefficient = 0.637, P < 0.0001). Under clonidine, a significant positive time 
correlation at RMMA/SB onset is still present for A2 (lag 0 coefficient = 0.304, P = 0.002) 
and A3 (lag 0 coefficient = 0.569, P < 0.0001). However, the time correlations in clonidine 
nights were significantly higher in the 40 min preceding RMMA/SB episodes for both A2 
and A3 phases.  
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Discussion 
This experimental pharmacological study evaluated the relationship between 
RMMA/SB and CAP phase A. Polysomnographic recordings showed that both CAP phase 
A patterns and RMMA/SB occurrence change under clonidine. Specifically, the cyclic rise 
in phase A2 and A3 frequency and RMMA/SB activity in the pre-REM periods were 
blunted under clonidine. Paradoxically, the number of RMMA/SB decreased and the 
number of phase A3 rose. In addition, in both placebo and clonidine nights, RMMA/SB 
episodes were temporally correlated with CAP phases A2 and A3 and their endogenous 
fluctuation across ultradian NREM/REM sleep cycles. Previous studies showed the 
association between CAP phases A2 and A3 with RMMA/SB, but no time correlation (9).  
The present study found that clonidine increases CAP time, CAP sequence, and 
phase A3, indicating increased arousal instability and sleep perturbation (16,17), probably 
related to clonidine action on the brainstem neuronal systems that regulate the switch from 
NREM to REM sleep (29). However, whether the effect of clonidine on sleep arousal 
instability is linked to the observed reduction in RMMA/SB episodes remains to be 
demonstrated (30). 
 
CAP as the Permissive Window for RMMA/SB Occurrence 
Previous studies have described RMMA/SB as a motor activity secondary to sleep 
arousal (8-10,13), and have associated it with CAP phase A (9). Our study provides new 
insights into the role of phase A and the differences between phases A1, A2, and A3. Phase 
A1 corresponds to the slow EEG oscillations, and is associated with the build-up and 
maintenance of NREM sleep (21,31,32). In contrast, arousal subtypes A2 and A3 are lower 
in NREM deep sleep and they increase linearly before REM sleep onset. The RMMA/SB 
occurrence pattern reflects the ultradian fluctuation in CAP phases A2 and A3. Phase A1 is 
also negatively correlated with RMMA/SB episodes, while phases A2 and A3 are strongly 
time-correlated with RMMA/SB onset. In fact, the time correlation between RMMA/SB 
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activity and phases A2 and A3 is preserved even in clonidine nights. Although the 
quantitative time-correlation analysis did not reveal a causal relationship between CAP 
phase A and SB, it suggests that phases A2 and A3 constitute the permissive physiological 
window for RMMA/SB generation during sleep.  
A recent study evaluating the time relationship between RMMA/SB episodes and 
autonomic nervous system activity showed a change in sympathetic/parasympathetic 
modulation starting approximately 8 to 4 minutes before RMMA/SB onset (12,13). Our 
analysis goes further to show that the balance between subtypes A1 to A3 shifts within the 
same time range as the previously described shift in sympathetic cardiac activity. This 
suggests that phase A changes are the EEG counterpart of the sympathetic/parasympathetic 
balance in sleep arousal (16). 
Other studies (33-36) support the facilitatory role of CAP phase A in the occurrence 
of motor events during sleep. For example, periodic limb movements in sleep (PLMS) have 
been reported to occur frequently within CAP, with 96% of PLMS episodes observed in 
phases A2 and A3 (37). However, the CAP itself does not generate these movements 
during sleep; instead, it is the temporal window in which arousal and motor events are 
grouped and in which their rhythmic occurrence is facilitated.  
 
Putative Effects of Clonidine on SB and CAP  
Clonidine is an α2-adrenergic agonist that acts on multiple sites in the central and 
peripheral nervous systems (38). It has both a direct and indirect influence on the 
autonomic nervous system (39,40), sleep cycles (41), motor control (42,43), and most 
probably arousal instability.  
Clonidine exerts a strong sympathetic inhibitory effect by altering the balance from 
sympathetic to parasympathetic tone (4,39) due to activation of the α2-adrenergic 
autoreceptors and post-synaptic receptors in the brainstem and the imidazoline-I1 receptors 
in the rostral ventrolateral medulla (44). By preventing sympathetic rise, clonidine may 
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blunt the cascade of arousal-related neurovegetative responses that precede RMMA/SB 
episodes, thereby inhibiting SB.  
Clonidine also has marked effects on sleep macrostructure (4). Significant increases 
in stage 2 as well as reduced deep and REM sleep duration have been reported (1-3). REM 
sleep onset appears to be strongly influenced by the adrenergic and noradrenergic systems 
(45,46). The neurotransmitters in these systems are implicated in inhibitory mechanisms 
that mainly involve postsynaptic α2-adrenoceptors in the locus coeruleus area of the 
brainstem (47). However, clonidine may also activate non-adrenergic neurons in the 
pontine reticular formation and thereby exert an indirect influence on the GABA-ergic and 
cholinergic neurons that modulate REM sleep onset (48-50). In the present study, clonidine 
strongly reduced REM sleep duration, blunting the cyclic rise of CAP phases A2 and A3 in 
the NREM/REM transition period. Thus, clonidine perturbation of the NREM/REM 
ultradian cycle may by itself have prevented RMMA/SB onset. This fluctuation in ultradian 
arousal may be required for RMMA/SB occurrence. Experimental protocols using 
pharmacological or physical REM alteration (REM sleep deprivation or enhancing 
methods) may help determine the nature of this influence (51-53).  
Clonidine may also affect motor control pathways. RMMA/SB are spontaneous 
motor events that occur during sleep. So far, the exact mechanism responsible for the 
generation of RMMA/SB remains unknown. Possible contributing factors include 
autonomic sympathetic cardiac activity (13,54), the hypothalamic-adrenal axis (55-57), 
genetics (58,59), and complex neurochemical influences involving catecholamines, 
serotonin, histamine, acetylcholine, or orexin (60). Moreover, because clonidine affects the 
noradrenergic pathways, it may indirectly influence dopamine release from the nucleus 
striatum (40,61,62). However, there is only weak evidence for the role of catecholamines in 
generating RMMA/SB, with conflicting results and a lack of randomized controlled trials 
(60,63,64).  
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Conclusion 
RMMA/SB is associated with and facilitated by CAP phase A2 and A3 rhythms 
within a sleep arousal. However, under clonidine, increased CAP phase A3 frequency 
(arousal pressure) is observed, with a paradoxical reduction in RMMA/SB activity. 
Although CAP phases A2 and A3 could reflect permissive physiological windows, 
RMMA/SB generation could be influenced by other factors besides arousal pressure. 
Notably, fluctuations in the NREM/REM ultradian cyclic arousal may be required for 
RMMA/SB to occur.  
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Figure 3.1.1 CAP and RMMA distribution over NREM/REM sleep cycles. 
The NREM/REM sleep cycle distribution of CAP phases A1, A2, and A3 (number/h), and 
RMMA/SB activity (episodes/h) are displayed for placebo (black circles) and clonidine 
(white circles) nights. Vertical dotted lines represent each NREM/REM sleep cycle. Mean 
values (SEM) are shown. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
c1 = first sleep cycle; c2 = second 
sleep cycle; c3 = third sleep cycle; c4 
= fourth sleep cycle; RMMA/SB = 
rhythmic masticatory muscle 
activity/sleep bruxism. 
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Figure 3.1.2 Cross-correlation between RMMA/SB episodes and CAP phases.  
The cross-correlation plots between RMMA/SB episodes and CAP phases A1, A2, and A3 
are displayed for placebo (A) and clonidine (B) nights. Horizontal upper and lower lines 
denote significant P value at 0.05. The vertical line denotes lag 0, or RMMA/SB onset. 
Each lag lasts 4 minutes (minus 40 min before SB onset and plus 40 min after SB onset). 
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Table 3.1.1 CAP variables during placebo and clonidine nights  
 
 PLACEBO NIGHT CLONIDINE NIGHT P value 
CAP rate (%) 27.8 ± 1.2 27.3 ± 1.4 0.65 
CAP time (min) 99.8 ± 4.6 127.7 ± 6.1 <0.001 
CAP sequence (n) 36.5 ± 1.3 44.4 ± 1.8 0.001 
A1 (n) 99.4 ± 9.1 84.5 ± 8.2 0.19 
A2 (n) 40.1 ± 5.2 48.8 ± 6.6 0.12 
A3 (n) 59.2 ± 6.2 96 ± 13.9 0.01 
A1 (%) 49.2 ± 2.7 37.9 ± 3.6 0.01 
A2 (%) 19.8 ± 1.7 21.2 ± 2.5 0.47 
A3 (%) 31 ± 3.5 40.9 ± 4.5 0.03 
Phase A duration (s) 8.9 ± 0.4 9.1 ± 0.4 0.58 
Phase B duration (s) 21.6 ± 0.5 24.6 ± 0.6 <0.001 
CAP cycle duration (s) 30.5 ± 0.7 33.7 ± 0.6 <0.001 
A1 duration (s) 5.6 ± 0.2 5.5 ± 0.2 0.5 
A2 duration (s) 7.9 ± 0.3 7.7 ± 0.4 0.58 
A3 duration (s) 15.2 ± 0.6 13.5 ± 0.6 0.03 
 
Data are presented as mean ± SEM. CAP refers to cyclic alternating pattern.  
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Abstract 
Rhythmic masticatory muscle activity (RMMA) is the characteristic 
electromyographic pattern of sleep bruxism (SB), a sleep-related motor disorder associated 
with sleep arousal. Sleep arousals are generally organized in a clustered mode known as the 
cyclic alternating pattern (CAP). CAP is the expression of sleep instability between sleep 
maintaining processes (phase A1) and stronger arousal processes (phases A2 and A3). This 
study aimed to investigate the role of sleep instability on RMMA/SB occurrence by 
analyzing CAP and electroencephalographic (EEG) activities. The analysis was performed 
on the sleep recordings of 8 SB subjects and 8 controls who received sensory stimulations 
during sleep. Baseline and experimental nights were compared for sleep variables, CAP, 
and EEG spectral analyses using repeated measure ANOVAs. Overall, no differences in 
sleep variables and EEG spectra were found between SB subjects and controls. However, 
SB subjects had higher sleep instability (more phase A3) than controls (p=0.05). The 
frequency of phase A3 was higher in the pre-REM sleep periods (p<0.001), where peaks in 
RMMA/SB activity were also observed (p=0.05). When sleep instability was 
experimentally increased by sensory stimuli both groups showed an enhancement in EEG 
theta and alpha power (p=0.04 and 0.02 respectively), and significant increases in sleep 
arousal and all CAP variables. No change in RMMA/SB index was found within either 
groups (RMMA/SB occurred in all SB subjects and only one control during the 
experimental night). These findings suggest that CAP phase A3 may act as a permissive 
window rather than a generator of RMMA/SB activity in predisposed individuals.  
 
 
Keywords 
Sleep bruxism, rhythmic masticatory muscle activity, sleep instability, cyclic alternating 
pattern, EEG spectral analysis 
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Introduction   
Sleep bruxism (SB) is a common sleep-related movement disorder characterized by 
tooth grinding or clenching (1, 2). The typical movement pattern of SB is the rhythmic 
masticatory muscle activity (RMMA). Almost 60% of normal sleepers engage in RMMA 
during sleep, but with a frequency three times lower than in SB subjects (3). RMMA/SB 
episodes occur more frequently during NREM sleep stage 1 and 2. Only  10% are observed 
during REM sleep (3-5). Evidence on the pathophysiology of RMMA/SB supports the 
hypothesis that RMMA/SB is associated with autonomic sympathetic-cardiac activity and 
sleep arousals (5-8). Sleep arousal is defined as a brief awakening (at least 3 seconds) 
characterized by increased electroencephalographic (EEG), muscle, and heart activity 
without return to consciousness (9). Arousals are the response of the sleeping brain to 
external (environmental) and internal (physiological or pathological) stimuli. Sleep arousals 
normally occur between 6 to 14 times per hour of sleep.  
Within NREM sleep, the majority of these arousal responses have been found to 
occur in an orderly, repetitive manner known as the cyclic alternating pattern (CAP). CAP 
is characterized by sequences of transient electrocortical events (phase A of CAP) that are 
distinct from the background EEG activity (phase B of CAP). A CAP sequence is 
composed of a succession of CAP cycle (A-B phases), which recurs with a periodicity of 
20-40 seconds. CAP variables serve as polysomnographic markers of unstable sleep; in 
contrast the absence of CAP (scored as non-CAP when the interval between two successive 
A phases is more than 60 seconds) reflects stable and consolidated sleep (10-12). The 
arousal phase of CAP, phase A, is further classified into three subtypes of increasing 
arousal strength: A1, A2, and A3 (13). Sleep patterns associated with phase A1 are thought 
to be unstable but preserved by the cortical mechanisms that reinforce and protect sleep 
maintenance. By contrast, phase A2 represents a transition phase toward increased arousal 
pressure (phase A3). The occurrence of phases A2 and A3 correspond to a higher arousal 
activity and sleep instability, usually coupled with an increase in muscle tone and cardio-
respiratory rate (12, 14-16). It has been observed that most RMMA/SB episodes occur in 
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clusters with a periodicity of 20-30 seconds (7), similar to the physiological arousal rhythm 
of CAP. Moreover, 88% of RMMA/SB events scored during NREM sleep have been found 
to occur within CAP phase A, particularly subtype A3 (5).  
A previous study has shown that following experimentally induced arousals, 
RMMA/SB activity occurs more frequently in SB subjects compared to controls. Thus, 
suggesting that SB subjects may have a higher responsiveness to sleep arousal (17). 
However, whether the shift in balance from sleep-maintaining processes toward arousal 
processes effects RMMA/SB activity remains unknown. The aim of the present study was 
to examine the role of sleep instability on RMMA/SB occurrence. This was achieved by 
analyzing CAP variables and quantitative EEG activity in subjects whose sleep was 
disturbed by experimental sensory stimuli.  
 
 
Materials and Methods 
Subjects 
This study analyzed polysomnographic data on 16 young subjects who participated 
in a previously published experimental study (17). The sample comprised of 8 SB subjects 
and 8 age- and gender-matched controls (Table 1). SB subjects were selected based on 
tooth-grinding history (more than 3 nights/week) and the presence of clinical signs and 
symptoms suggestive of SB (tooth wear, masseter muscle hypertrophy, morning jaw 
muscle fatigue or tenderness). Control subjects had none of these clinical findings. SB 
diagnosis was then assessed in the second night of audio-video sleep recording based on the 
standard polysomnographic research diagnostic criteria (18). Only SB subjects with an 
RMMA/SB index ≥ 4 episodes per hour of sleep were included. None of the participants 
had a history or showed signs of sleep or medical disorders. None of the participants were 
taking medications. The experimental protocol was approved by the research ethics board 
of the Hôpital du Sacré-Coeur in Montreal.  
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Study design 
As described in a previous publication (17), all subjects underwent three or four 
nights of audio-video polysomnographic recordings. The first night was used for 
habituation to the sleep laboratory environment. The second night was used to establish SB 
diagnosis in SB subjects and to confirm the absence of SB in control subjects. The 
experimental protocol was conducted during the third and/or fourth nights. The baseline 
night (night 2) was compared to the experimental night (night 3 or 4) that consisted of SB 
and control subjects being stimulated by a vibro-tactile and/or auditory stimulation 
(VT/AD) as generated by AC motors in contact with the subject’s arm. The VT/AD stimuli 
were used to induce experimental arousals without eliciting a complete awakening from 
sleep. Stimuli were delivered for a duration of 1 second at 60-second intervals during all 
sleep stages (17).  
 
Sleep data collection and scoring 
The following polysomnographic variables were recorded, as described in the 
previous publication (17): EEG, electro-oculogram, electrocardiogram, chest respiratory 
movements, and electromyogram from the suprahyoid, masseter, temporalis and tibialis 
muscles. Sleep stages and sleep arousal were scored according to the standard criteria (19, 
20). RMMA/SB activity was analyzed according to published research diagnostic criteria 
(18). CAP was scored according to the published rules (21). Each CAP phase A was 
visually detected during NREM sleep using Somnologica (Embla, USA) then classified 
into subtypes A1, A2, or A3. The following CAP parameters were then evaluated: total 
CAP time, CAP rate, number and duration of CAP sequence, number and duration of A 
phases, number and duration of B phases, and number and percent of subtypes A1, A2, and 
A3. 
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Data analyses and statistics 
The duration of the first 4 NREM/REM sleep cycles was normalized within each 
subject by dividing NREM periods into 20 intervals and REM periods into 5 intervals to 
obtain 100 intervals for the entire night (22, 23). Furthermore, each sleep cycle was 
averaged into four NREM sections and one REM section (each made by 5 intervals). Power 
spectra of EEG delta (0.50–4.00 Hz), theta (4.00–8.00 Hz), and alpha activities (8.00–13.00 
Hz) were analyzed over 4-second mini-epochs on the EEG central derivation computed by 
fast Fourier transform (FFT) after excluding mini-epochs of EEG artifacts. Mini-epoch 
values were averaged for each interval. Further, the number of RMMA/SB episodes and 
CAP phases A1, A2, and A3 per hour of sleep were calculated for each NREM and REM 
sleep section separately.  
Statistical analysis was performed using SPSS (SPSS Inc., Chicago, IL, USA). 
Repeated-measures ANOVAs were performed for group comparisons and influence of 
VT/AD stimulus, with group as the between subject variable and VT/AD as the within 
subject variable. Repeated measures ANOVA were also performed for EEG spectral 
analyses, CAP variables, and RMMA/SB episodes distribution over sleep cycles. In the 
EEG spectral analyses data are expressed as log10 because they did not follow a normal 
distribution. NREM and REM sleep were evaluated separately. Huynh-Feldt correction for 
sphericity was applied to all ANOVA calculations. P value was considered significant 
when ≤ 0.05.  
 
 
Results 
Sleep bruxism, sleep arousal and CAP variables 
All SB subjects had a RMMA/SB index greater than 4 episodes/h of sleep (mean 7.1 
± 0.9). SB subjects showed a higher number and percentage of CAP phase A3 (1.5 times 
more than controls, p=0.05 and 0.002 respectively; Table 3.2.1, Group column), and a 
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longer duration of overall phase A compared to controls (p=0.025; Table 3.2.1, Group 
column). The other sleep and CAP variables did not differ between groups. 
  The VT/AD stimulus during sleep did not affect RMMA/SB frequency over night 
for both groups (Table 1, VT/AD column; and Figure 3.2.1). Sleep arousal index was 
increased (p=0.001), but a significant interaction was observed between group and VT/AD 
variables (p=0.02). Hence, we performed paired sample t-tests for this index for each group 
separately. This post hoc analysis showed that the number of sleep arousals during the 
experimental night was significantly higher than during baseline night in control subjects 
only (p=0.001) (Figure 3.2.1). The application of VT/AD stimuli also increased CAP time 
by 34% (p<0.001), as well as CAP rate, CAP sequence, and number of phases A1, A2, and 
A3 for both groups (Table 3.2.1). The number of A3 phases found in the experimental 
nights of the control subjects was increased to a value similar to that seen in the baseline 
nights of the SB subjects (Figure 3.2.1). 
 
RMMA/SB and CAP phase A distribution in relation to sleep cycles 
In SB subjects, RMMA/SB episodes occurred with higher frequency (number of 
episodes/hour of sleep) in the pre-REM intervals and followed a linear crescendo pattern 
from NREM toward REM sleep in the baseline night (p=0.05). In the experimental night, 
the frequency of RMMA/SB episodes over sleep cycles remained unchanged (Figure 3.2.2). 
Overall, there was no group difference in the distribution across sleep cycles of CAP phases 
A1, A2, and A3 occurrence. However, SB subjects showed higher frequency (number/h) of 
phase A3 in both baseline and experimental nights (p=0.01). Phase A1 frequency followed 
a quadratic distribution (p=0.003). Indeed, phases A2 and A3 frequencies increased linearly 
during NREM sleep, peaking in the transition period between NREM and REM sleep (both 
p<0.001). The frequency of CAP phases A2 and A3 was significantly increased for both SB 
subjects and controls when VT/AD stimuli were applied (p=0.03 for A2 and 0.0006 for A3) 
(Figure 3.2.2).  
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Power spectral analysis of EEG delta, theta, and alpha activities  
SB and control subjects showed no difference in the NREM/REM ultradian 
homeostatic fluctuation of delta activity. Delta power gradually declined from the first 
sleep cycle to the third sleep cycle (p<0.001), with very low activity during REM sleep. 
The VT/AD stimuli did not affect delta power in either group (p=0.5). Theta and alpha 
power did not differ between SB subjects and controls (p=0.7 and p=0.3 respectively), but 
they were higher in the experimental night compared to baseline for both groups (p=0.04 
for theta and p=0.02 for alpha activities)(Figure 3.2.3).  
 
 
Discussion 
The present study describes the occurrence of RMMA/SB episodes in relation to 
CAP phase A with and without experimental sleep perturbation for SB and control subjects. 
Overall, SB subjects did not differ from controls for sleep variables and EEG spectral 
analysis. However, the analysis of sleep microstructure (CAP variables) revealed that SB 
subjects had more CAP phase A3 than controls. In the experimental night, both groups 
showed greater sleep instability without major changes in sleep homeostasis (e.g., sleep 
cycles, delta activity). SB subjects showed a higher RMMA/SB index than controls at 
baseline, as reported in the previous publication (17). In addition, this difference between 
groups in RMMA/SB index was maintained in the experimental night when sleep arousals 
were induced. However, no changes in RMMA/SB activity were observed within groups 
from baseline to VT/AD night (RMMA/SB activity was observed in all SB subjects and 
only one control). These data provide new insight into how sleep instability affects the 
genesis of RMMA/SB episodes within normal sleep processes. 
RMMA/SB is described as a sleep-related motor activity secondary to sleep arousal 
(5, 7, 8, 24). Its association with phase A of CAP has also been previously reported (5, 25). 
However, recent evidence supports the hypothesis that sleep arousal and particularly phase 
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A of CAP are not the generator of RMMA/SB activity, but rather the permissive window 
for its occurrence during sleep (26). The present study supports this hypothesis.  
The SB subjects of this study displayed higher sleep arousal strength (phase A3) 
compared to controls. However, overall sleep instability was within a normal range since 
the other CAP variables did not differ between groups. EEG spectral analysis did not reveal 
significant differences between SB and control subjects for delta, theta and alpha activities, 
suggesting that sleep homeostatic processes are normal in young and otherwise healthy SB 
subjects. Delta and theta activities are the EEG hallmarks of NREM slow wave sleep, also 
known as deep or restorative sleep (27). In particular, the power density in the delta band, 
usually referred as slow wave activity (SWA), has proven to be a very useful and popular 
parameter to quantify the homeostatic sleep pressure and to indirectly estimate sleep quality 
(28-30). Delta activity follows the ultradian NREM/REM sleep cycle and shows a 
physiological decline in the course of sleep that reflects the inner decline of sleep 
propensity. This pattern was observed in SB subjects as well as in controls. The analysis of 
CAP variables and EEG activity revealed that SB subjects had normal sleep maintenance 
processes but higher sleep instability compared to control subjects. Since arousals are a 
physiological structural component of sleep that ensures the reversibility of sleep in 
response to sensorial inputs, noisy environments, and movements (11), it could be that the 
higher sleep instability found in the baseline nights of the SB subjects was attributed to the 
RMMA/SB motor events themselves.  
For the experimental nights, since they involved applying sub-threshold 
stimulations, an increase in CAP (or sleep instability) would be expected (31). In fact, CAP 
is the more sensitive response to internal or external factors of perturbation at the micro-
structural level of sleep. Sensory stimulations, such as acoustic or vibratory inputs 
administered during sleep have been shown to induce a CAP sequence and increase CAP 
rate (32, 33).  The analysis of sleep data performed in this study on the experimental nights 
did reveal an increase in the sleep arousal index and all CAP variables for both SB and 
control subjects: i.e., an increase of arousal influence and sleep instability. However, the 
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ultradian fluctuation of delta activity was preserved in both groups. In contrast, theta 
activity was increased in the experimental night, indicating a more sensitive response of 
this frequency band to sensory inputs during sleep. Furthermore, alpha activity was also 
enhanced when the VT/AD stimuli were applied. Since the alpha frequency band is the 
major component contributing to the spectral power density of REM sleep and sleep 
arousal (34), the experimental perturbations successfully induced sleep arousal within 
normal sleep process in both groups. Interestingly, only control subjects showed a 
significant increase in sleep arousal in the experimental night compared to baseline. This 
finding may suggest that different arousal responsiveness to external perturbing stimuli 
exists between the two groups. It can be hypothesized that the arousal response to the 
VT/AD stimuli in the SB group, which consisted of young and healthy subjects, reached a 
plateau. New experimental studies are needed to better understand this finding. However, 
the CAP analysis performed revealed that the VT/AD stimuli disrupted sleep 
microstructure in both groups. Although the phases A of CAP were experimentally 
increased, control subjects did not develop RMMA/SB activity (except for one control 
subject). Therefore, arousal and sleep instability seem to be facilitating but not sufficient 
factors for RMMA/SB occurrence during sleep. Other predisposing or initiating factors are 
probably required.  
Previous studies on the genesis of RMMA/SB episodes have suggested that 
autonomic and central nervous system activations may have a primary role (7, 35-37). The 
occurrence of RMMA/SB episodes reached its peak in the pre-REM sleep section of the 
sleep cycle when also higher frequency of CAP phases A2 and A3 were observed. The pre-
REM period is characterized by more rapid EEG rhythms and greater autonomic and 
muscle activities (21, 38), supporting the hypothesis that RMMA/SB might be facilitated in 
the pre-REM sleep period.   
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Study Limitations and Future Research  
The present study is characterized by a complex experimental protocol that was 
designed to examine the role of sleep arousal on RMMA/SB occurrence. However it suffers 
from some limitations. First of all, the small sample of subjects recruited in this sleep 
laboratory experimental study reduces its external validity. Moreover, since in the paradigm 
of this study only instantaneous VT/AD sensory stimulations were used, we cannot 
speculate on how SB subjects may respond to other types of perturbing stimuli applied 
during sleep. For example, it is unknown to our knowledge how biofeedback devices that 
deliver electrical pulses to inhibit EMG muscle activity during sleep affect sleep arousal 
and sleep instability.  
The relationship between SB and sleep arousal is a challenging field. Further studies 
are required to better understand what are the triggers of RMMA/SB activity during sleep, 
as this is still unknown. Experimental protocols using pharmacological or physical 
manipulation of the NREM/REM sleep cycle may assist in determining the nature of SB 
genesis.  
 
 
Conclusions 
The present study supports the hypothesis that sleep arousal (CAP phase A) is not 
the generator of RMMA/SB movements, but rather provides the permissive window for 
these sleep motor events to occur during an unstable sleep condition (11, 39). That is, other 
predisposing and initiating factors are required to generate RMMA/SB episodes (40, 41). In 
particular, this motor activity seems to be facilitated by transient increases in arousal 
pressure (phases A2 and A3) and autonomic-sympathetic activation, which are observed in 
the pre-REM sleep periods. 
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Figure 3.2.1 Comparison between control and SB subjects for RMMA/SB index, sleep 
arousal index and number of CAP phase A3 in baseline and experimental (VT/AD) 
nights.  
 
 
* significant value in ANOVAs for group 
comparison. 
** significant value in ANOVAs for VT/AD 
comparison. 
§ significant value in paired t-tests (post hoc 
analysis). 
Standard error bars are included. 
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Figure 3.2.2 RMMA/SB activity (episodes/h) and CAP phases A1, A2, A3 (number/h).  
 
Graphs show the distribution over NREM/REM sleep cycles for controls (CTL; black 
circles) and SB subjects (SB; white circles) in baseline and experimental (VT/AD) nights. 
Vertical dotted lines delimit each sleep cycle. Only the first three sleep cycles are displayed 
due to missing data for the last one.  
 
 
c1 refers to the first sleep cycle; c2 to the second sleep cycle; c3 to the third sleep cycle; 
RMMA/SB to rhythmic masticatory muscle activity/sleep bruxism. 
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Figure 3.2.3 Power spectral analysis of EEG delta (0.5–4.0 Hz), theta (4.0–8.0 Hz) and 
alpha (8.0–13.0 Hz) activities.  
Graphs show the distribution over NREM/REM sleep cycles for controls (CTL; black 
circles) and SB subjects (SB; white circles) in baseline and experimental (VT/AD) nights. 
Vertical dotted lines delimit each sleep cycle. Only the first three sleep cycles are displayed 
due to missing data for the last one.  
 
 
 
c1 refers to the first sleep cycle; c2 to the second sleep cycle; c3 to the third sleep cycle. 
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Table 3.2.1 Demographic, RMMA/SB, sleep, and CAP variables during baseline and 
experimental nights in 8 controls and 8 SB subjects. 
 
 
 
 
(*) Significant interaction (group x VT/AD) was found for sleep arousal index (p =0.02). 
No significant interaction was found for all the other variables (see Results).  
Data are presented as mean ± SEM or median (min-max). Repeated measures ANOVA was 
performed and p value was considered significant when ≤ 0.05. P values in the group 
column represent the comparison between control subjects and SB subjects (baseline and 
experimental nights combined). P values in the VT/AD column represent the comparison 
between baseline and experimental nights (control and SB subjects combined).  
VT/AD refers to vibratory-auditory stimulation applied in the experimental night; RMMA 
to rhythmic masticatory muscle activity; SB, sleep bruxism; REM, rapid eye movement; 
CAP, cyclic alternating pattern.  
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Abstract 
Sleep-related bruxism (SB) and wake-time tooth clenching (TC) have been 
associated with temporomandibular disorders (TMD), headache, sleep and behavioral 
complaints. The study aimed to assess the prevalence and risk factors of these signs and 
symptoms in a 7-17 year old population (n=604) seeking orthodontic treatment. Data were 
collected by questionnaire and a clinical examination assessing craniofacial morphology 
and dental status. SB was reported by 15% of the population, TC by 12.4%. The SB group 
(n=58) was mainly composed of children (67.3% ≤12 years old); the TC group (n=42) of 
adolescents (78.6% ≥13 years old). Over 60% of SB subjects were found to be a dental 
class II and 28.1% a brachyfacial type. Compared to controls (n=220), SB subjects were 
more at risk of experiencing jaw muscle fatigue (adjusted odds ratio; AOR=10.5), headache 
(AOR=4.3), and loud breathing during sleep (AOR=3.1). Compared to controls, TC 
subjects reported more TMJ clicking (AOR=5), jaw muscle fatigue (AOR=13.5), and 
several sleep and behavioral complaints. Sleep- and wake-time parafunctions are frequently 
associated with signs and symptoms suggestive of TMD, sleep and behavioral problems. 
Their clinical assessment in the orthodontic treatment planning is recommended.  
 
 
 
Keywords – Headache, sleep bruxism, sleep disorders, temporomandibular disorders, tooth 
clenching 
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Introduction 
Bruxism, reported during sleep or during wake-time, is a stereotypical movement 
characterized by tooth grinding or clenching. Bruxism is commonly observed in children 
and adolescents with an overall prevalence of 8-38 % (1-3). This wide range in prevalence 
is due to the fact that the majority of epidemiological studies on bruxism has been based on 
self-reports and often fails to distinguish wake-time from sleep bruxism. Despite some 
similarities, wake-time and sleep bruxism are suspected to have different etiologies and 
physiopathologies (4). 
Wake-time bruxism is considered an oral parafunctional activity mainly 
characterized by sustained masticatory muscle contractions.  It is defined in the clinic as 
tooth clenching (TC)(5). The subject is often not aware of the habit. TC activity seems to be 
exacerbated by anxiety and is associated with lower stress coping responses (6, 7). Wake-
time bruxism is also considered to be the cause of temporomandibular joint (TMJ) and 
masticatory muscle pain (5). Long-lasting tooth clenching, particularly at low contraction 
levels, has been associated with pain in the jaw and cranial muscles (8, 9). This form of 
post-exercise pain is considered to be a consequence of tonic muscular hyperactivity of the 
masticatory muscles (especially the lateral pterygoid, temporal and masseter muscles), 
which may or may not adapt to overload (8, 10). 
Sleep bruxism (SB), is a sleep-related movement disorder also classified as a 
parafunction in dentistry (11, 12). SB is characterized by episodes of rhythmic masticatory 
muscle activity (RMMA) of the masseter and temporalis muscles that can be observed on 
electromyographic recordings performed during sleep (4). Grinding sounds due to tooth 
contacts may or may not occur during RMMA/SB episodes. However, this is the 
pathognomonic sign of SB that is usually reported by the subject, bed partners, and parents. 
Although the etiology of SB remains unknown, its physiopathology is partly explained by a 
re-activation of cerebral and autonomic nervous systems during periods of sleep instability 
(a process called sleep arousal) (13). Genetic predisposing factors and psychosocial 
components (such as anxiety and stress sensitivity) also seem to play a role in the 
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mechanisms that regulate the occurrence of SB (14, 15). However, further studies are 
needed to increase our understanding of the central physiopathology of SB. 
Especially in children, SB has been described in relation to behavioral problems 
(e.g., hyperactivity, attention deficit, sleepiness, poor school performance), with a frequent 
comorbidity with the Attention Deficit and Hyperactivity Disorder (ADHD)(16-18). 
In addition, SB has been associated with sleep disordered breathing (SDB), in 
particular with snoring and obstructive sleep apnea (19-21). Up to half of children with 
sleep apnea also present SB (22). Two clinical open studies have also demonstrated that the 
prevalence of SB decreases in pediatric patients after a tonsillectomy or adenotonsillectomy 
performed to treat SDB (22, 23). SDB can occur in the presence of adenotonsillar tissue 
hypertrophy, craniofacial abnormalities, and neuromuscular deficits. While the cause and 
effect links have yet to be demonstrated, it has been suggested that such conditions create 
airway obstruction (24); the resulting intermittent airflow cessation, oxygen desaturation 
and sleep fragmentation are serious causes of metabolic, cardiovascular and neuro-
cognitive morbidity in children (25). Certain evidence supports the hypothesis that SB 
activity may help to reinstate airway patency following an obstructive respiratory event 
during sleep (26). However, the relation between SB and SDB, as well as its health 
consequences, needs to be further investigated.  
Both SB and TC habits may have detrimental consequences for orofacial structures, 
e.g. temporomandibular disorders (TMD), orofacial pain, headache, muscle discomfort or 
fatigue upon awakening, masticatory muscle hypertrophy, tooth wear and fractures (27). 
However, little data is available regarding the type of impact these disorders have on the 
pediatric population.  
The present study aims to evaluate the prevalence of reported sleep- and wake-time 
bruxism and related conditions in a pediatric population, and assess the role of SB and TC 
as risk factors for: TMD signs and symptoms, sleep problems, and behavioral complaints. 
To achieve these objectives, we performed a subgroup analysis on a population of 7-17 
year-olds seeking orthodontic treatment in a university based center (28).  
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Materials and methods 
Population 
The study population was composed of a multi-ethnic sample of 604 subjects 
(82.4% Caucasians) recruited at the Orthodontic Clinic of the University of Montreal 
during clinical screening examinations. Subjects were between 7 and 17 years of age (mean 
age ± SD, 13 ± 2.28 years old).  All subjects were seeking orthodontic treatment for 
different forms of craniofacial anomalies and/or aesthetic reasons. The study was conducted 
in accordance with the institutional ethical standards. All subjects and their parents or 
guardians gave their written consent to participate in the study.  
 
Instruments: questionnaire and clinical evaluation 
This cross-sectional investigation was conducted using a four section-questionnaire, 
which consisted of questions regarding medical and dental history, bruxism, tooth 
clenching, TMD, sleep disorders (e.g., cessation of breathing suggestive of sleep apnea, a 
delay of more than 30 min in falling asleep suggestive of insomnia), and daytime 
behaviors. The majority of the questions were of the dichotomous “yes” or “no” type. In 
selected cases with multiple variables, the data was reduced: “never” and “rarely” into 
“no”; “often” and “always” into “yes”. The entire questionnaire was in French. The sleep 
section was composed from a modified and translated version of the Pediatric Sleep 
Questionnaire (29) and the validated French version of the Pittsburg Sleep Quality Index 
(30). The parents or guardians present at the clinical examination were asked to complete 
the questionnaire with their children on their behalf.  
An experienced orthodontist (AP), blind to the questionnaire answers, examined all 
subjects by performing a standard orthodontic clinical evaluation (31). The clinical 
examination consisted of an orthodontic evaluation of various standard dental, skeletal, 
functional and aesthetic factors. The facial evaluation included profile analysis (convex, 
straight or concave), frontal view for facial thirds analysis (brachyfacial, mesofacial or 
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dolicofacial) and mandibular plane angle visualisation (flat, normal, or steep). Asymmetries 
of the facial to dental midlines were noted. Tonsil size (normal or hypertrophy with greater 
than 50% obstruction), tongue size (small, normal, large, or scalloped), lateral mandibular 
movements (normal or limited), amount of overjet, amount of overbite and maximal mouth 
opening were also assessed. Palatal vault shape was noted as either deep, round, or flat. 
Finally, a visual clinical evaluation of the dental components of the malocclusion, molar 
and canine Angle classifications, and number and location of crossbites were charted (28).  
 
Variables 
The presence of SB was assessed with the question: “Does your child grind his/her 
teeth during sleep?” The presence of TC was assessed using the question: “Does your child 
clench his/her teeth during daytime?” Other oral parafunctions were also assessed using 
questions concerning lip and nail biting and gum chewing.  
SB and wake-time TC were then analyzed in relation to demographic variables (age, 
gender and body mass index), craniofacial morphology, other orofacial habits, TMD signs 
and symptoms (e.g. temporomandibular joint clicking and locking, tooth wear, dental 
occlusion, jaw muscle fatigue, pain, headache), sleep complaints (e.g. poor sleep quality, 
frequent awakenings, daytime sleepiness, sleep disordered breathing, parasomnias), and 
daytime behaviors (e.g. lack of attention and organization, agitation) (Annex 1).  
 
Data analyses 
Based on the above-mentioned selected questions, the entire sample was divided 
into the following three groups: 1) control subjects (CTL), who did not report SB or TC or 
other oral parafunctions (such as lip and nail biting); 2) SB subjects (SB), who reported SB 
only; 3) TC subjects, who reported wake-time tooth clenching only. A fourth group was 
initially identified: the group of subjects reporting both SB and TC. However, due to the 
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small sample size and the absence of any statistical difference between this latter group 
(SB+TC) and SB or TC groups, it was omitted from the present study.  
Statistical comparisons between groups were performed using Pearson Chi-square 
Test and Fisher’s Exact Test. Binary Logistic Regression was performed in order to control 
for the age, gender and body mass index (BMI) factors; adjusted odds ratios (AOR), with 
the 95% confidence intervals (CI), were also calculated to assess the strength of the 
association. Independent variables with results p<0.2 from univariate analyses were 
incorporated into the logistic regression analysis. Statistical significance was assessed at 
p≤0.05. Data analysis was performed using SPSS (SPSS Statistics, Version 17.0.0 for 
Macintosh, Chicago, Illinois).  
 
 
Results 
In the entire sample, 15% reported SB and 12.4% TC. The prevalence of other 
variables over the 604 subjects is shown in Table 3.3.1.  
 
Bruxism (SB, TC), age, gender and body mass index 
Following the distribution of data according to reports of SB or TC, three groups 
were identified: 1) the CTL group (220 subjects); 2) the SB group, (58 subjects) and 3) the 
TC group (42 subjects). Twenty-four subjects reported both SB and TC. However, 
significant differences for any of the variables evaluated were not evident when compared 
with SB or TC groups separately. It seems that the risks for TMD, sleep, or behavioral 
complaints are not increased when SB and TC coexist. For this reason and for the small 
sample size, data concerning the statistical comparison for this latter group of subjects has 
been omitted. The remainder of subjects did not meet the inclusion criteria of any of the 
groups.  
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Variables concerning medical and dental history did not statistically differ between 
groups (data not shown). Group comparisons for TMD, sleep and behavioral signs and 
symptoms are reported in the following paragraphs and tables.  
A significant age difference was observed between groups. The mean age ± SD for 
the SB group was 12.0 ± 2.3; for the TC group 13.6 ± 2.4; and for the CTL group 12.2 ± 
2.2 (overall ANOVA, p=0.001; SBvsCTL, p=0.5; SBvsTC, p=0.001; TCvsCTL, 
p<0.0001). Considering the age distribution between children (aged ≤ 12 years old) and 
adolescents (≥ 13 years old), the SB group was mainly composed of children (67.3%), 
while the TC group was predominantly adolescents (78.6%) (Pearson chi-square, 
p<0.0001). Control subjects were equally distributed between children and adolescents. No 
gender difference was observed between the three groups (p=0.5).  
BMI was evaluated based on age- and sex-specific charts used to calculate BMI in 
pediatrics (32). Using percentiles, subjects were classified into four BMI categories 
(underweight, healthy weight, overweight, and obese) (33). The majority of the sample was 
in the healthy weight range (70.3% of CTL, 85.5% of SB and 83.3% of TC subjects). Nine 
CTL subjects and 1 SB subject were underweight, while 18 CTL, 1 SB and 3 TC subjects 
were obese. Due to the small numbers in certain categories, we regrouped the BMI variable 
into 2 categories: normal weight (healthy weight) and overweight (overweight + obese). No 
difference was observed between the three groups (p=0.09; Pearson chi-square).  
 
Craniofacial characteristics  
At the clinical examination, no difference between the three groups was observed 
for the following variables: palatal morphology, tongue size and tonsil size. 
SB subjects were assessed to be brachyfacial type in 28.1% of the group and dental 
class II in 60.3%. These prevalence values were significantly higher than in control subjects 
(p=0.001 and 0.01 respectively; Table 3.3.2). Interestingly, SB subjects showed a lower 
prevalence of posterior crossbite compared to controls (15.5% vs 33.8% respectively; 
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p=0.006). No difference was observed between TC group and controls for facial 
morphology, dental class and crossbite prevalence (Table 3.3.2). Overall, there were no 
differences between groups for maximal mouth opening (mean 50.3 mm; sd 6.2). However, 
limited lateral movements were observed in TC subjects compared to control and SB 
subjects (p=0.005 and 0.02 respectively).  
 
TMD signs and symptoms  
SB and TC subjects showed no statistical difference for other reported oral 
parafunctions such as: biting lips (26.3% for the SB group; 36.6% for the TC group), biting 
nails (47.4% for the SB group; 51.2 % for the TC group) and biting pencils or pens (20.7% 
for the SB group; 28.6% for the TC group). Control subjects were selected based on the 
absence of these oral parafunctions.  
The prevalence of tooth wear complaints was significantly higher in SB and TC 
subjects compared to control subjects (14% for SB, 9.8% for TC and 1.8% for CTL 
subjects). However, after controlling for the age factor, only SB subjects seem to be more at 
risk of reporting tooth wear (AOR 8.8). Complaints such as TMJ clicking, uncomfortable 
dental occlusion, jaw muscle fatigue and difficulties in yawning were significantly more 
frequent in SB and TC subjects than control subjects. Moreover, 12% of SB subjects 
reported experiencing frequent headaches in comparison to 4.1 % of controls (p=0.05) 
(Table 3.3.3).  
 
Sleep complaints 
Both SB and TC subjects reported more sleep problems than controls (Table 3.3.4). 
More specifically, the SB group reported significantly higher frequencies of daytime 
sleepiness, feeling unrefreshed in the morning, difficulties waking up in the morning, and 
failing to fall asleep within 30 min at least 3 times/week (suggestive of insomnia). The SB 
group also showed a higher prevalence of loud breathing during sleep compared to controls 
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(p=0.009). The TC group reported experiencing daytime sleepiness, feeling unrefreshed in 
the morning, and frequent awakenings more frequently than controls. Over 57% of the TC 
group reported having a dry mouth on awakening, suggestive of oral breathing during sleep 
(p=0.001). Other parasomnias, such as nightmares and nocturnal enuresis, and sleep 
disordered breathing, such as snoring and sleep apnea (cessation of breathing reported 
during sleep), did not differ between groups (Table 3.3.4).  
 
Behavioral complaints 
Several behavioral complaints were significantly higher in SB and TC groups 
compared to controls. SB and TC subjects were described as not listening when spoken to, 
as being easily distracted and as interrupting or intruding other people’s conversations. No 
difference was observed between SB and TC subjects (Table 3.3.5). 
 
Odds Ratio 
Adjusted Odds Ratio (AOR) was calculated for each group comparison. When 
compared to controls, either the bruxism groups (SB and TC) revealed that AOR were 
significantly higher for the following reported complaints: 1) orofacial: tooth wear, 
uncomfortable occlusion, jaw muscle fatigue, difficulties in yawning; 2) sleep-related: 
daytime sleepiness, feeling unrefreshed in the morning, difficulties awakening in the 
morning; 3) behavioral: easily distracted by external stimuli and prone to interrupting 
others (Table 3.3.6). The comparison between the SB group and the TC group revealed 
only a few variables with high and significant AOR: mouth breathing (AOR=4.2; CI=1.5-
11.2; p=0.004), feeling unrefreshed in the morning (trend; p=0.06), difficulty awakening in 
the morning (AOR=2.6; CI=1-6.9; p=0.04) and feeling hot during sleep (AOR=5.4; CI=1.7-
17); p=0.004). All these findings were higher in the TC subjects compared with the SB 
subjects.  
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Discussion 
The present study investigated the association between wake-time and sleep-related 
bruxism with TMD signs and symptoms, sleep problems and behavioral complaints in a 
pediatric population (7-17 years old) seeking orthodontic treatment.  
The prevalence of SB and TC in our sample reflects previous reports in literature 
concerning both general and orthodontic populations (21, 34). Both SB and wake-time 
tooth clenching are common in pediatrics. However, in this study these oral parafunctions 
appeared to be two separate entities observed in different populations; SB was more 
prevalent in children ≤12 years old, while wake-time TC in adolescence ≥ 13 years old. The 
reduction in SB prevalence with aging has already been reported in the literature (4). In the 
present study, the lower SB frequency in older subjects may have been related to the fact 
that parents visit their children’s bedroom less often after the age of twelve, which may 
influence SB reports. In any case, it has been demonstrated that more than 86% of adults 
with SB report having been bruxers in childhood (14). A genetic predisposition might 
explain the onset of SB in early ages and its probable lifelong persistency. Other 
environmental and development factors, however, may also influence the occurrence of SB 
and its consequences on the craniofacial apparatus. In contrast, wake-time TC seems to be 
more prevalent in adolescents and young adults, the same population in which a peak in 
TMD problems has been observed (35, 36). Longitudinal studies in both SB and TC 
samples may help clarify these issues.  
Tooth wear is widely reported in literature as being the distinctive dental sign of 
bruxism (both awake and during sleep). Although tooth wear cannot be used as an absolute 
diagnostic criteria for SB (37), SB results as a significant risk factor for tooth wear in 
children and adolescents (AOR 8.8). However, in this study tooth wear was established 
only by questionnaire. Thus, the reliability of the finding, although significant, should be 
evaluated with caution.  
SB subjects also seem to be more at risk of experiencing jaw muscle fatigue, 
difficulties in opening the jaw wide (i.e. yawning), and perceiving an uncomfortable dental 
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occlusion. Complaints concerning chewing performance and occlusal bite stability are 
frequently reported by TMD patients (38). Several studies have previously investigated SB 
as a sign/cause of TMD in pediatric populations (39). The present findings seem to support 
a potential role for SB mostly in the musculoskeletal/myogenous components of TMDs 
(muscle soreness or fatigue).  
Interestingly, SB subjects had a lower prevalence of posterior crossbite compared to 
controls. Dental crossbite, especially if unilateral and posterior, has been considered as a 
potential risk factor for the development of TMD in children and adolescents (34), although 
its causal relationship with TMD remains highly debated, with some evidence suggesting 
no association (40, 41). The present results suggest that SB and crossbite are likely to be 
non-related risk factors for TMD signs and symptoms.  
Subjects who reported TC during wake-time appeared to be more at risk of 
experiencing TMJ clicking, locking, jaw muscle fatigue, uncomfortable dental occlusion 
and difficulties in yawning. Moreover, they reported problems during sleep due to some 
form of pain. The presence of these TMD signs and symptoms suggests that wake-time TC 
is a harmful oral activity for the craniomandibular apparatus and may support its role as an 
etiological or contributing factor to the development of TMD (9, 42). 
SB subjects reported frequent headaches three times more than controls with an 
AOR of 4.3. The association between SB and headache has already been observed in both 
adults and children (43, 44). Moreover, it has been shown in literature that children with 
headaches frequently have concomitant sleep problems, such as SDB and SB, and a higher 
incidence of TMD (45, 46). In the present study, information on headache characteristics 
(e.g. pain intensity, pain quality, time of onset, and duration) was not collected, thus 
speculation on the specific types of headaches (e.g. tension type) and potential causes 
cannot be made in this study population.   
Both SB and TC groups reported more sleep complaints compared with the control 
group. Although the overall sleep quality was not judged as poor by either group, the 
feeling of non-refreshing sleep in the morning, daytime sleepiness, frequent awakenings 
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during sleep and a long sleep latency (>30 minutes to fall asleep), were frequently reported. 
These symptoms may suggest the presence of sleep disorders, especially of SDB. However, 
no significant association was found between SB and snoring or sleep apnea complaint-
reports. This may be due to the small sample size and to the limits of the methodology 
used. Parents may not be aware of respiratory pauses during sleep, though they may hear 
snoring or tooth grinding sounds. Although snoring was reported with similar prevalence in 
the three groups, 23.3% of subjects in the SB group reported loud breathing during sleep 
(significantly higher than controls; AOR 3.1). These subjects may be at risk of developing 
habitual snoring or respiratory disturbances in the future, and predisposing or aggravating 
factors may be already present (47). However, this remains speculative since specific 
evaluations of nasal cavities or oropharyngeal structures were not performed (e.g. nasal 
fibroscopy). Thus, no conclusion can be drawn and further studies are recommended.  
SDB signs and symptoms such as mouth breathing, snoring and daytime sleepiness, 
have been also related to long-face morphology (dolichofacial trait), maxillary transverse 
deficiency (narrow palate), and retrognathia (48, 49). In the study sample, 60.3 % of SB 
subjects presented a dental class II. However, they also showed a higher prevalence of 
brachyfacial phenotype when compared to controls. The retrognathic profile may be seen as 
a predisposing factor for SDB, while the brachyfacial phenotype (short and broad face) is 
known to be the typical characteristic face of a bruxer with hypertrophic masseter muscles. 
Although an association has been shown in the literature, there is not enough evidence to 
support a cause-effect relationship between specific craniofacial morphology and SDB. 
Whether the SDB is caused by abnormalities of the craniofacial structures, or the abnormal 
craniofacial development is due to functional limitations in the respiratory traits, remains to 
be established.  
As reported in the literature, the present findings confirm the association between 
bruxism and some behavioral habits/complaints. In particular, both SB and TC subjects 
seem to be easily distracted and interrupt others more than twice as controls. These 
behaviors, suggestive of ADHD-like behaviors, may be the manifestation of specific 
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psychosocial factors or personality traits that have been suggested to be related to bruxism 
in children and adolescents. For example, the prevalence of thought disorders, conduct 
disorders and antisocial disorders has been found to be higher in bruxers compared to non-
bruxers (50). Other characteristics, such as neuroticism, perfectionism, aggressiveness, 
higher sensitivity to stress and maladaptative coping strategies seem to be related to an 
increased risk of developing bruxism (51, 52).  
The present study has some limitations. First of all, all subjects were seeking 
orthodontic treatment at the Orthodontic Clinic of the University of Montreal. Therefore, 
the present findings should be extrapolated with caution since the external validity is not 
yet established. Furthermore, the methodology is limited in its scope: intra-examiner error 
testing was not performed. The reliability of the findings is based on the parents and 
children reports. The eventual presence of false positive and false negative cases must be 
considered in all three groups. Finally, the small size of the SB and TC groups analyzed 
should be taken into account. Due to the limited sample studied, it is possible that existing 
differences between groups were not detected (type II errors). Based on the results of the 
present study, a post-hoc sample size estimation performed on the variable “sleep 
discomfort due to pain” revealed that over 1000 controls and 300 bruxers would be needed 
to have an 80% power to detect a difference of 4.2% between groups (4.6% of CTL and 
8.8% of SB). For practical reasons, such sample sizes would be difficult to reach.  
In conclusion, the present study supports, at least in a pediatric population seeking 
orthodontic treatment, that sleep bruxism and wake-time bruxism are two different 
conditions with little overlap. Whether this is due to age and developmental maturation 
factors is unknown at this time. Further research and clinical trials are required to better 
understand and define the relationship between oral parafunctions and TMD, SDB, and 
behavioral signs and symptoms. However, in each group, subjects reporting the presence of 
specific orofacial, sleep or behavioral complaints may be at risk for developing further 
health problems. It is therefore mandatory that dentists investigate children and adolescents 
with sleep bruxism and wake-time tooth clenching in the presence of sleep or behavioral 
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complaints or reports. The patient at risk should be referred to a specialist (i.e., 
orthodontist, sleep medicine expert, psychologist) in order to assess the presence of co-
morbidity, to perform an early diagnosis (if indicated using polysomnographic tools), and 
to identify the best therapeutic approach for symptom management.  
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Table 3.3.1 Prevalence of variables in the study population (n=604). 
Prevalence % (95% CI) 
Sleep bruxism 15 (12 – 18) 
Wake-time bruxism (tooth clenching) 12.4 (9.6 – 15.2) 
Tooth wear 5.3 (3.5 – 7.1) 
TMJ clicking 2.8 (1.5 – 4.2) 
Jaw muscle fatigue  5.1 (3.4 – 6.9) 
Morning TMJ pain 4.8 (3.1 – 6.5) 
Headache 5.6 (3.8 – 7.5) 
Mouth breathing 34 (30.2 – 37.8) 
Loud breathing (during sleep) 17.7 (14.7 – 20.8) 
Snoring 25.6 (22.1 – 29.1) 
Sleep apnea 1.8 (0.8 – 2.9) 
Daytime sleepiness 7.3 (5.2 – 9.4) 
Feeling unrefreshed in the morning 20.7 (17.9 – 23.3) 
Easily distracted 26.7 (23.2 – 30.3) 
Agitated 7.7 (5.5 – 9.8) 
Interrupts or intrudes on others 11.8 (9.2 – 14.4) 
  
Values are given as percentage (95% CI).  
TMJ stands for temporomandibular joint. 
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Table 3.3.2 Craniofacial morphology and dental characteristics for control (CTL), 
sleep bruxism (SB) and wake-time tooth clenching (TC) subjects.  
 
 
 
Table 3.3.3 Temporomandibular (TMD) signs and symptoms, oral habits and 
parafunctions for control (CTL), sleep bruxism (SB) and wake-time tooth clenching 
(TC) subjects.  
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Table 3.3.4 Sleep complaints for control (CTL), sleep bruxism (SB) and wake-time 
tooth clenching (TC) subjects.  
 
 
Table 3.3.5 Behavioral complaints for control (CTL), sleep bruxism (SB) and wake-
time tooth clenching (TC) subjects.  
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Table 3.3.6 Dental, temporomandibular disorders (TMD), sleep and behavioral 
complaints.  
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Annex 1. The questionnaire used in the study. 
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Abstract  
Introduction: Sleep bruxism (SB) is a sleep-related movement disorder characterized by 
tooth grinding and/or clenching, frequently associated with snoring, sleep-disordered 
breathing, and headaches. This study assesses the efficacy of a mandibular advancement 
appliance (MAA) for SB management in symptomatic adolescents reporting frequent 
headache and snoring.  
Methods: Sixteen adolescents (mean age 14.9±0.5) reporting SB, frequent headache 
(>1day/week), and/or snoring underwent four ambulatory polysomnographic recordings for 
baseline (BSL; 1 night) and wearing the MAA during sleep (3 nights). SB diagnosis was 
confirmed by BSL recordings. The MAA was worn in three different positions (free splints 
– FS; neutral position – NP; and advanced to 50% of maximum protrusion – A50) for one 
week each in random order (FS–NP–A50 or NP–A50–FS, in compliance with titration 
order NP–A50). Headache complaints were assessed with pain intensity questionnaires 
using a 0–100 visual analogue scale in the morning after each PSG recording.  
Results: Overall, sleep variables did not differ across the four nights. SB index (episodes/h 
of sleep) decreased with use of the MAA, and up to 60% in A50 position (p=0.004; 
ANOVA). Snoring was measured as the % of sleep time spent snoring. The subgroup (n=8) 
with >3.7% snoring showed a significant improvement with the MAA: snoring decreased 
linearly (-93%; p=0.002). Prior to the MAA, headache intensity was reported (n= 16) at 
42.7±5/100 mm. It showed a decreasing trend from 21 to 51% with the MAA (p=0.07).  
Conclusion: Short-term use of an MAA appears to reduce SB as well as snoring and 
headache complaints in adolescents. However, interactions between SB, breathing during 
sleep, and headache as well as the long-term effectiveness and safety of the MAA in 
adolescents need further investigation.  
 
 
Keywords: Sleep bruxism, headache, snoring, adolescents, mandibular advancement 
appliance. 
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Introduction 
Sleep bruxism (SB) is a sleep-related movement disorder characterized by tooth 
grinding and clenching. It is frequently observed in pediatrics. Recent epidemiological 
studies have reported SB prevalence ranging from 13% to 38% in children and adolescents 
(1-5) The etiology of SB is still under investigation. Genetic, physiological, neurological, 
and psychosocial factors may be involved in the genesis of the rhythmic masticatory 
muscle activity (RMMA) that occurs frequently (at least >2 episodes/h of sleep) in patients 
with SB (6, 7).  
Repeated and sustained masticatory muscle activity during sleep may have a 
number of clinical consequences on the stomatognatic system, such as tooth wear, tooth 
damage, muscle fatigue, orofacial pain, temporomandibular disorders (TMD), and 
headache (HA) (1, 6, 8-11). SB may be also concomitant with other medical disorders, 
particularly other sleep disorders. These include parasomnias (e.g., sleep walking, sleep 
talking, enuresis), periodic limb movements during sleep, restless leg syndrome (RLS), and 
sleep-disordered breathing (SDB) (12-18). All these conditions may share common 
pathophysiological factors. In particular, it has been hypothesized that co-activation of the 
jaw-opening and jaw-closing muscles during RMMA may re-open the upper airway in 
response to an obstructive respiratory event such as obstructive sleep apnea (6, 19, 20). 
However, the relationship between SB and these comorbidities remains to be assessed, and 
further research is needed to determine whether these are cases of intersecting prevalence 
or if one condition causes or exacerbates the other.  
It is noteworthy that in clinical settings, subjects reporting SB in association with 
pain, HA, or sleep complaints need further clinical investigation, and treatments are usually 
required. This study assesses in adolescents reporting SB, HA, and snoring the 
effectiveness of a mandibular advancement appliance (MAA), which has previously been 
used to separately manage SB, HA, and SDB (21-25). We hypothesized that the MAA 
could improve breathing during sleep to the benefit of all concomitants complaints that may 
share common pathophysiological substrates.   
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Material and Methods 
This study followed a randomized controlled cross-over experimental trial design. 
The protocol was approved by the Ethics Review Board of the Hôpital du Sacré-Coeur de 
Montréal, and was conducted in compliance with the hospital’s clinical ethical standards. 
All participants and at least one of their parents signed a written consent form and received 
compensation for participating in the study.  
 
Study sample 
Participants were recruited through announcements (previously approved by the 
Ethics Review Board) posted on the university campus and in the dental clinics of the 
University of Montreal from winter 2009 to summer 2011. Volunteer participants were 
initially interviewed by the research staff by phone (either directly or through their parents). 
Participants with a positive history of SB with HA or snoring were invited to come to the 
university research lab for a clinical examination and an initial ambulatory 
polysomnographic (PSG) assessment.  
The inclusion criteria were age from 12 to 19 years and a history of SB associated 
with frequent HA (>1/week) and/or snoring. Reports of SB and snoring were assessed in 
the first night of PSG recording (BSL). HA intensity was assessed using a questionnaire 
with a 0–100 mm visual analogue scale (VAS). Headache was self-reported, with no 
clinical diagnosis. HA criteria were based on the definition of probable episodic tension-
type HA (International Classification of Headache Disorders, ICHD-II, by the International 
Headache Society (26)). Exclusion criteria were diagnosed migraine, cluster HA, 
orthodontic treatments, severe medical diseases, and regular medications use.  
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Study protocol 
At the first visit, candidates filled out questionnaires to assess general health, sleep 
quality, pain, headache, and bruxism complaints.  
The clinical examination (performed by MCC) included an assessment of dental, 
temporomandibular joint, and masticatory muscle status. Jaw movements, including 
maximal opening, laterality, and protrusion, were also measured.  
The first ambulatory PSG was usually performed on the day of the clinical 
examination. It was used to both confirm the SB diagnosis and to establish a baseline 
(BSL) night. Because the ambulatory PSG system allowed the participants to sleep in their 
own bed at home, a habituation night was not required.  
Candidates who met the inclusion criteria were invited to come to the dental clinic 
for dental impressions and radiograms. X-rays, including a panoramic view and a lateral 
cephalogram, were performed to rule out contraindications to MAA use and to assess 
craniofacial features.  
The MAA was manufactured by a specialized dental laboratory (Dentec Laboratory, 
Quebec City, Canada) and was provided by ResMed (Narval O.R.M.™ CC, USA and 
France). The appliance is an optimized mandibular retainer device comprising upper and 
lower custom-made semi-rigid splints that are vacuum-pressed onto the patient’s tooth 
molds. The two splints are linked by a tractable flexible joint designed to mimic the 
physiological articulation of the tempormandibular joint (TMJ). This enables jaw 
movement and allows setting and adjusting mandible protrusion according to the 
individual’s advancement capability (Figure 3.4.1). This MAA is highly comfortable. The 
material is flexible and its minimal size means there is no invasion of tongue space and no 
contact with incisors. This prevents tooth tilting and minimizes post-wear dental sensitivity. 
Once the individually fitted MAA was customized, it was given to the participant and 
adjusted. Participants were instructed to wear it during sleep only. All participants wore the 
MAA in three different positions (one week each) in random order: free splints (FS), 
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neutral position (NP), and advanced to 50% of maximum protrusion (A50). FS position was 
obtained by removing the connectors between the upper and lower splints so that only the 
dental surfaces were covered, allowing a full range of jaw movement. In NP position, the 
mandible was retained in maximum intercuspidation (set as the participant’s normal 
occlusion). Although no advancement is obtained, this setting prevents the jaw from 
moving backward during sleep. The A50 position was obtained by shortening the 
connectors to retain the mandible at 50% of the previously measured maximum protrusion.  
Each MAA position was tested for one week followed by a washout period (5–7 
days) to avoid a potential carry-over effect. The three positions were randomized into two 
sequences: 1) FS, NP, A50; or 2) NP, A50, FS, in compliance with a titration paradigm 
(NP–A50). Participants were randomly allocated to one of the two sequences. Appliance 
compliance was monitored using self-report questionnaires. After each week with the 
MAA, participants underwent PSG recordings while wearing the device during sleep. 
Participants underwent a total of four ambulatory PSGs: one baseline and three sleeping 
with the MAA.  
 
Ambulatory PSG 
An ambulatory PSG system (Siesta, Compumedics, Australia) was used to perform 
a full sleep study at the participant’s home (level 2). Participants came to the research lab in 
the late afternoon. The research staff placed all the electrodes on the participants, who then 
left the lab. Participants returned the PSG system the following day. Participants and their 
parents were instructed to start PSG recording in the evening once everything was correctly 
set and the participants were lying in bed (corresponding to lights off). Participants were 
instructed to stop the system in the morning at awakening (lights on).  
Sleep data were checked the next day. If any technical problems had compromised 
the data, recording was repeated the following day. The overall success rate of the 
ambulatory PSG recordings was 86%.  
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The following channels were recorded: EEG (F3M2, F4M1, C3M2, C4M1, O1M2, 
O2M1); EOG (right and left); ECG (3 derivations); and EMG from the suprahyoid muscles 
and the right and left masseter and temporalis muscles (essential for RMMA scoring). 
Respiratory parameters were assessed by recording abdominal and thoracic respiratory 
effort, airflow (oro-nasal cannula), and oxymetry. A microphone was used to measure 
snoring during the PSG recording at the participant’s home.  
For the offline analysis, data were visually scored according to the American 
Academy of Sleep Medicine Criteria (27). Despite the absence of audio-video recordings, 
RMMA was scored according to standard published rules (28, 29). In absence of an 
international consensus on which respiratory scoring criteria should be used in adolescents 
(i.e., pediatric vs. adult criteria), we decided to score breathing events according to the 
AASM criteria for children based on a recent publication that showed their greater 
sensitivity (27, 30). All nights were scored blind to the presence/absence and position (e.g. 
FS, NP, A50) of the MAA. 
 
Statistical Analysis 
Based upon Landry-Schönbeck et al.(23), a sample size of 16 subjects was 
estimated as sufficient to detect a decrease in RMMA index of 40% from baseline with the 
NP (effect size 0.77), with a power of 0.80 and at an alpha level of 0.05. Statistical 
comparisons between BSL, FS, NP, and A50 data were made using repeated measures 
ANOVA and pairwise tests (significant at p ≤ 0.05). Abnormally distributed data (Shapiro-
Wilk normality statistic < 0.05) were normalized by applying Log10. In the case of 
randomly missing data, a mixed model analysis was applied to include all participants in 
the analysis. Data were analyzed using SPSS (IBM SPSS Statistics, Version 17.0.0 for 
Macintosh, Chicago, IL, USA).  
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Results 
Demographic, sleep, and dental characteristic of the sample at baseline 
Of the many adolescents screened by phone interviews, 23 candidates were invited 
to the research lab to undergo a clinical examination and the first ambulatory PSG. Of 
these, 16 (8 F, 8 M; mean age 14.9±0.5 years) met the inclusion criteria and completed the 
study (no drop out).  
At the clinical examination, all 16 participants reported tooth-grinding during sleep. 
Eleven of these were aware of SB because it was reported by their parents, whereas the 
remaining participants were told by other sources (e.g., friends, siblings, dentist). The 
majority (12/16) also reported daytime tooth clenching and other daytime oral 
parafunctions such as lip, nail, or cheek biting or gum chewing.  
In the screening questionnaire, all participants reported frequent HA (>1/week) in 
the morning (11/16), during the day (10/16), and/or in the evening (11/16). HA pain was 
described as a feeling of tightening and pressing on the head without other associated 
symptoms (e.g., nausea, photophobia). The mean HA intensity assessed on a 0–10 mm 
visual analogue scale (VAS) was 42.75±5 on the screening questionnaire and 48±6.2 on 
clinical examination. Only six of the 16 participants reported occasional use of analgesics 
(e.g., ibuprofen or acetaminophen) for intense HA.  
Seven participants reported nonrefreshing sleep. However, scores on the Epworth 
Sleepiness Scale and the Pittsburg Sleep Quality Index were within normal limits (mean 
value ± SEM of 7.3 ± 1.1 and 5.7 ± 0.6 respectively). 
Mild to moderate snoring was reported by most participants (12/16), whereas none 
was aware of having sleep apnea. All participants were healthy (i.e., no medical or 
neurological diseases), and had a normal body mass index.  
During the clinical examination, participants were also assessed for dental status, 
orthogantic profile, Mallampati score, and TMJ parameters (e.g., mandibular range of 
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motion, presence of muscular or TMJ pain) (Table 3.4.1). Only three participants presented 
mixed dentition (i.e., dentition containing both primary and secondary teeth). However, an 
adequate MAA retention and fit was obtained in all cases.  
 
Sleep variables  
The sleep variables recorded by the ambulatory PSG system in the BSL, FS, NP, 
and A50 nights are presented in Table 3.4.2. Overall, no significant difference was found 
between the four nights for sleep duration; wake time after sleep onset; sleep efficiency and 
percentage of sleep stages N1, N2, N3, and R; sleep cycles; number of awakenings; arousal 
index; or sleep stage shifts. However, in a pairwise comparison between nights, the % of 
stage N2 sleep significantly decreased between BSL and NP nights (p=0.03) and between 
BSL and A50 nights (p=0.02), and a trend was observed between BSL and FS nights 
(p=0.06).  
A sequence effect (group with the sequence FS, NP–A50 vs. group with the 
sequence NP–A50, FS) was ruled out using t-tests for the following variables: sleep 
duration, arousal index, number of awakenings, and RMMA index. No differences between 
groups were observed.  
 
Sleep bruxism 
Data on RMMA and other masticatory muscular activity are presented in Table 
3.4.2. Participants’ reports of SB were confirmed by the first PSG recording (BSL night). 
RMMA episodes were identified and scored during sleep and wake epochs. SB was 
diagnosed and participants were included in the study if the RMMA index was greater than 
2 episodes per h of sleep. However, for the statistical analysis, the RMMA index reported 
in Table 3.4.2 refers to episodes occurring during sleep only. 
With the MAA, the RMMA index decreased significantly (overall p=0.01), linearly 
from BSL toward FS, NP, and A50 nights (p=0.007). Specifically, the RMMA index 
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decreased by 16.8% from BSL to FS night (p=0.02), 40% from BSL to NP night (p=0.02), 
and 60.5% from BSL to A50 night (p=0.004). However, no significant difference was 
observed between the three MAA positions. Only one participant showed an increase in 
RMMA index, and only in the night with the MAA in advanced position (A-50). In the 
BSL night, 69.7% of RMMA episodes were associated with sleep arousal (during a <5 sec 
time window). This association remained present in the MAA nights.  
Parallel to the RMMA index, the burst index decreased linearly (p=0.01), with an 
overall significant decrease between BSL and FS, NP, and A50 nights (p=0.02), with no 
differences between the three MAA positions.  
Conversely, the index of other muscular events recorded on the masseter and 
temporalis EMG channels increased significantly and linearly in the nights with the MAA 
(p=0.03). Because these muscular events involved the masticatory muscles but did not meet 
the RMMA scoring criteria, they were classified separately. In the absence of standard or 
validated criteria, we selected only episodes lasting from 0.5 to 10 sec during sleep (criteria 
derived from the AASM criteria for leg movements during sleep (27)). These other 
masticatory muscular activities increased by 20% with the MAA in the FS night (p=0.1), 
35.7% in the NP night (p=0.01), and 34.3% in the A50 night (p=0.04).  
 
Snoring and breathing during sleep 
In the absence of a standard validated method to measure and report snoring, we 
quantified it as the % of sleep spent snoring. From the PSG recordings, overall snoring did 
not change (p=0.1; Table 3.4.2). However, using the median value of the BSL night as a 
cut-off, two groups of eight participants each were identified (above or below 3.7%). The 
≥3.7% group showed a significant reduction in snoring (p=0.002), which decreased linearly 
(p=0.007) by 79% in the FS nights (p<0.001), 95.8% in the NP night (p=0.005), and 93% in 
the A50 night (p=0.008). However, no difference was observed between the three MAA 
positions. In the <3.7% group, no significant difference was found between nights.  
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Airflow and oxygen saturation were the only PSG variables with random missing 
data due to technical problems during the unattended recordings (2/64 nights for airflow, 
and 6/64 for oxymetry). We therefore performed a mixed model analysis to compare these 
variables across BSL, FS, NP, A50 nights. Results are presented in Table 3.4.2. The apnea-
hypopnea index (AHI), at <1 episode/h of sleep at BSL, showed no significant difference 
between the four nights (p=0.5). Oxygen saturation levels were also within normal limits 
and showed no difference between nights.   
 
Headache complaints 
Headache complaints were assessed on a VAS scale the day after each PSG 
recording. Overall, HA intensity showed an improving trend, decreasing by 21-51% from 
the initial reported intensity (p=0.07). However, due to the heterogeneous nature of the HA 
(morning vs. daytime) in our sample and the methodology applied (morning questionnaire), 
no significant difference was detected between the four nights. For the six participants who 
reported HA in the morning only, a significant reduction of HA intensity (-57%) was 
observed between BSL and NP night (p=0.03).  
In the morning questionnaire, participants were also asked to assess their sleep 
quality during PSG recording on a VAS scale (0–100 mm). They rated it at 58.2±5.2 at 
BSL, 56.5±6 with the MAA in FS position, 52.1±6.4 with the MAA in NP position, and 
53.7±7.6 with the MAA in A50 position (overall p=0.9).  
 
Subjective assessment of the mandibular advancement appliance 
The MAA was subjectively assessed using another questionnaire filled out after 
each wearing period in FS, NP, and A50 position. Data are presented in Table 3.4.3. 
Comfort decreased significantly and linearly with position advancement (p=0.03). No 
change was found between the three MAA positions for all other assessed variables.  
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Discussion 
The present study adds to the current literature new insights on the effectiveness and 
mechanisms of MAA. Our results suggest that short-term use of an MAA during sleep in 
symptomatic SB adolescents may help reduce RMMA and improve snoring and HA. We 
examined adolescents with comorbidities, which are frequently observed in daily clinical 
practice. However, these conditions rarely receive further attention or a confirmed 
diagnosis. In fact, SB incidence is usually underestimated, snoring is considered normal, 
and HA complaints are ignored. Yet early diagnosis and treatment are vital in this young 
population to prevent later consequences (e.g., damage to the stomatognatic system, the 
impact on academic performance of chronic pain and/or HA, risks of SDB-related 
cardiovascular and metabolic disorders).  
Several types of oral appliances have been tested and have shown varied 
effectiveness in managing SB (21-23, 31-34). However, the actual mechanism of action 
remains unknown (35). Historically, the effectiveness of oral appliances in SB has been 
attributed to various factors, such as by covering tooth surfaces, modifying peripheral 
sensory inputs, and/or adjusting occlusal status. In the case of the MAA studied here, we 
hypothesize that the improved breathing during sleep could result in fewer SB episodes.  
Consistent with previous studies in young adults (21-23), our findings confirm the 
short-term effectiveness of MAA in adolescents with SB, HA, and snoring. However, 
although progressive clinical improvement was achieved, no significant difference was 
found between the occlusal free splint position (control) and the neutral or advanced 
positions (active jaw retaining or repositioning). This finding suggests other possible 
explanations: decreased SB motor activity may be due to the appliance’s restriction of jaw 
movements and/or its influence on masticatory muscle spindle input (e.g., information on 
muscle length, jaw position). However, although these peripheral sensory factors are known 
to influence the central generation pattern (CGP) of mastication during wakefulness (36, 
37), their role in the genesis and regulation of RMMA during sleep remains unclear (20, 
38).  
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As reported in the literature, oral appliances may also exacerbate SB (22). In our 
sample, only one participant showed a clear increase in RMMA with the MAA in advanced 
position. However, the uncontrolled PSG recording condition (at the participant’s home) 
does not guarantee that the MAA was worn properly throughout the night. The appliance 
used in this study did not include an intra-device compliance chip, which would be very 
useful for objectively monitoring sleep time with the MAA.  
During sleep, other motor activities may occur that involve the orofacial and 
masticatory muscles, such as lip sucking, swallowing, yawning, and head movements. 
These activities account for an estimated 40% of all muscular events in individuals with SB 
(39, 40). In contrast to previous findings (22), we recorded significant increases in other 
masticatory muscle activities when the MAA was worn. It remains to be demonstrated 
whether this result is related to the low classification specificity of these movements due to 
the absence of video recording, or whether the wearing of an MAA may have changed the 
observable EMG pattern instead of acting on the genesis of SB-related movements.  
Of the many treatments that have been tested for the management of SB (e.g. oral 
appliances, medications, behavioral therapy), none has been demonstrated effective in 
curing the disorder (i.e., completely abolishing SB) (32). As for other spontaneous 
movements during sleep (e.g., periodic limb movements)(41, 42), it has been suggested that 
more than one type of RMMA episode occurs, e.g., isolated RMMAs, arousal related-
RMMAs, breathing-related RMMAs, and leg- or body-movement-related RMMAs. These 
movements may vary in their response to different treatments that specifically address 
related factors.  
Recent hypotheses about SB genesis include sleep-disordered breathing, in which 
the SB-related co-contraction of jaw-opening and jaw-closing muscles acts to reopen the 
airway after an obstructive respiratory event. This hypothesis needs to be tested in SB 
patients with concomitant SDB. In fact, our population was composed of SB adolescents 
with mild to moderate snoring only. Therefore, improved airflow and oxygen saturation 
during sleep may not have been detectable. However, the group of participants with higher 
snoring (arbitrarily set at >3.7% of sleep spent snoring) showed a significant improvement 
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with the MAA, as well as decreased RMMA. To our knowledge, an MAA is rarely applied 
to manage snoring or SDB in pediatrics, where more radical or definitive treatments, such 
as adenotonsillectomy or orthodontics, are preferred (43, 44). However, oral devices may 
be used as a temporary treatment, or when indicated, to mimic and test the potential effects 
of orthopedic therapy or orthognatic surgery, which are usually performed toward the end 
of adolescence (45).  
Headache complaints, especially in the morning, have been related to both SB and 
SDB (11, 46, 47). Putative pathophysiological mechanisms include repeated and sustained 
muscle contractions in SB and recurrent hypoxia and hypercapnia in SDB. However, these 
hypotheses remain to be validated, and many other factors may be involved. In the present 
study, for example, the majority of participants were also aware of daytime oral 
parafunctions such as tooth clenching or nail and lip biting. These are recognized risk 
factors for the development and maintenance of forms of orofacial pain, including headache 
(1, 48). The coexistence of wake-time bruxism may explain the partial effect of the MAA 
on the subjectively assessed HA complaints, the only symptom to show an improvement 
trend in our study sample.  
Due to the limitations of this study, our results need to be further investigated and 
confirmed in future studies. First, we were unable to determine the effects of airway 
opening and improved oxygenation during sleep on RMMA activity and HA complaints. 
According to the post-hoc sample size estimation, in order to show a statistically significant 
difference between the three MAA positions, more than 100 participants would be needed 
for the RMMA index and more than 200 for HA complaints. Note, however, that a more 
homogeneous sample (e.g., morning headache only) would probably have diminished the 
required sample size. Other limitations concern the methodology. Whereas the ambulatory 
PSG system ensured high participation and compliance, especially in adolescents (only 
25% of our sample, i.e. four participants, all aged > 16 years old, would have participated if 
the study had been conducted in a hospital-based sleep center instead of at home), the lack 
of a sleep technician to attend the full recording increased the number of technical failures, 
  
 
127
missing data, and uncontrolled conditions. Moreover, the absence of a concomitant audio-
video recording reduced the scoring specificity for SB and other orofacial and masticatory 
movements. To subjectively assess headaches, an HA diary would have been more accurate 
to monitor variations in intensity and occurrence. Finally, the study protocol was designed 
to test the MAA effect in the short term only. Long-term treatment may be necessary to 
gain a significant improvement for signs and symptoms related to SB, HA, and SDB.  
 
 
Conclusion 
Short-term use of an MAA appeared to reduce SB and improve snoring and 
headache complaints in adolescents. However, the interactions between SB, breathing 
during sleep, and headache as well as the long-term effectiveness and safety of an MAA in 
adolescents need to be further investigated.  
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Figure 3.4.1 The mandibular advancement device.  
 
 
 
from ResMed Narval O.R.M® CC (www.resmed.com) 
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Table 3.4.1 Demographic, dental and oropharyngeal data for the study sample (n=10) 
assessed during the clinical examination.  
 
Demographic Data 
Gender distribution: 8 F, 8 M 
Mean age:  14.9 ± 0.5 years 
Clinical Characteristics of Oropharyngeal Structures 
Mean maximum mouth opening: 50.2 ± 1.5 mm  
Mean maximum jaw protrusion: 8.1 ± 0.4 mm  
Dental and skeletal Class (based on cephalometric assessment)  
Class I Class II Class III 
3/16 (18.75%) 11/16 (68.75%) 2/16 (12.5%) 
Mallampati Score  
Type I Type II Type III Type IV 
3/16 (18.75%) 7/16 (43.75%) 4/16 (25%) 2/16 (12.5%) 
 
Data are presented as mean ± SEM, or number and %.  
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Table 3.4.2 Polysomnographic variables for the baseline night and the three nights 
with the mandibular advancement appliance. 
 
Data are presented as MEAN values ± SEM or MEDIAN (min–max). P values are 
calculated with ANOVA. If normality test (Shapiro–Wilk) < 0.05, data of that variable were 
normalized by applying Log10. Significant differences are in bold characters. 
 
PSG Variables BSL night 
(no device) 
FS night 
(free splints) 
NP night 
(neutral position) 
A50 night 
(50% advanced) 
P value 
Sleep variables  
Total sleep time (min) 414.5 ± 14.4 396.6 ± 23.5 390.7 ± 21.3 398.3 ± 18.8 0.8 
Wake time after sleep onset 
(min) 
11 
(2.7–46) 
11.7 
(1–74.7) 
19.2 
(2.3–101.3) 
11.3 
(11.3) 
0.6 
Sleep efficiency (%) 96.7 
(91–99.3) 
96.6 
(82.1-99.6) 
94.4 
(76.4–99.2) 
95.8 
(86.8–98.7) 
0.2 
Sleep latency (min) 17.2 ± 2.5 23.4 ± 5.2  26.8 ± 6.5 23.2 ± 5.9 0.5 
REM sleep latency (min) 136.1 ± 11.5 99.3 ± 8.9 136 ± 17.3 106.6 ± 11.7 0.1 
Stage N1 (%) 3 
(2–10) 
3.1 
(0.7–8.5) 
4.9 
(1.9–8.1) 
3.4 
(1.3–9.2) 
0.2 
Stage N2 (%) 42.5 ± 2.1 37.9 ± 2.2 38.9 ± 2 38.3 ± 1.6 0.1 
Stage N3 (%) 36 ± 2.4 40.1 ± 2.9 38.5 ± 2.2 39.4 ± 2.3 0.3 
Stage R (%) 17.1 ± 1 18.1 ± 1.3 17.8 ± 1.1 18.4 ± 1.1 0.7 
NREM/REM sleep cycles (n) 4.5 
(2–5) 
4 
(3–6) 
4 
(2–6) 
4 
(3–8) 
0.5 
Awakenings (n) 16  
(6–52) 
21 
(2–53) 
30.5 
(5–75) 
21 
(7–62) 
0.4 
Arousals (n/h) 11.6 
(4.8–27.5) 
10.8 
(3.4–40.2) 
12.3 
(4.5–22.3) 
13.4 
(3.3–26.4) 
0.4 
Sleep stage shifts (n/h) 28.6 ± 1.6 29.1 ± 1.7 30.5 ± 2 30.6 ± 2.3 0.6 
Sleep-related masticatory movement variables  
RMMA index (n/h) 3.8 
(1.8–7) 
3.2 
(0.1–6.4) 
2.3 
(0–7) 
1.5 
(0.1–15.5) 
0.01 
Burst index (n/h) 18.65 
(8.9–51) 
19.1 
(0.6–46.8) 
12.4 
(0–41.6) 
10.3 
(1–116.1) 
0.02 
Other masticatory muscular 
activity (n/h)* 
7 
(3–12.6) 
8.4 
(2.3–18.7) 
9.5 
(2.9–20.6) 
9.4 
(3–18.8) 
0.03 
Sleep-related breathing variables  
Snoring (% of sleep spent 
snoring) (n=16) 
 
     Group ! 3.7% (n=8) 
 
     Group < 3.7% (n=8) 
3.7 
(0.1–67.4) 
 
21.4 
(3.8–67.4) 
2.9 
(0.1–3.5) 
3.9 
(0.1–25.9) 
 
4.5 
(0.2–19.9) 
3.9 
(0.2–25.9) 
1.5 
(0–17.1) 
 
0.9 
(0–13) 
2.6 
(0–17.1) 
2.3 
(0.26.6) 
 
1.5 
(0–14.7) 
3.8 
(0–26.6) 
0.1 
 
 
0.002 
 
0.7 
Apnea-hypopnea index § (n=16) 
0.7 ± 0.2 
(n=14) 
1 ± 0.4 
(n=16) 
1 ± 0.2 
(n=16) 
0.6 ± 0.1 
0.5 
Oxygen saturation level (%)§ 
    Overnight mean value 
     Overnight minimum value 
     Overnight maximum value 
(n=12) 
97.6 ± 0.2 
94.4 ± 0.5 
99.7 ± 0.1 
(n=15) 
97.4 ± 0.2 
94.1 ± 0.5 
99.6 ± 0.1 
(n=16) 
97.5 ± 0.1 
94.5 ± 0.3 
99.5 ± 0.1  
(n=15) 
97.7 ± 0.1 
94.6 ± 0.4 
99.8 ± 0.1 
 
0.2 
0.8 
0.2 
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The mandibular advancement appliance (MAA) was worn in three different positions (free 
splints, FS; NP, neutral position; and A50, advanced to 50% of maximum jaw protrusion). 
After the first baseline night (BLS), to comply with a titration paradigm, the three positions 
were randomized into two sequences: 1) FS, NP, A50; or 2) NP, A50, FS. Participants were 
randomly allocated to one of two sequences. For table clarity, nights with the MAA are 
presented in order from active control to advanced, disregarding the two randomized 
sequences. 
RMMA refers to rhythmic masticatory muscle activity. 
*Other masticatory muscular activities are events recorded on the masseter and temporalis 
EMG channels that did not meet the RMMA scoring criteria and could not be classified due 
to the absence of a video recording (i.e., it was impossible to distinguish between 
swallowing, coughing, etc.). Only episodes occurring during sleep with duration of 0.5–10 
sec were included in the analysis (extrapolated from AASM 2007, criteria for leg 
movements). 
§ Mixed general model for the presence of random missing data. Sample size is indicated 
for each variable and each night.  
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Table 3.4.3 Self-report results from the questionnaire assessing the mandibular 
advancement appliance (MAA).  
 
Variable FS night 
(free splints) 
NP night 
(neutral position) 
A50 night 
(50% advanced) 
P value 
Appliance adaptation period (days) 3.6 ± 0.7 3.5 ± 0.5 5.4 ± 1.6 0.2 
Time wearing the appliance 
(h/night) 
7.6 ± 0.3 7.6 ± 0.3 7.5 ± 0.4 0.4 
Nights per week with the appliance 
(n) 
5.5 ± 0.4 6 ± 0.6 5.3 ± 0.3 0.7 
MAA Comfort (VAS) 57.8 ± 5.6 48.1 ± 5.3 40.7 ± 6.8 0.03 
Overall MAA satisfaction (VAS) 63.9 ± 5.8 68.2 ± 5 58.9 ± 5.6 0.3 
Overall MAA effectiveness (VAS) 65.7 ± 5.6 73.6 ± 4.4 60 ± 7.6 0.1 
Sleep quality with the appliance 
(VAS) 
57.1 ± 6.3 62.9 ± 6.1 53.9 ± 6.5 0.6 
 
Data are presented as mean ± SEM. VAS stands for visual analog scale (0–100 mm). P 
values are calculated with ANOVA. Significant differences are in bold characters.  
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The following pages will be dedicated to discuss the main findings of the four research 
articles included in this thesis. In accordance with the structure of this work, the first 
section will focus on the etiology and pathophysiology of RMMA during sleep, as 
supported by our new results (Section 4.1). The second section will summarize the 
epidemiological and clinical features of SB in pediatrics, and it will discuss the putative 
mechanisms that may explain the effect of MAA on RMMA during sleep (Section 4.2). 
Finally, the scientific and clinical relevance of the findings, the study limitations, and the 
future research directions will be considered (Sections 4.3 and 4.4).  
 
 
4.1 CAP Phase A as the “Permissive Window” for Rhythmic 
Masticatory Muscle Activity during Sleep 
The first two research articles included in this thesis aimed at further investigating 
the nature of the relationship between RMMA and sleep arousal. To achieve this objective, 
cyclic alternating pattern (CAP), a scoring method used to assess sleep instability (82), was 
analyzed in two different experimental protocols.  
Previous studies have described RMMA as a motor activity secondary to sleep 
arousal (61, 63, 64, 66), and have made an association between RMMA and phase A of 
CAP (61, 252). Moreover, the majority of RMMA episodes were shown to occur in 
clusters, with the most frequent interval between 20 and 30 seconds (64), a periodicity that 
recalls the physiological arousal rhythm described as CAP (83). 
The present data confirm the time-correlation between RMMA and CAP phase A, 
albeit with marked differences between phases A1, A2, and A3. For example, phase A1, 
which appears to reflect the cyclic homeostatic fluctuation of delta power (253, 254), 
reaches the highest frequency during the first NREM/REM sleep cycle and progressively 
declines across the successive sleep cycles. Conversely, arousal subtypes A2 and A3 are 
lower in relation to NREM deep sleep and increase before REM sleep onset. The RMMA 
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pattern of occurrence reflects CAP phase A2 and A3 modulation, reaching a peak during 
the pre-REM intervals of the sleep cycle (see Figure 3.1.1 page 53, and Figure 3.2.2 page 
74).  
The association between RMMA occurrence and CAP phase A was preserved even 
when external disturbing factors were applied and sleep instability was experimentally 
enhanced (either with clonidine or sensory stimulations). As expected in these conditions, 
CAP variables increased in both SB and control subjects. At the contrary, RMMA 
frequency was either decreased (under clonidine) or unchanged (under sensory 
stimulations). Taking these results together, we concluded that CAP phase A (i.e., sleep 
arousal) is not the generator or trigger of RMMA during sleep, rather the “permissive 
window” that facilitates, in period of unstable sleep, the occurrence of these motor events. 
 
4.1.1 Evidence from the Experimental Trial with Clonidine 
In a previous study conducted in our laboratory, a single dose of clonidine was 
shown to reduce RMMA by approximately 60% in SB subjects (240). This major effect has 
been used as a proof of concept to support the hypothesis that RMMA is the consequence 
of a cascade of physiological phenomena starting with the activation of sympathetic 
nervous system (See Figure 1.3 page 22). In fact, by shifting the balance between 
sympathetic and parasympathetic tone toward this latter one, clonidine blocks the cascade 
of autonomic events that seem to precede RMMA onset, thus preventing RMMA 
occurrence during sleep. However, the modulation of sleep arousal and sleep instability 
under clonidine was not evaluated earlier.  
Clonidine is a potent sympathetic drug known to alter the NREM/REM sleep 
structure (255, 256). In our study, the most evident change was the marked suppression or 
complete abolishment of REM sleep. Based on the standard sleep scoring criteria (18, 257), 
REM sleep is identified when specific low amplitude, mixed frequency EEG patterns (e.g., 
sawtooth waves), rapid eye movements, and muscle hypotonia occur. A quantitative 
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analysis performed on the EEG, EOG and EMG channels confirmed that clonidine 
suppressed REM sleep in all SB subjects. In particular, significant difference in the EEG 
spectral analysis − mostly affecting slow wave activity and spindles − minor rapid eye 
movements, and higher levels of EMG activity were observed under clonidine (Carra et al. 
article in preparation. Abstracts (258, 259)). The suppression of REM sleep is a sensitive 
indicator of the drug effect on the central noradrenergic cells that regulate the NREM/REM 
switch. The homeostatic and circadian drives naturally push the sleeping individual toward 
REM sleep but clonidine blunts the occurrence of this sleep phase.  
According to the reciprocal-interaction model (260, 261), the NREM/REM sleep 
cycle is generated by a finely regulated discharge of two brainstem cell groups that have 
self-excitatory and self-inhibitory connections and reciprocal firing pattern. In particular, 
the cholinergic REM-ON neurons, located in the laterodorsal-peducolopontine tegmentum, 
fire immediately before and during REM sleep, whereas the noradrenergic REM-OFF 
neurons, sited in the locus coeruleus, operate during NREM sleep and stop firing during 
REM sleep. The cessation of firing of the REM-OFF neurons seems to be a pre-requisite 
for the generation of REM sleep (107, 262). Therefore, the REM sleep suppression 
observed under clonidine may be related to the drug action on the postsynaptic α2-
adrenoceptors in the brainstem (263).  
Under clonidine, the drastic alteration of the NREM/REM sleep cycle was 
paralleled by the alteration of the cyclic rise of CAP phase A2 and A3 in the pre-REM 
periods. It has been hypothesized that the abundance of CAP phase A1 in the descending 
phase of the sleep cycle is the EEG expression of the cerebral mechanisms involved in the 
build-up and maintenance of deep NREM sleep and may reflect the REM-OFF cell activity. 
Conversely, CAP phases A2 and A3 are predominant in the period preceding the onset of 
REM sleep (ascending phase) and may express the REM-ON drive (83). Thus, the increase 
in CAP variables (e.g., CAP time, CAP sequence, number and percentage of CAP phase 
A3) observed under clonidine may be related, among others, to its adrenergic action in the 
brainstem.  
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In the brainstem, the arousal system acts as a control mechanism that paces the 
progression of NREM/REM sleep cycle and protects sleep architecture against destabilizing 
stimulations. Arousals are active adaptative responses of the sleep regulatory mechanisms, 
which tend to remove the stimulus-disturbance effect and re-establish an internal 
equilibrium (75). The analysis of CAP enriches the neurophysiological information on 
phasic arousals and supplies an appropriate framework for investigating periodic 
phenomena such as movements disorders, like periodic limb movements during sleep 
(PLMS) or sleep bruxism. Physiologic, paraphysiologic and pathologic motor activities 
during NREM sleep are almost always associated with a stereotyped arousal pattern 
characterized by an initial increase in EEG delta power and heart rate, followed by a 
progressive activation of faster EEG frequencies (91, 92). These findings suggest that 
motor patterns are already written in brain codes (central pattern generator) embraced with 
autonomic sequence of EEG events, but require a certain degree of activation (i.e., arousal) 
to become visibly apparent. Whether the outcome is a physiologic movement, a muscle jerk 
or a major epileptic attack will depend on a number of ongoing factors but all events share 
the common trait of arousal-activated phenomena (93). However, CAP is not the generator 
of sleep-related movements, rather it operates as a gating-control rhythm that set the pace 
of their periodic appearance. In particular, CAP phase A offers a permissive window for the 
activation of motor episodes, while CAP phase B provides the refractory background for 
their occurrence (91, 264).  
Despite the increased sleep instability, RMMA were reduced under clonidine. This 
paradox may be explained by the fact that clonidine strongly disrupted the NREM/REM 
sleep cycles. It is noteworthy, however, that clonidine acts on multiple sites, in the central 
nervous system as well as in the periphery, influencing the autonomic nervous system, the 
sleep-wake cycles, the arousal processes and the muscle tone (258, 265-269). It is therefore 
arduous to establish the precise mechanism by which clonidine reduces RMMA during 
sleep. Nonetheless, its effect could be linked to the alteration observed in the pattern of 
occurrence of CAP phases A2 and A3. In facts, the well-demonstrated peak during the pre-
REM periods is blunted under clonidine (See Figure 3.1.1 page 53). The loss of the 
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ultradian NREM/REM sleep cycle and the parallel physiological fluctuation of CAP A 
phases may possibly explain the effect of clonidine on RMMA occurrence.   
Finally, the cross-correlation analysis performed to assess the temporal association 
between RMMA episodes and CAP phase A, showed a positive correlation for RMMA 
onset and A2 and A3 phases in both placebo and clonidine nights. These data suggest that 
whenever an RMMA event occurs, it is likely to be associated with the more powerful and 
facilitatory arousal phases (264).  
 
4.1.2 Evidence from the Experimental Trial applying Sensory 
Stimulations during Sleep  
Data derived from the sleep recordings of SB and control subjects during the 
arousal-eliciting protocol (Chapter 3, Section 3.2) corroborate the “permissive window” 
interpretation (270).  
Overall, SB subjects did not differ from controls for sleep variables and quantitative 
EEG spectral analysis. Conversely, SB subjects showed a higher number of CAP phase A3 
than controls. In the experimental night, when the VT/AD stimulations were applied, both 
groups of subjects showed greater sleep instability (i.e., increased CAP variables) without 
major changes in sleep homeostasis (e.g., delta activity). However, notwithstanding the 
increased number of phases A2 and A3, RMMA occurrence was neither augmented nor 
induced in SB subjects or controls. This result may be explained by the fact that CAP phase 
A does not switch on the generator of movements during sleep, but rather provides the 
facilitatory background for the periodic occurrence RMMA in predisposed individuals.  
Other considerations should also be pointed out. First of all, it appears that young 
and otherwise healthy SB subjects have a normal sleep structure, physiologic sleep 
homeostatic processes, and sleep instability within normal range. The only variable that 
differ between SB and control subjects in baseline conditions is the distribution between the 
differ subtypes of CAP phase A. In particular, SB subjects have a greater number per hour 
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of phase A3, the most powerful arousal phase. It seems, therefore, that what distinguish SB 
subjects from control is not the incidence of arousal, rather the magnitude of it (61, 66, 
270). As arousals are a physiological structural component of sleep that ensures its 
reversibility in response to sensory inputs, noisy environment and movements (75), this 
increased number of CAP phase A3 may be also related to the higher number of RMMA 
during sleep that characterized SB subjects.  
A range of variable arousal phenomena has been described in the literature 
according to the different combinations of associated EEG, behavioral, and autonomic 
activities (75, 271). Cortical arousal is distinguished from subcortical arousal, which is 
identified when autonomic activation is associated with a transient EEG patterns different 
from the conventional AASM arousal, and from behavioral arousal (also called movement 
arousal), which is described as any increase in EMG activity accompanied by a change in 
any other EEG channel (257). Cortical arousal can be generated directly by the cortex 
under the impulse of the physiologic evolution of sleep (e.g., the transition from NREM to 
REM sleep), or in response to a sensory perturbation, such as respiratory interruption (e.g., 
respiratory effort-related arousal, RERA), noisy environment, alteration of blood pressure 
or heart rate, painful stimuli, and motor activities (91, 134, 272, 273). The filter that gates 
the information to the cortex is situated in the thalamo-cortical connections where the 
incoming signals are blocked or attenuated via synaptic inhibition. In any case, the 
involvement of the brain makes arousal a unitary phenomenon, in which activation is 
modulated through a hierarchy of phasic responses ranging from slow high-amplitude (i.e., 
CAP subtypes A1) to fast low voltage EEG patterns (i.e., CAP subtypes A3) (82). In fact, 
the differentiation between CAP phases A1, A2, and A3 reflects theses differences, in 
which A1 corresponds to the “synchronization arousal” associated with only mild 
autonomic and muscular activation, whereas A3 is characterized by desynchronized EEG, 
and more powerful autonomic and behavioral activations (75, 82).  
Other sleep-related movement disorders, such as PLMS, have been observed in 
association with CAP phases A2 and A3, supporting the facilitatory role of arousal phase A 
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(91). As in PLMS subjects (91, 273), the greater arousal instability found in SB subjects 
may be due to RMMA motor events per se or to the effects of external disrupting factors, 
such as VT/AD stimuli (or clonidine) in experimental conditions. Furthermore, these results 
support the hypothesis that RMMA is probably initiated and regulated by different 
mechanisms, such as the autonomic sympathetic cardiac activity (64, 94), the 
hypothalamic-adrenal axis (32, 115, 116), genetic factors (68), or complex neurochemical 
influences (20, 51), rather than sleep arousal alone.  
In fact, the strong association and time-correlation between RMMA and CAP phase 
A3 do not establish a cause-and-effect relationship between these two phenomena. Indeed, 
in the experimental condition in which sub-threshold sensory stimulations were applied, the 
increased sleep instability was not associated with the development of RMMA in controls, 
or the increase of RMMA in SB subjects. Thus, arousal and sleep instability seem to be 
facilitating but not sufficient factors for RMMA occurrence during sleep. Other 
predisposing factors that distinguish controls from SB subjects, and possible triggers still 
need to be identified.   
 
 
4.2 Sleep Bruxism, Snoring, and Headache: a Triad that 
Needs Further Investigations  
A more clinical perspective characterized the last two research articles included in 
this thesis. In particular, they were aimed to study SB as a common sleep disorders 
frequently associated with other orofacial, sleep, and behavioral problems. Taking into 
account the methodology applied, new evidence has been provided to support the 
comorbidity between SB and HA, sleep problems and behavioral complaints. Conversely, 
further research will be needed to support the complex, and still unclear, relationship 
between SB and breathing during sleep.  
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4.2.1 Evidence from the Epidemiological Survey on a Pediatric 
Population  
The cross-sectional investigation was conducted on a 7 to 17 years old population 
seeking orthodontic treatment (Chapter 3, Section 3.3). Based on questionnaires, the 
prevalence of SB was 15%, falling into the range of prevalence already reported in the 
literature. Interestingly, the prevalence of wake-time bruxism (i.e., tooth clenching, TC) 
was also assessed. More than 12% of the population reported to have TC habit during the 
day. The identification of these subgroups allowed calculating the risk for SB subjects and 
TC subjects compared to controls. The design of the study and the statistical approach do 
not allow establishing a cause-effect relationship between two conditions, rather they 
describe the strength of the association between independent variables.  
SB and TC appear to be two distinct disorders; not only they occur in two different 
physical state (during sleep vs. during wakefulness), but they seem to affect two different 
populations. SB in fact, was more prevalent among children aged less than 12 years, 
whereas TC was predominantly reported by adolescents. Although this finding needs to be 
replicated and further investigated, some interpretations could be advanced. SB is a sleep-
related movement disorders in which a genetic predisposition may play an important role. 
Little evidence is already available, although no specific genes, polymorphisms, or pattern 
of inheritance have been yet identified (68). On the other hand, TC during wake-time seems 
to be a learned behavior, an adaptive response or a coping strategy that an individual 
develops a bit later in life, when psychosocial factors and stressful events begin to be 
involved. It is not excluded, however, that SB and TC also share common risk factors, and 
coexist in the same individual. Longitudinal studies could help clarifying this aspect.  
Focusing on SB only, the results of this cross-sectional investigation showed that 
children with SB are at increased risk of having a dental class II, tooth wear, jaw muscle 
fatigue, uncomfortable dental occlusion, frequent headache, loud breathing during sleep, 
and several sleep-related complaints (e.g., unrefreshing sleep, daytime sleepiness). Some of 
these findings deserve to be further discussed. First of all, the relationship between SB, 
headache, and sleep.  
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It has been already reported that children suffering from migraine and tension-type 
headache may have shorter sleep duration, longer sleep latency, difficulties to get asleep, 
and frequent awakenings. Migraine children frequently present parasomnias (e.g., sleep 
talking, sleepwalking, nightmares), sleep bruxism, snoring, sleep-disordered breathing and 
daytime sleepiness (148, 174, 274). Therefore, headache can be the presenting symptom of 
several sleep disorders, which could be misdiagnosed: in several cases of adult migraine, 
the polysomnographic study revealed the presence of a primary sleep disorder, and the 
treatment of the underlying clinical condition (e.g., PLMS, obstructive sleep apnea) greatly 
improved the symptom headache (275). This could be the case also in some SB children. In 
fact, in our study SB children were at higher risk for loud breathing during sleep, possibly a 
precursor of SDB. However, the report of sleep apnea was not different between SB 
subjects and controls. These data could be explained by the limits of the methodology used. 
Children and their parents may not be aware of breathing pauses during sleep, while they 
may hear tooth-grinding noises even from a separate room. 
SDB and particularly obstructive sleep apnea (OSA) may cause headaches, with up 
to 70% of OSA patients suffering from headaches (275-277). Although this head pain 
seems to be a non-specific symptom (277), the types of headache in OSA have mainly 
features of tension-type headache, migraine or chronic migraine (278) often reported in the 
morning. The pathophysiology of morning headache in OSA patients is not clearly 
understood: the role of intermittent hypoxemia is controversial and only a weak relationship 
has been found with sleep parameters. However, treatment with continuous positive airway 
pressure (CPAP) devices may improve or resolve headache in a subset of OSA patients 
(279). 
 In a more recent study on 90 children with headache, it was showed that SDB were 
more frequent in children with migraine (56.6%) and nonspecific headache (54%) 
compared to chronic migraine (27%). Moreover, 50% of children with tension-type 
headache manifested SB vs. 2.4% of children with non-tension headache (175). 
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Literature data on a particular form of headache, cluster headache (CH), also 
showed that OSA can trigger CH attacks. Furthermore, CH has been reported as an 
associated disorder of OSA with comorbidity between 31% and 80% of the cases (280).  
Considering the high prevalence of comorbid SB, headaches, and SDB putative 
underlying mechanisms may be suggested: headache could be either related to the 
musculoskeletal tension in the masseter and temporalis areas following excessive activation 
during sleep (i.e., SB), or to the concomitant obstructive respiratory events associated with 
oxygen desaturation and sleep fragmentation (i.e., upper airway resistance syndrome, SDB) 
(See Figure 1.4 page 28). Lastly, the possibility of intersecting epidemics cannot not be 
excluded.  
Data collected in this cross-sectional investigation were the rationale to design an 
experimental trial using specific EMG recordings and breathing monitoring during sleep in 
order to investigate the aforementioned hypotheses. 
 
4.2.2 New Insights on the Role of Mandibular Advancement 
Appliances 
Based on recent reviews on the available treatments for SB, the use of mandibular 
advancement appliances (MAA) appears to be the most effective in reducing RMMA 
during sleep (203, 204). These data have been confirmed in two experimental 
polysomnographic trials conducted in our laboratory, which tested different designs of 
MAA in a short-term treatment for SB subjects. RMMA index was decreased by 47 to 83% 
when the mandible was in the advanced position (reaching 75% of the maximum jaw 
protrusion)(229, 230).  
MAA are also used in the treatment of snoring and mild to moderate case of 
obstructive sleep apnea (281-283), and they have been recently found effective in the 
management of morning headache in non-apnea patients (231). Although promising, all 
these findings rely on short-term experimental trial performed on small samples of adult 
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subjects. There is a need to systematically evaluate the efficacy of oral appliances using 
follow-up polysomnograms (also a long-term), and to develop more objective measures of 
real-time compliance and efficacy of MAA (e.g., an intra-device thermal chip to monitor 
the duration of use).  
Our study (Chapter 3, Section 3.4) confirms the short-term effectiveness of MAA 
also in adolescents with SB, snoring, and HA. However, although progressive clinical 
improvement was achieved, no significant difference was found between the free splints 
(control position), and the neutral or advanced positions (active jaw retaining or 
repositioning). Moreover, residual RMMA episodes and increase of other muscular 
activities involving the masticatory muscles were observed.  
From a clinical point of view, the use of MAA did not cause any side effects, pain 
or intolerable discomfort in our sample of adolescents. We selected a group of subjects 
aged between 12 and 19 years to avoid the primary dentition. Only three subjects presented 
a mixed dentition, which, however, did not hamper the MAA fitting. All our participants 
adapted easily to the MAA and did not report any worsening of their sleep quality while 
sleeping with the appliance. None of the MAA broke during the trial, suggesting a good 
resistance of this device also in subjects with SB. However, it must notice that the MAA 
was used only for a short-term treatment. MAA safety and longevity, as well as patient’s 
compliance need to be re-assessed in long-term trials.  
The present findings also suggest new explanations on the putative mechanisms of 
action by which MAAs would act on RMMA occurrence. The different hypotheses will be 
examined in the following sections.  
 
4.2.2.1 Mandibular advancement appliances and breathing  
During sleep, a general reduction in airflow (i.e., hypoventilation) and a decreased 
respiratory rate are physiologically observed. These are the consequences of the loss of the 
wakefulness respiratory control, and the sleep-related decrease in the ventilatory responses 
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to hypoxemia and hypercapnia (59, 284). Moreover, at sleep onset the activity of 
respiratory muscles falls, with a predominant effect on those muscles that combine 
respiratory and non-respiratory (e.g., postural and behavioral) functions, such as the 
pharyngeal muscles (285). This causes a transient decrease in ventilation and increased 
upper airway resistance even in healthy individuals (286). The pharynx is a highly 
collapsible and most vulnerable structure of the upper airway, since it lacks substantial 
bony or rigid support. Most frequently, the airway obstruction involves the velopharynx or 
retropalatal area, which presents the minimum caliber of the upper airway, and the 
oropharynx or retroglossal area, where soft tissue structures like the soft palate, tongue and 
tonsils promote airway obstruction (285, 287). The patency of the pharynx during 
respiration is almost completely dependent on the activity of the pharyngeal dilator 
muscles, such as the palatoglossus, the levator and tensor veli palatini, the genioglossus, the 
geniohyoideus, the pharyngeal constrictors, and also the masseter and pterygoid muscles, 
which contraction influences the position of the mandible and contributes to the 
maintenance of upper airway patency (288).  
When a partial or complete obstruction of the upper airway takes place, the 
subsequent hypoxia and hypercapnia may elicit an arousal from sleep. Arousals are 
efficient physiological protective mechanism that contributes in removing the precipitating 
cause of collapse and reestablishing upper airway patency. Indeed, arousal is generally 
associated with a substantial increase in the activity of pharyngeal dilator muscles and 
sympathetic nervous system. Although effective, sleep arousal does not prevent episodes of 
obstructive apnea/hypopnea to cyclically reoccur and, on the other hand, it may have 
detrimental effects on sleep continuity and sleep quality.  
The primary mechanism of action of an MAA seems to be mechanical. Despite the 
slight differences related to the MAA design, it keeps the jaw in a more anterior position, 
thus the tongue and the related soft tissues, resulting in an increased anterior-posterior and 
lateral dimensions of both the velopharynx and oropharynx (289, 290). These changes are 
thought to be mediated by mechanical stretching of the palatoglossal and palatopharyngeal 
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arches, through which exist intricate linkages with the muscle of the tongue, soft palate, 
lateral pharyngeal walls, and mandibular attachments. By increasing and stabilizing the 
upper airway space, the MAA prevents the collapse of the pharyngeal structures and 
improves respiration during sleep. The progressive advancement of the mandible, which 
can be reached in dependence on the individual jaw range of motion and MAA design, is an 
important factor that can influence the effectiveness of the treatment in SDB.  
Our hypothesis was that the improved breathing during sleep with an MAA might 
be also responsible for the reduction of RMMA episodes, which occur as a “reaction” to 
slight upper airway obstruction or upper airway resistance. This explanation is supported by 
the superior efficacy of MAA compared to stabilization splints, and by the progressive 
improvement achieved when the MAA was in the advanced position. However, no 
significant difference was found in our study between the three tested MAA positions. If 
SB is a response to sleep-related hypoventilation or upper airway resistance, also in the 
absence of frank episodes of obstructive sleep apnea, remains to be demonstrated.  
 
4.2.2.2 Mandibular advancement appliances and the masticatory system 
By repositioning the jaw, the MAA may also exert some actions on the masticatory 
system. The masticatory muscles, including the masseter and the temporalis, are involved 
in many functions, such as chewing, swallowing, talking, and breathing. Chewing is a 
repetitive motor activity driven by the central pattern generator (CPG) within the central 
nervous system (45). The CPG is responsible of initiating and maintaining the pattern and 
the pace of this motor activity. The integration of peripheral influences from sensory inputs, 
such as those from muscle spindles, temporomandibular joint, oral mucosal, and 
periodontal mechanoreceptors, is necessary to control or fine-tune the rhythmic jaw 
movements. In particular, the trigeminal motoneuron activities are influenced by jaw 
muscle spindle afferents that carry information about muscle length, jaw position, and, to 
certain extent, tension (45). It cannot be excluded that the use of an MAA changes these 
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inputs. However, jaw muscle spindle activity has not yet been studied during sleep, and the 
role of peripheral sensory information, as well as the masticatory and respiratory CPG 
interactions on the onset and regulation of RMMA is still unknown (50, 291).  
Alternatively, the reduction of SB-related motor activity observed with an MAA 
may be due to use of a semi-rigid oral appliance composed by two linked splints, which 
markedly restrict the range of jaw movements. However, we reported, in contrast to 
previous findings (230), that other orofacial muscular activities were increased with the 
MAA. These activities may include lip sucking, talking, swallowing, yawning, head 
movements, which are accounted for 40% of the muscular events in SB subjects in normal 
conditions (13, 14). Their increase (approximately by 35%) may be related to the lower 
scoring specificity and sensitivity of the study, since it was carried out with an ambulatory 
PSG system in absence of audio-video recordings. However, it could also been explained 
by the hypothesis that the use of a MAA would influence and change the observable EMG 
pattern of movement, rather that altering the efferent inputs to the CPG. In other words, the 
trigger of RMMA during sleep is preserved, but the bulky appliance does not allow scoring 
it since the characteristic EMG features (e.g., rhythmic bursts of 0.25-2 seconds) are not 
recognizable. This hypothesis might also be supported by a recent article, which studied 
masticatory muscle EMG activity during sleep in SB subjects wearing different designs of 
oral appliances, i.e., occusal splint vs. free maxillary-mandibular appliance vs. connected 
maxillary-mandibular appliance (design very similar to a MAA)(292). The authors found 
that the restriction of mandibular movements due to the connected maxillary-mandibular 
appliance do not exert a major influence on jaw-muscle activity compared to the other 
designs. However, they interestingly found that there was a specific suppression of phasic 
EMG episodes no matter the type of oral device. Conversely, the jaw muscles tonic activity 
was not modified by the use of such devices (292). Although these recent supporting data, 
further analyses on the periodicity and occurrence (e.g., in relation to sleep arousal) of 
orofacial motor activities, and further research on the effect of oral appliance on EMG 
activities during sleep would be extremely useful to elucidate this issue.  
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Finally, it remains to be assessed whether the effectiveness of MAA on headache 
complaints is linked to the improvement of breathing (i.e., oxygen saturation, sleep 
fragmentation), to the reduction of masticatory muscular activity during sleep, to both, or it 
may be attributed to other mechanisms, e.g., a placebo effect. These hypotheses remain 
possible, and the questions remain open.  
 
4.2.2.3 More than one type of RMMA? 
Of the many treatment approaches tested for SB, none completely abolished 
RMMA episodes during sleep (203). Based on this refractory effect, it may be suggested, as 
for other spontaneous movements during sleep (e.g., period limb movements), that there is 
more than one type of RMMA.  
In the case of PLMS, for example, leg movements are frequently observed in 
association of cortical arousals and/or breathing events. In patients with OSA, PLMS 
typically occur synchronously with breathing resumption at the end of the apnea event, and 
are often suppressed by continuous positive airway pressure (CPAP) treatment (293-296). 
These PLMS may have a different pathogenesis compared to PLMS in other sleep 
disorders, (e.g., insomnia, narcolepsy), in terms of neurotransmitter or nervous pathways 
implicated in their generation.  
In parallel, isolated or idiopathic RMMA, arousal related-RMMA, breathing-related 
RMMA, and leg or body movement-related RMMA could be distinguished. These events 
may all share common etiologic factors, but their occurrence may be regulated and paced 
by different related phenomena during sleep. Moreover, each type of RMMA may be more 
responsive to the specific treatment that particularly addresses the different related factors. 
The scientific and clinical relevance of the aforementioned theory need to be assessed in 
future investigations.  
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4.3 Scientific and Clinical Relevance of the Findings 
The findings of this thesis added to the current literature new insights on the 
etiology, pathophysiology, and management of SB. A better understanding of the 
pathogenesis and regulation of rhythmic masticatory muscle activity during sleep is 
essential to identify evidence-based treatments that will improve the quality of care 
provided in clinical settings. This was in fact the two-folds objective of the thesis (from the 
title: “Rhythmic Masticatory Muscle Activity during Sleep: Etiology and Clinical 
Perspectives”). 
From a scientific perspective, the analysis of CAP allowed defining the role of sleep 
arousal, which had been considered a potential trigger or cause of RMMA for many years. 
Based on our data, sleep arousal is not the generator of motor events during sleep, rather the 
“permissive window” in which these events become manifest. Classical polysomnographic 
measures used to assess sleep quality (e.g., sleep efficiency, sleep latency, sleep arousal) 
were not able to finely describe the micro-structural components of sleep. As in a hierarchy 
of PSG measures, CAP variables appear to be the most sensitive scoring method to any 
source of internal and external perturbation during sleep, even in young healthy individual 
affected by SB only (our study population).  
We reported for the first time the effect of a widely known medication, clonidine, 
on the macro- and micro-structure of sleep. This may provide evidence for other medical 
disorders in which clonidine is administered (e.g., menopause symptoms; opioid 
withdrawal syndrome), and support further research in the field. Moreover, the scoring and 
analysis of CAP will be extremely useful to assess the manifold deterioration of sleep in 
case of SB patients affected by other sleep disorders, such as insomnia, SDB, and RLS. In 
case of concomitant pain syndrome (e.g., TMD) as well, CAP can be used to investigate the 
source of sleep perturbation that is clinically manifest with varying symptoms, like fatigue, 
sleepiness, and neuro-cognitive dysfunction. Not lastly, it would be interesting to analyze 
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CAP in order to assess the effect of different treatments for SB, and other sleep disorders, 
on sleep stability and arousal pressure.  
From a clinical perspective, our research provides scientific evidence to support the 
clinical impression that SB is often concomitant with other sleep and medical disorders. In 
the knowledge transfer process, we tried to increase the awareness that SB, a well-known 
burden for dentists, is much more than tooth wear, as it is frequently associated with 
orofacial pain, TMD, headaches, behavioral problems, and sleep complaints, including 
more severe sleep disorders, like sleep-disordered breathing. Dentists are responsible for 
the detection and prevention of SB detrimental consequences on patients’ oral health. 
However, they are also called to be part of a multidisciplinary team of sleep specialists 
(e.g., pulmonologists, neurologists, psychologists), which represents the most efficient 
approach in the field of sleep medicine.  
In particular, our research attempts to offer guidance to dentists and orthodontics in 
the diagnostic and therapeutic processes of SB and comorbid conditions. Their role could 
be cardinal in screening sleep disorders and identify risk factors in dental patients.  
  It has been proven that a wide range of craniofacial anatomical abnormalities 
contributes to airway collapsibility during sleep and predisposes individuals to develop 
SDB (297, 298). These include the reduced size of craniofacial bony structures (e.g. 
micrognatia, reduced mandibular body length, skeletal class II), and the retro-positioning of 
the maxilla-mandibular complex, which compromise the pharyngeal airspace. These 
craniofacial abnormalities are primarily inherited, but many environmental and functional 
factors can also influence the craniofacial development towards conditions of airspace 
narrowing (299, 300). Also the pediatric SB subjects in our epidemiological study (Section 
3.3) have been found to be a skeletal/dental class II (i.e., retrognathic profile) with a 
frequency significantly higher than controls, suggesting a possible predisposing conditions 
to SDB that deserves further investigations (301).  
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An increasing amount of literature is nowadays dedicated at identifying preventing 
procedures or treatments that can act on craniofacial structures.  Firstly, the orthodontic and 
orthopedic treatments have a great influence on these structures, by guiding the craniofacial 
growth during childhood and correcting eventual abnormalities in youth (302). The great 
importance of screening pediatric patients, identifying risk factors, and promote early 
diagnosis and treatment is related to the severe consequences that untreated SDB or OSA 
can cause during childhood and later in life. These include: very poor sleep quality, 
sleepiness, behavioral disturbances, learning deficits, cardiovascular morbidity, metabolic 
disturbances, and failure to thrive (303-307). This long list of medical problems highlights 
the clinical relevance of pursuing research in the objective of identifying preventive 
procedures and effective treatments.  
We also reported for the first time in the literature the use of an MAA in adolescents 
in the management of symptomatic SB. Our results demonstrated that in a short-term basis, 
this treatment approach seems to be effective, well-tolerated, and safe even in this 
population. No side effect was recorded and high compliance was reported. Moreover, 
sleep quality was not affected by the use of MAA in any tested position. These results on 
the positive short-term effect of MAA may serve as pilot data for new long-term clinical 
trials. In fact, the use of MAA represents a non-pharmacologic treatment option that 
deserves high consideration in the management of sleep disorders, such as SB, HA pain, 
and SDB, especially in pediatrics. In the perspective of a multifactor etiology, it could also 
be suggested to study the effect of a combined therapy, i.e., MAA + CBT, for the treatment 
of SB and other sleep disorders (e.g., insomnia comorbid with SDB or snoring). This 
approach may have high clinical relevance, considering its characteristics of being 
conservative, reversible, and safe.  
Finally, the use of an ambulatory PSG system to study sleep bruxism has never been 
applied before in adolescents. Although this methodology needs to be validated, it seems to 
be a powerful and advantageous tool that should be considered in future experimental and 
epidemiological studies (See Section 4.4.2).  
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4.4 Study Limitations and Future Directions 
Study limitations, present in all the four research articles, should be considered 
when interpreting the present results.  
Concerning the first two articles (Sections 3.1 and 3.2), the major limitation is 
related to the small sample of subjects recruited (due to the strict recruitment criteria 
applied), and the highly experimental settings. Although significant and reciprocally 
confirmatory, these results cannot be generalized without caution. Other pharmacological 
or physical manipulation of sleep physiology (e.g., REM sleep deprivation or induction) 
may assist in determining the role of other arousal-related factors that participate in RMMA 
occurrence.  
The epidemiological survey instead (Section 3.3) was conducted on a large pediatric 
population. However, all subjects included in the study were seeking orthodontic treatment 
at the Orthodontic Clinic of the University of Montreal. Since the external validity of the 
present results has not yet been proven, these findings cannot be extrapolated to the general 
population. Moreover, the survey was mainly based on questionnaires, whose reliability is 
always limited, and which was missing questions to investigate stress and anxiety related 
complaints that may also be involved in the genesis of both sleep and wake-time bruxism.  
Finally, the experimental trial with the MAA in adolescents (Section 3.4) suffers 
from some limitations related to the methodology applied. For example, the headache 
complaint was studied though questionnaires that were filled by the subjects the day of each 
PSG recording (i.e., after 1 week of MAA treatment). Since our sample was selected based 
on the report of frequent headache (>1/week) disregarding the time of the day, we may 
have not intercepted neither the actual benefit of the MAA nor a potential worsening. A 
different subject selection (e.g., subjects reporting frequent HA only in the morning), or a 
different assessment tool (e.g., HA diary), would have helped minimize at these problems.  
Moreover, although the sample size was estimated a priori, the number of subjects enrolled 
in the study was not sufficient to show significant differences between the three MAA 
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positions tested during the protocol. Thus, we could not confirm or deny the main 
hypothesis on the role of opening the airway and improving breathing during sleep on 
RMMA and headache complaints.   
 In order to confirm and further investigate the main research hypotheses of this 
thesis, further analyses need to be done.  
 
4.4.1 What I Would Do Differently 
In order to test the hypothesis that a common underlying pathogenetic mechanism 
links SB, HA, and breathing during sleep, I would suggest the followings:  
- The relationship between SB and SDB should have been studied in a population of 
adolescents with frank OSA (AHI >2). The high incidence of obstructive 
apnea/hypopnea events would have allowed performing time-correlation analyses 
between RMMA and OSA, also in respect to sleep arousal and oxygen saturation 
levels. Then, the use of an MAA would have helped teasing out the role of breathing in 
the genesis of RMMA during sleep.  
- To understand the role of respiration in SB, the monitoring of CO2 levels would have 
been very useful to investigate possible oscillation in the hypoxia and hypercapnia 
levels, which may be responsible of arousal and RMMA, even in absence of frank 
episodes of obstructive sleep apnea.  
- To understand the pathophysiology of HA in relation of SB, I should have included 
and compared two groups: a group of SB subjects reporting frequent HA in the 
morning (upon awakening), and a group of SB subjects reporting frequent HA during 
the day (toward the evening). The first group is suspected to be a sleep-breathing type 
of HA, whereas the latter one is more probably a form of tension-type HA secondary to 
wake-time bruxism, sleep bruxism, or TMD. There is a need to finely define the 
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overlap and the different characteristics of these forms of HA, which may also coexist 
in the same patient.  
 
4.4.2 What Needs to Be Done 
Based on the present findings, my future research agenda could be: 
- The validity of ambulatory PSG recordings to diagnose SB needs to be assessed. To 
date, the published scoring criteria for RMMA are based on in-lab PSG data combined 
with an audio-video recording (level I). The highly controlled setting (e.g., sleep lab 
with sleep technicians attending the PSG) and the presence of a video camera zoomed 
on the face of the sleeping individual, ensure very good level of specificity and 
sensitivity in identifying RMMA episodes during sleep. These factors are obviously 
lost in a home PSG recording. However, other advantages are present, such as the more 
comfortable and natural sleep environment, and the higher participant’s compliance in 
the study.  
We therefore designed a study to validate this promising tool for both research and 
clinical purposes. Ten subjects slept with the ambulatory PSG system while an audio-
video recording was performed. Their nights will be scored with and without video, 
and concordance tests will be applied in order to define the specificity and sensitivity 
associated with the scoring of RMMA in absence of the standard required criteria (i.e., 
video). Preliminary analyses suggest a mean concordance rate of 68% (Carra et al., 
article in preparation).  
- The epidemiology of SB needs to be studied with tools that allow an objective 
assessment of this sleep disorders. In this case, sophisticated although simplified 
recording methods (PSG level III and IV) could be applied in large populations in 
order to have a confirmed diagnosis of SB and related sleep disorders, which are 
frequently unreported by the subjects since they all occur during sleep (e.g., snoring or 
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sleep apnea). Moreover, confounding factors and differential diagnosis (e.g., with 
wake-time bruxism) could be more reliably assessed. 
- Longitudinal cohort studies are also needed to identify the predisposing and risk factors 
that differentiate children with SB from controls. In particular, anatomical (e.g., 
craniofacial morphology and development), functional (e.g., mouth vs. nasal 
breathing), and psychosocial factors (e.g., personality traits and stressors) are the major 
candidates that should be assessed with objective and quantitative measures (e.g., 3D 
imaging, psychological questionnaires/interview) in children with and without SB.  
-  Sleep instability and CAP should be analyzed in adolescents with SB and 
comorbidities (e.g., snoring and headache), and the effect of an MAA on CAP 
variables should be evaluated (it has not yet been done). As for rapid maxillary 
expansion done in SDB children (308), it would be interesting to show that an effective 
treatment with an MAA would normalize sleep instability by reducing RMMA and 
improving breathing during sleep. I plan to realize this project as my first research 
study once I will be back in my own town Parma, Italy.  
- Finally, new research avenues should be explored to elucidate the etiological 
hypotheses on the genesis of RMMA during sleep. The role of many mechanisms 
involved in sleep regulation, homeostatic process, circadian rhythm, and 
neuroendocrine systems remains unknown.  
Recently discovered hormones responsible of appetite and feeding behaviors, like 
ghrelin and leptin, may be implicated in the genesis of sleep-related rhythmic motor 
activities, like RMMA. There is evidence, in fact, that ghrelin has a physiological role 
in meal initiation in humans, whereas leptin suppresses appetite (309). Ghrelin levels 
rise in the first hours after sleep onset and progressively decrease toward the end of the 
night. Leptin levels during sleep counteract ghrelin ones, maintaining a relatively 
steady high level throughout the night. A hypothetical unbalance in the ghrelin/leptin 
ratio or specific ghrelin fluctuations during sleep may initiate abnormal behaviors 
related to feeding, such as rhythmic jaw muscle activities, at an incorrect time (e.g. 
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during sleep). Furthermore, the unconsumed feeding would not inhibit ghrelin 
secretion, thus allowing the “chewing” event to reoccur. Ghrelin secretion also appears 
to be directly stimulated by the sympathetic nervous system in rats (310). This finding 
is also clinically supported in sleep apnea patients, who have high sympathetic nervous 
activity and increased ghrelin levels (311).  
The episodic and transient autonomic reactivations, considered the permissive window 
for the activity of trigeminal motorneurons, may also provide excitatory or 
disinhibitory mechanisms in ghrelin secretion regulation. Hypocretin system as well 
may be involved, activating brainstem arousal centers, increasing sympathetic tone and 
promoting feeding behaviors (312). This unexplored research field may be proposed as 
a new interesting perspective to elucidate the multiple mechanisms associated with the 
genesis of SB. Clinical trials could be designed to define the 24 h profile of leptin and 
ghrelin in sleep bruxism subjects and to challenge ghrelin secretion and sleep bruxism 
activity, for example in conditions of sleep restriction.  
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Conclusion 
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Sleep bruxism (SB) is a common sleep disorder characterized by recurrent rhythmic 
masticatory muscle activity (RMMA), which occurs in periods of sleep instability mostly 
associated with sleep arousal. Sleep arousal is coupled with surges of sympathetic nervous 
system activity, heart rate, and blood pressure, which may prelude to the RMMA. In fact, 
sleep arousal is considered the “permissive window” for the occurrence of motor events 
during sleep that follow a periodic fluctuation over the NREM/REM sleep cycle. 
Conversely, the trigger or cause, as well as the function, of RMMA are still unknown; the 
hypothetic role in physiologic functions, such as breathing, needs further investigations.  
There is evidence, however, that SB is frequently concomitant with other medical 
problems or complaints (e.g., headache, sleep disorders), which should be taken into 
account in the clinical assessment and management of this sleep disorder. The use of 
mandibular advancement appliances could be an effective treatment option in cases of SB 
associated with snoring and headache. More research should be dedicated at studying the 
long-term effectiveness, compliance, and side effects of this treatment in both adult and 
pediatric populations.  
 
This thesis represents just a little step forward in the research field of sleep bruxism. 
When I began my PhD, I felt it was like a mountain to climb, and once reaching the top I 
would have found the answer. I learnt that a researcher never stops climbing. New findings 
are immediately followed by new questions, in a never-ending process that feeds our 
interest and curiosity every day. I hope to pursue this path with the same motivation that 
drove me to this achievement.  
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